Engineered Class 2 V-type CRISPR system
Patent Information
- Application Number
- JP2023533837
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-09
- Filing Date
- 2021-12-02
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2041-12-02
AI Technical Summary
Existing Class 2, type V CRISPR/Cas systems, such as Cas9, have low editing efficiency and limited target recognition, particularly with 5' PAM sequences, necessitating the development of improved CRISPR/Cas systems for efficient gene editing in eukaryotic cells.
Engineering modified Class 2, type V CRISPR proteins (CasX variants) and guide RNAs (gRNAs) with enhanced characteristics, such as improved binding affinity and editing efficiency, to form stable ribonucleoprotein complexes for targeted nucleic acid modification.
The engineered CRISPR systems demonstrate significantly enhanced editing efficiency and specificity, enabling precise gene editing in eukaryotic cells, including improved on-target activity and reduced off-target effects.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Nos. 63 / 121,196, filed December 3, 2020, 63 / 162,346, filed March 17, 2021, and 63 / 208,855, filed June 9, 2021, the contents of each of which are incorporated by reference in their entirety.
[0002] INCORPORATION-BY-REFERENCE TO SEQUENCE LISTING The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: Computer-readable copy of the Sequence Listing (Filename: SCRB_031_03WO_SEQLIST_ST25, Recording Date: December 1, 2021, File Size: 5.61 MB). [Background technology]
[0003] CRISPR-Cas systems in bacteria and archaea confer a form of adaptive immunity against phages and viruses. Intensive research over the past decade has elucidated the biochemistry of these systems. CRISPR-Cas systems consist of Cas proteins, responsible for acquiring, targeting, and cleaving foreign DNA or RNA, and CRISPR arrays containing tandem repeats flanked by short spacer sequences that guide the Cas proteins to their targets. Class 2 CRISPR-Cas is a streamlined version in which a single RNA-bound Cas protein is responsible for binding to and cleaving the target sequence. The programmable nature of these minimal systems has facilitated their use as a versatile technology that is revolutionizing the field of genome engineering.
[0004] To date, only a few Class 2 CRISPR / Cas systems have been widely used. Among these, Type V is unique in that it utilizes a RuvC-like endonuclease (RuvC) domain that recognizes a 5' PAM sequence distinct from the 3' PAM sequence recognized by Cas9 and forms a staggered cut in target nucleic acids with 5, 7, or 10 nt 5' overhangs (Yang et al., PAM-dependent target DNA recognition and cleavage by C2c1 CRISPR-Cas endonuclease. Cell 167:1814 (2016)). However, wild-type Cas and guide sequences in Type V have low editing efficiency. Therefore, there is a need in the art for additional Class 2, Type V CRISPR / Cas systems (e.g., combinations of Cas proteins and guide RNAs) that are optimized and / or offer improvements over previous generation systems for use in various therapeutic, diagnostic, and research applications. Summary of the Invention
[0005] The present disclosure relates to guide ribonucleic acids (gRNAs), engineered class 2, type V CRISPR proteins, and systems of engineered class 2, type V CRISPR proteins and guide ribonucleic acids (gRNAs) used to modify target nucleic acids of genes in eukaryotic cells. In some embodiments, the present disclosure provides engineered class 2, type V proteins that contain one or more modifications to a domain of a reference CasX and exhibit one or more improved characteristics compared to the reference CasX protein of SEQ ID NO: 2. In other embodiments, the present disclosure provides engineered sequence variants of CasX variant proteins, such as CasX491 (SEQ ID NO: 336) or CasX515 (SEQ ID NO: 416), where the class 2, type V proteins contain at least one modification to a domain of the CasX variant and exhibit one or more improved characteristics compared to the CasX variant protein. In some embodiments, the Class 2, Type V variant can form a complex with a guide ribonucleic acid (gRNA), and the complex can bind to and cleave a target nucleic acid, the target nucleic acid comprising a non-target strand and a target strand.
[0006] In some embodiments, the disclosure provides a guide ribonucleic acid (gRNA) comprising a single-guide composition capable of binding to a Class 2, Type V variant protein, wherein the gRNA comprises at least one modification in a region compared to the gRNA of SEQ ID NO: 2238 or SEQ ID NO: 2239. In some embodiments, the modified region of the scaffold of the gRNA comprises (a) an extended stem-loop, (b) a scaffold stem-loop, (c) a triplex, and (d) a pseudoknot. In some cases, the scaffold extension stem of the variant gRNA further comprises a modification to the bubble. In other cases, the scaffold of the gRNA further comprises a modification to the triplex loop region. In other cases, the scaffold of the variant gRNA further comprises a heterologous RNA in the extended stem that comprises a hairpin sequence.
[0007] In some embodiments, the present disclosure provides a gene editing pair comprising an engineered class 2, type V protein and gRNA variant of any of the embodiments described herein, wherein the gene editing pair exhibits at least one improved characteristic compared to a gene editing pair comprising a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, and a gRNA of SEQ ID NO:4 or SEQ ID NO:5. In certain embodiments, the engineered class 2, type V protein comprises a sequence selected from the group consisting of SEQ ID NOs: 247-592 and 1147-1231 set forth in Table 3, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto, and the gRNA is a sequence selected from the group consisting of SEQ ID NOs: 2101-2332 and 2353-2398 set forth in Table 2, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto. In certain embodiments, the engineered class 2, type V protein comprises a sequence selected from the group consisting of SEQ ID NOs: 270-592 and 1147-1231, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto, and the gRNA is a sequence selected from the group consisting of SEQ ID NOs: 2238-2332 and 2353-2398, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto.In certain embodiments, the engineered class 2, type V protein comprises a sequence selected from the group consisting of SEQ ID NOs: 415-592 and 1147-1231, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto, and the gRNA is a sequence selected from the group consisting of SEQ ID NOs: 2281-2332 and 2353-2398, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto.
[0008] In some embodiments, the present disclosure provides polynucleotides and vectors encoding the engineered class 2, V-type variant proteins, gRNA variants, and gene-editing pairs described herein. In some embodiments, the vectors are viral vectors, such as adeno-associated viral (AAV) vectors. In other embodiments, the vectors are CasX delivery particles, called XDPs, that contain the RNPs of the gene-editing pairs.
[0009] In some embodiments, the disclosure provides cells comprising the polynucleotides, vectors, engineered class 2 and V proteins, and gRNAs described herein. In other embodiments, the disclosure provides cells comprising a target nucleic acid edited by the methods of the editing embodiments described herein.
[0010] In some embodiments, the present disclosure provides kits comprising the polynucleotides, vectors, engineered class 2 and type V proteins, gRNAs, and gene editing pairs described herein.
[0011] In some embodiments, the present disclosure provides a method of editing a target nucleic acid, comprising contacting the target nucleic acid with a Class 2, Type V protein and a gRNA variant described herein, wherein the contacting results in editing or modification of the target nucleic acid.
[0012] In some embodiments, the disclosure provides a method of editing a target nucleic acid in a cell population, comprising contacting the cells with one or more of the gene editing pairs described herein, wherein the contacting results in the editing or modification of the target nucleic acid in the cell population.
[0013] In other embodiments, the present disclosure provides a method of treating a subject in need thereof, comprising administering a gene editing pair of any of the embodiments described herein, or a vector comprising or encoding a gene editing pair.
[0014] In another aspect, provided herein is a gene editing pair, a composition comprising a gene editing pair, or a vector comprising or encoding a gene editing pair for use as a medicament.
[0015] In another aspect, provided herein is a gene editing pair, a composition comprising a gene editing pair, or a vector comprising or encoding a gene editing pair for use in a method of treatment, the method comprising editing or modifying a target nucleic acid, optionally wherein the editing is performed in a subject having a mutation in an allele of a gene, wherein the mutation causes a disease or disorder in the subject, and preferably wherein the editing changes the mutation to a wild-type allele of the gene, or knocks down or knocks out the allele of the gene that causes the disease or disorder in the subject.
[0016] Incorporation by Reference All publications, patents, and patent applications mentioned herein are incorporated by reference as if each individual publication, patent, or patent application were specifically and individually indicated to be incorporated by reference. The contents of WO 2020 / 247882, WO 2020 / 247883, and WO 2021 / 113772, which disclose CasX variants and gRNA variants and methods for delivering them, are incorporated by reference in their entireties. [Brief explanation of the drawings]
[0017] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which: [Figure 1]
[0023] Figure 1 is a graph of the results of an assay to quantify the active fraction of RNPs formed by sgRNA174 (SEQ ID NO: 2238) and CasX variants 119, 457, 488, and 491, as described in Example 8. The sequences corresponding to the sgRNA and CasX variants are provided in Tables 2 and 3, respectively. Equimolar amounts of RNP and target were co-incubated, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Biphasic matches of combined replicates are indicated. "2" refers to the reference CasX protein of SEQ ID NO: 2. [Figure 2] Figure 1 shows quantification of the active fraction of RNPs formed by CasX2 (reference CasX protein of SEQ ID NO: 2) and modified sgRNAs, as described in Example 8. Equimolar amounts of RNP and target were co-incubated, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Biphasic matches of combined replicates are shown. [Figure 3]Figure 1 shows quantification of the active fraction of RNPs formed by CasX491 and modified sgRNA under guide-restricted conditions, as described in Example 8. Equimolar amounts of RNP and target were co-incubated, and the amount of cleaved target was determined at the indicated time points. A two-phase fit of the data is shown. [Figure 4] Figure 1 shows quantification of the cleavage rates of RNPs formed by sgRNA174 and CasX variants, as described in Example 8. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point, except for 488 and 491, where a single replicate is shown. Monophasic matches of combined replicates are shown. [Figure 5] Figure 1 shows quantification of the cleavage rates of RNPs formed by CasX2 and sgRNA variants, as described in Example 8. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Monophasic matching of combined replicates is shown. [Figure 6] Quantification of the initial rates of RNPs formed by CasX2 and sgRNA variants is shown, as described in Example 8. The first two time points from previous cleavage experiments were fitted to a linear model to determine the initial cleavage rates. [Figure 7] Figure 1 shows quantification of the cleavage rates of RNPs formed by CasX491 and sgRNA variants as described in Example 8. Target DNA was incubated with a 20-fold excess of the indicated RNPs at 10°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of the time points are shown. [Figure 8] Figure 1 shows quantification of the competent fraction of RNPs of CasX variants 515 and 526 complexed with gRNA variant 174 compared to the RNP of reference CasX 2 complexed with gRNA 2, using equimolar amounts of the indicated RNPs and complementary targets, as described in Example 8. Biphasic fits are shown for each time course or combined replicate set. [Figure 9]Quantification of the cleavage rates of RNPs of CasX variants 515 and 526 complexed with gRNA variant 174 compared to the RNP of reference CasX 2 complexed with gRNA 2, using a 20-fold excess of the indicated RNPs, as described in Example 8. [Figure 10A] Figure 1 shows quantification of cleavage rates of CasX variants against a TTC PAM, as described in Example 5. Target DNA substrates with identical spacers and the indicated PAM sequences were incubated with a 20-fold excess of the indicated RNPs at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 10B] Figure 1 shows quantification of cleavage rates of CasX variants against CTC PAM, as described in Example 5. Target DNA substrates with identical spacers and the indicated PAM sequences were incubated with a 20-fold excess of the indicated RNPs at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 10C] Figure 1 shows quantification of cleavage rates of CasX variants against a GTC PAM, as described in Example 5. Target DNA substrates with the same spacer and the indicated PAM sequence were incubated with a 20-fold excess of the indicated RNP at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 10D] Figure 1 shows quantification of cleavage rates of CasX variants against the ATC PAM, as described in Example 5. Target DNA substrates with the same spacer and the indicated PAM sequence were incubated with a 20-fold excess of the indicated RNP at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 11A] Figure 1 shows quantification of RNP cleavage rates of CasX variant 491 and guide 174 against the NTC PAM, as described in Example 5. Time points were taken over a 2-minute period and the cleaved fraction was graphed for each target and time point, although for clarity only the first 2 minutes of the time course is shown. [Figure 11B]Figure 1 shows quantification of RNP cleavage rates of CasX variant 491 and guide 174 against the NTT PAM, as described in Example 5. Time points were taken over a 10 minute period and the fraction cleaved was graphed for each target and time point. [Figure 12A] Figure 1 shows quantification of cleavage by RNPs formed by sgRNA174 and CasX variant 515 using spacers of 18, 19, or 20 nucleotides in length, as described in Example 9. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Monophasic matches of combined replicates are shown. [Figure 12B] Figure 1 shows quantification of cleavage by RNPs formed by sgRNA174 and CasX variant 526 using spacers of 18, 19, or 20 nucleotides in length, as described in Example 9. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Monophasic matches of combined replicates are shown. [Figure 13]
[0023] Figure 1 is a schematic diagram showing an example of a CasX protein and scaffold DNA sequence for packaging in adeno-associated virus (AAV). The DNA segment between the AAV inverted terminal repeats (ITRs), consisting of the DNA encoding CasX and its promoter, and the DNA encoding the scaffold and its promoter, is packaged into the AAV capsid during AAV production. [Figure 14]Figure 2 shows the results of an editing assay comparing gRNA scaffolds 229-237 to scaffold 174 in mouse neural progenitor cells (mNPCs) isolated from Ai9-tdtomato transgenic mice, as described in Example 21. Cells were nucleofected with the indicated doses of p59 plasmid encoding CasX491, the scaffold, and spacer 11.30 (5'AAGGGGCUCCGCACCACGCC3', SEQ ID NO: 17) targeting mRHO. Editing at the mRHO locus was assessed by next-generation sequencing (NGS) 5 days after transfection, and shows that editing with constructs carrying scaffolds 230, 231, 234, and 235 demonstrated greater editing compared to the construct carrying scaffold 174 at both doses. [Figure 15] Figure 2 shows the results of an editing assay comparing gRNA scaffolds 229-237 and scaffold 174 in mNPC cells, as described in Example 21. Cells were nucleofected with the indicated doses of p59 plasmids encoding CasX491, the scaffold, and spacer 12.7 (5'CUGCAUUCUAGUUGUGGUUU 3', SEQ ID NO: 1146), which targets a repeat element that prevents expression of the tdTomato fluorescent protein. Five days after transfection, editing was assessed by FACS to quantify the percentage of tdTomato-positive cells. Cells nucleofected with scaffolds 231-235 showed approximately 35% greater editing at the high dose and approximately 25% greater editing at the low dose compared to the construct with scaffold 174. [Figure 16]
[0023] Figure 1 shows an exemplary method for generating CasX protein and guide RNA variants of the present disclosure using Deep Mutational Evolution (DME). In some exemplary embodiments, DME constructs and tests nearly all possible mutations, insertions, and deletions in biomolecules and combinations / multiples thereof, providing a nearly comprehensive and unbiased assessment of the biomolecular fitness landscape and paths in sequence space toward a desired outcome. As described herein, DME can be applied to both CasX proteins and guide RNAs. [Figure 17A] FIG. 1 shows the cryoEM structure of the Deltaproteobacteria CasX protein:sgRNA RNP complex (PDB ID: 6YN2), which contains two stem-loops, a pseudoknot, and a triplex, as described in Example 13. [Figure 17B] The secondary structure of the sgRNA of SEQ ID NO: 4, identified from the structure shown in (A), is shown using the tool RNAPDBee2.0 (rnapdbee.cs.put.poznan.pl / , the tool 3DNAS / DSSR, and the VARNA visualization tool). The RNA region is indicated. Residues that were not evident in the PDB crystal structure file are indicated by plain text letters (i.e., not circled) and are not included in the residue numbering. [Figure 18] FIG. 1 is a schematic diagram of regions and domains of guide RNAs used to design scaffold libraries, as described in Example 13. [Figure 19] FIG. 11 is a pie chart of the relative distribution and design of scaffold libraries with both unbiased mutations (double and single mutations) and targeted mutations (to triplexes, scaffold stem bubbles, pseudoknots, and extended stems and loops) as shown, as described in Example 13. [Figure 20]
[0039] Figure 1 is a schematic diagram of triplex mutagenesis designed to specifically incorporate alternating triplex-forming base pairs into triplexes, as described in Example 13. Solid lines indicate Watson-Crick pairs in the triplex. Nucleotides in the third strand are shown as dotted lines, representing non-canonical interactions with purines in the duplex. In the library, each of the five positions shown was substituted with all possible triplex motifs (G: GC, T: AT, G: GC) = 243 sequences. The sequence is ACUGGCGCUUUUAUCUGAUUACUUUGAGAGCCAUCANNNAUCAAAG (SEQ ID NO: 1022). [Figure 21] 10 is a bar graph with the results of the enrichment values of reference guide scaffolds 174 and 175 in each screen, as described in Example 13. [Figure 22]FIG. 10 is a scatter plot showing the log enrichment values for each measured single nucleotide substitution, deletion, or insertion measured in each of two independent screens of mutant libraries for guide scaffolds 174 and 175, as described in Example 13. [Figure 23] 1 is a heat map for single mutants in guide scaffolds 174 and 175, showing specific mutable regions in the scaffolds across the sequence, as described in Example 13. Yellow shading reflects values with similar enrichment to the reference scaffold. Red shading indicates increased enrichment (and therefore activity) compared to the reference scaffold. Blue shading indicates loss of activity compared to the wild-type scaffold. White indicates missing data (or substitutions resulting in the wild-type sequence). [Figure 24] Scatter plot comparing the log2 enrichment of single nucleotide mutations on reference guide scaffolds 174 and 175, as described in Example 13. Only mutations to similar positions between 174 and 175 are shown. The results suggest that, overall, guide scaffold 174 is more tolerant of change than 175. [Figure 25] FIG. 1 is a bar graph showing the mean (and 95% confidence interval) log enrichment values for a set of scaffolds in which pseudoknot pairs were shuffled so that each new pseudoknot had the same composition of base pairs but a different order within the stem, as described in Example 13. Each bar represents a set of scaffolds with the indicated G:A (or A:G) pair positions (see diagram on the right). 291 pseudoknot stems were tested. The numbers above the bars indicate the number of stems with a G:A (or A:G) pair at each position. [Figure 26] 57 is a schematic diagram of the pseudoknot sequences of Figures 55 and 56 (given 5' to 3'), with the two strand sequences separated by an underline. [Figure 27]1 is a bar graph showing the mean (and 95% confidence interval) log enrichment values for scaffolds separated by the predicted secondary structure stability of the pseudoknot stem region, as described in Example 13. Scaffolds with highly stable stems (e.g., ΔG<−7 kcal / mol) had high enrichment values on average, while scaffolds with destabilized stems (ΔG≧−5 kcal / mol) had low enrichment values on average. [Figure 28] Heat map of all double mutants at positions 7 and 29 in scaffold 175, as described in Example 13. The pseudoknot sequence is given on the right, 5' to 3'. [Figure 29A] 1 shows editing results in ARPE-19 nucleofected cells using engineered guide 235 compared to 174 with an 11.1 spacer (with CasX491) targeting the P23 site of the Rho locus, demonstrating improved activity with the 235 variant, with increased on-target activity at WT exogenous RHO without off-target cleavage (due to the non-targeted spacer) in the mutant RHO reporter gene, as described in Example 21. [Figure 29B] 10 is a bar graph showing the fold change in editing levels of p59.491.235.11.1 normalized to benchmark p59.491.174.11.1 levels (set to a value of 1.0) in ARPE-1 cells nucleofected with 1000 ng of each plasmid, as described in Example 21. [Figure 30]Figure 1 shows the results of an editing assay comparing Cas nucleases 2, 119, 491, 515, 527, 528, 529, 530, and 531 in the custom HEK293 cell line PASS_V1.01, as described in Example 17. Cells were lipofected with 2 μg of p67 plasmid encoding the indicated Cas proteins. Five days later, cellular genomic DNA was extracted. PCR amplification and next-generation sequencing were performed to isolate and quantify the fraction of cells edited at the custom-designed on-target editing sites. For each sample, editing was assessed at target sites (individual dots) consisting of the following PAM sequences: 48 TTC, 14 ATC, 22 CTC, and 11 GTC individual sites, and the percentage of editing was normalized to the vehicle control. Cells lipofected with any nuclease showed higher average editing at the TTC PAM target site (horizontal bar) than that of the wild-type nuclease Cas2, except for Cas528. The relative preference of any given nuclease for four different PAM sequences is also depicted in a violin plot. Notably, Cas nucleases 527, 528, and 529 exhibit PAM preferences that differ substantially from that of the wild-type nuclease, Cas2. [Figure 31]This figure shows the results of an editing assay comparing improved Cas nuclease 491 with improved nucleases 532 and 533 in the custom HEK293 cell line PASS_V1.01, as described in Example 18. Cells were lipofected in duplicate with 2 μg of p67 plasmid encoding the indicated Cas proteins and a puromycin resistance gene and grown under puromycin selection. After 3 days, cellular genomic DNA was extracted. PCR amplification and next-generation sequencing were performed to isolate and quantify the fraction of cells edited at the custom-designed on-target editing sites. For each sample, editing was assessed at target sites consisting of the following PAM sequences: 48 TTC, 14 ATC, 22 CTC, and 11 GTC individual sites, and the percentage of editing was normalized to the vehicle control. Cells lipofected with CasX532 or 533 showed higher average editing than Cas491 at each of the PAM sequences in the TTC PAM target site, with the exception of CasX533. Error bars represent the standard error of the mean for n=2 biological samples. [Figure 32] 10 is a graph of a survival assay to determine the selective stringency of CcdB selection against different spacers when targeted by CasX protein 515 and scaffold 174, as described in Example 14. [Figure 33A] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the TTC PAM target site, as an average of three spacers, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 33B] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the TTC PAM target site, as an average of three spacers, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 33C]1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the TTC PAM target site, as an average of three spacers, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 33D] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the TTC PAM target site, as an average of three spacers, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 33E] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the TTC PAM target site, as an average of three spacers, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 34A] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates demonstrating biochemical cleavage at a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 34B] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates demonstrating biochemical cleavage at a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 34C]1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates demonstrating biochemical cleavage at a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 34D] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates demonstrating biochemical cleavage at a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 34E] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates demonstrating biochemical cleavage at a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 35A] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 35B] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 35C]1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 35D] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 35E] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the CTC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 36A] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the ATC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 36B] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the ATC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 36C] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the ATC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 36D]1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the ATC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 36E] 1 is a heat map of CasX515 variants demonstrating neutral or improved biochemical cleavage for each mutant at the ATC PAM target site as an average of three biological replicates in a single spacer, as described in Example 14. The figure shows results across the entire length of the CasX515 sequence. [Figure 37A] 10 is a graph showing the effect of spacer length on the ability to edit a target nucleic acid with RNPs in Jurkat cells, as described in Example 15, for spacer 15.3. [Figure 37B] 10 is a graph showing the effect of spacer length on the ability to edit a target nucleic acid using RNPs in Jurkat cells, as described in Example 15, for spacer 15.5. [Figure 38] 1 is a bar graph of selected CasX variant proteins and their editing efficiencies at four different PAM sequences (TTC, ATC, CTC, and GTC) for replicate samples, as described in Example 16. Data are shown as percent editing + / - standard deviation. [Figure 39] 1 is a bar graph showing the average editing efficiency of selected CasX nucleases compared to CasX491 at 48 different TTC PAM target sites, as described in Example 19. The propagated standard error of the mean of two experiments is plotted as an error bar. An asterisk indicates a significant difference between CasX527 and CasX491 (p=0.0000635 by Welch's two-tailed t-test). [Figure 40]FIG. 1 is a diagram based on the published cryoEM structure of the homologous reference CasX1 (SEQ ID NO: 1; Protein Data Bank Identification Number: 6NY2) showing the physical locations of the target DNA PAM sequence, the PAM interaction loop, the NTSB domain, and amino acid position 26, as described in Example 19. [Figure 41] 10 is a violin plot of selected CasX variant proteins and their editing efficiencies at 48 TTC PAM target sites, as described in Example 19. [Figure 42] Figure 10 is a bar graph of selected CasX variant proteins and their editing efficiencies compared to CasX491 at 48 TTC PAM target sites, as described in Example 19. Data are presented as the average relative editing efficiency, with CasX491 editing equal to 1.0. The gray dashed line indicates the editing efficiency of CasX119. For replicate samples, errors are + / - propagated SEM. [Figure 43] 1 is a bar graph showing the average editing efficiency as well as the average specificity ratio of selected CasX nucleases compared to CasX491, as described in Example 20. [Figure 44] FIG. 1 is a flow chart showing the qualitative relationship between the mutation combinations tested and their effect on both the activity and specificity of the resulting CasX variants, as described in Example 21. [Figure 45A] 1 shows the results of an AAV-mediated editing assay comparing gRNA scaffold 235 and scaffold 174, and guides 11.30 and 11.31 at the endogenous mouse Rho exon 1 locus in mNPCs across a range of MOIs, as described in Example 21. [Figure 45B] Figure 2 shows editing results as fold change in editing levels for scaffold 235 compared to guide 174 with spacer 11.30 (set to 1.0) in cells infected at 5.0e+5 MOI, as described in Example 21. [Figure 46]Schematic diagram showing the modifications made in the extended stem-loop in gRNA variant 175 incorporated into gRNA variant 235. Extended stem-loop of sgRNA175: SEQ ID NO: 1285, extended stem-loop of sgRNA325: SEQ ID NO: 1286. [Figure 47] Schematic diagram of gRNA variant 235, showing modifications in the triplex, scaffold stem bubble, and extended stem loop compared to gRNA variants 174 and 175. Pseudoknot and triplex loop: SEQ ID NO: 1287, scaffold stem and extended stem: SEQ ID NO: 1288. [Figure 48] FIG. 1 is a schematic diagram showing the positions of the bases within the MS2 hairpin, as described in Example 23. MS2 sequence in the diagram: SEQ ID NO: 1289. [Figure 49] Figure 10 is a graph of percent editing at the tdTomato locus as measured by tdTomato fluorescence for XDPs packaged with the indicated scaffold variants, with gRNA scaffolds 188 and 251 serving as base variants, as described in Example 23. Two MS2 versions (MS2 353 and MS2 WT) were used. [Figure 50] Figure 1 shows the improvement in EC50 values determined using NanoSight for editing at the tdTomato locus in NPCs compared to potency (scaffolds 188 and 251 served as basal controls) for XDPs packaged with the indicated gRNA scaffold variants, as described in Example 23. Two MS2 versions, MS2 353 and MS2 wild type (WT), were used. [Figure 51] FIG. 1 shows the correlation between MS2 hairpin affinity (KD) and EC50 for XDP packaged with the indicated gRNA scaffold variants, as described in Example 23. [Figure 52] FIG. 10 shows the correlation between MS2 hairpin affinity (KD) and potency for XDP packaged with the indicated gRNA scaffold variants, as described in Example 23. DETAILED DESCRIPTION OF THE INVENTION
[0018] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention, and that methods and structures within the scope of these claims and their equivalents be covered thereby.
[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present embodiments, suitable methods and materials are described below. In case of conflict, the present patent specification, including definitions, will control. Additionally, the materials, methods, and examples are illustrative only and are not intended to be limiting. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention.
[0020] definition The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the terms "polynucleotide" and "nucleic acid" encompass single-stranded DNA, double-stranded DNA, multi-stranded DNA, single-stranded RNA, double-stranded RNA, multi-stranded RNA, genomic DNA, cDNA, DNA-RNA hybrids, and polymers that contain purine and pyrimidine bases or other naturally occurring, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.
[0021] "Hybridizable" or "complementary" are used interchangeably and mean comprising a sequence of nucleotides that allows a nucleic acid (e.g., RNA, DNA) to non-covalently bind (i.e., form Watson-Crick base pairs and / or G / U base pairs), "anneal," or "hybridize" (i.e., a nucleic acid specifically binds to a complementary nucleic acid) to another nucleic acid in a sequence-specific antiparallel manner under appropriate in vitro and / or in vivo conditions of temperature and solution ionic strength. It is understood that the sequence of a polynucleotide need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. It can have at least about 70%, at least about 80%, or at least about 90%, or at least about 95% sequence identity and still hybridize to a target nucleic acid sequence. Furthermore, a polynucleotide can hybridize over one or more segments without intervening or adjacent segments participating in the hybridization event (e.g., a loop or hairpin structure, a "bulge," a "bubble," etc.).
[0022] For purposes of this disclosure, a "gene" includes a DNA region that encodes a gene product (e.g., protein, RNA), as well as all DNA regions that regulate the production of the gene product, regardless of whether such regulatory sequences are adjacent to the coding and / or transcribed sequence. Thus, a gene can include accessory elements, including, but not necessarily limited to, promoter sequences, terminators, translational regulatory sequences (e.g., ribosome binding sites and internal ribosome entry sites), enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and locus control regions. A coding sequence encodes a gene product upon transcription or transcription and translation. A coding sequence of this disclosure may include a fragment of an open reading frame and need not include the entire length. A gene can include both the transcribed strand and the complementary strand, including the anticodon.
[0023] The term "downstream" refers to a nucleotide sequence located 3' of a reference nucleotide sequence. In certain embodiments, the downstream nucleotide sequence relates to the sequence following the start of transcription. For example, the translation start codon of a gene is located downstream of the transcription start site.
[0024] The term "upstream" refers to a nucleotide sequence located 5' to a reference nucleotide sequence. In certain embodiments, an upstream nucleotide sequence relates to a coding region or a sequence located 5' to the transcription start site. For example, most promoters are located upstream of the transcription start site.
[0025] The term "adjacent to," with respect to a polynucleotide or amino acid sequence, refers to sequences that are next to or adjacent to each other in a polynucleotide or polypeptide. One of skill in the art will understand that two sequences can be considered adjacent to each other and still encompass a limited amount of intervening sequence, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or amino acids.
[0026] The term "accessory element" is used interchangeably herein with the term "accessory sequence" and is intended to include, inter alia, polyadenylation signals (poly(A) signals), enhancer elements, introns, posttranscriptional regulatory elements (PTREs), nuclear localization signals (NLSs), deaminases, DNA glycosylase inhibitors, additional promoters, factors that stimulate CRISPR-mediated homology-directed repair (e.g., in cis or trans), transcriptional activators or repressors, self-cleaving sequences, and fusion domains (e.g., fusion domains fused to a CRISPR protein). It is understood that the selection of the appropriate accessory element or elements will depend on the encoded component (e.g., protein or RNA) to be expressed, or whether the nucleic acid contains multiple components that require different polymerases or is not intended to be expressed as a fusion protein.
[0027] The term "promoter" refers to a DNA sequence that contains a transcription initiation site and additional sequences to facilitate polymerase binding and transcription. Exemplary eukaryotic promoters include elements such as a TATA box and / or a B recognition element (BRE), which aid or enhance the transcription and expression of an associated transcribable polynucleotide sequence and / or gene (or transgene). Promoters can be produced synthetically or derived from known or naturally occurring promoter sequences or from another promoter sequence. Promoters can be proximal or distal to the gene being transcribed. Promoters can also include chimeric promoters, which contain a combination of two or more heterologous sequences to confer specific properties. Promoters of the present disclosure can include variants of promoter sequences that are similar in composition but not identical to other promoter sequences known or provided herein. Promoters can be classified according to criteria related to the expression pattern of the associated coding or transcribable sequence or gene operably linked to the promoter (e.g., constitutive, developmental, tissue-specific, inducible, etc.). Promoters can also be classified according to their strength. When used in the context of a promoter, "strength" refers to the rate of transcription of the gene controlled by the promoter. A "strong" promoter means a high rate of transcription, and a "weak" promoter means a relatively slow rate of transcription.
[0028] The promoter of the present disclosure may be a polymerase II (Pol II) promoter. Polymerase II transcribes all protein-coding and many non-coding genes. A typical Pol II promoter contains a core promoter, a sequence of approximately 100 base pairs surrounding the transcription start site, which serves as a binding platform for Pol II polymerase and associated general transcription factors. A promoter may contain one or more core promoter elements (e.g., a TATA box, a BRE, an initiator (INR), a motif ten element (MTE), a downstream core promoter element (DPE), or a downstream core element (DCE)), although core promoters lacking these elements are known in the art.
[0029] The promoter of the present disclosure can be a polymerase III (Pol III) promoter. Pol III transcribes DNA to synthesize small ribosomal RNAs, such as 5S rRNA, tRNA, and other small RNAs. Typical Pol III promoters use internal regulatory sequences (sequences within the transcribed portion of a gene) to support transcription, although upstream elements, such as a TATA box, may also be used. All Pol III promoters are contemplated within the scope of the present disclosure.
[0030] The term "enhancer" refers to a regulatory DNA sequence that regulates the expression of an associated gene when specific proteins called transcription factors bind to it. Enhancers can be located in the introns of a gene or 5' or 3' of the coding sequence of a gene. Enhancers can be proximal to the gene (i.e., within tens or hundreds of base pairs (bp) of the promoter) or distal to the gene (i.e., thousands, hundreds of thousands, or even millions of bp away from the promoter). A single gene can be regulated by more than one enhancer, all of which are contemplated within the scope of this disclosure.
[0031] As used herein, a "post-transcriptional regulatory element (PRE)" (e.g., a hepatitis PRE) refers to a DNA sequence that, when transcribed, generates a tertiary structure that can exhibit post-transcriptional activity that enhances or promotes expression of an associated gene operably linked to it.
[0032] As used herein, "post-transcriptional regulatory element (PTRE)" (e.g., hepatitis PTRE) refers to a DNA sequence that, when transcribed, generates a tertiary structure that can exhibit post-transcriptional activity that enhances or promotes expression of an associated gene operably linked to it.
[0033] As used herein, "recombinant" means that a particular nucleic acid (DNA or RNA) is the product of various combinations of cloning, restriction, and / or ligation steps, resulting in a construct having structural coding or non-coding sequences distinguishable from the endogenous nucleic acid found in natural systems. Generally, DNA sequences encoding structural coding sequences can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of synthetic oligonucleotides, to provide a synthetic nucleic acid that can be expressed from a recombinant transcription unit contained in a cell or a cell-free transcription and translation system. Such sequences can be provided in the form of an open reading frame uninterrupted by internal untranslated sequences, or introns, typically present in eukaryotic genes. Genomic DNA containing the relevant sequence can also be used in forming recombinant genes or transcription units. Sequences of untranslated DNA can be present 5' or 3' from the open reading frame, where such sequences do not interfere with the manipulation or expression of the coding region and may, in fact, act to regulate production of the desired product by various mechanisms (see "enhancer" and "promoter" above).
[0034] The term "recombinant polynucleotide" or "recombinant nucleic acid" refers to something that does not occur in nature, e.g., something that is created through human intervention, by the artificial combination of two otherwise isolated segments of sequence. This artificial combination is often accomplished either by chemical synthesis means or by the artificial manipulation of isolated segments of nucleic acid (e.g., genetic engineering techniques). This can typically be done to replace codons with redundant codons that encode the same or a conservative amino acid, while introducing or removing sequence recognition sites. Alternatively, it can be done by ligating nucleic acid segments of desired functions together to produce a desired combination of functions. This artificial combination is often accomplished either by chemical synthesis means or by the artificial manipulation of isolated segments of nucleic acid (e.g., genetic engineering techniques).
[0035] Similarly, the term "recombinant polypeptide" or "recombinant protein" refers to a polypeptide or protein that does not occur in nature, e.g., one that is created through human intervention by the artificial combination of two otherwise separate segments of amino acid sequence. Thus, for example, a protein that includes a heterologous amino acid sequence is recombinant.
[0036] As used herein, the term "contacting" refers to establishing a physical connection between two or more entities. For example, contacting a target nucleic acid with a guide nucleic acid means that the target nucleic acid and the guide nucleic acid are made to share a physical connection (e.g., can hybridize if their sequences share sequence similarity).
[0037] "Dissociation constant" or "K d " are used interchangeably and refer to the affinity between a ligand "L" and a protein "P" (i.e., how tightly a ligand binds to a particular protein). The dissociation constant is given by the formula K d = [L][P] / [LP], where [P], [L], and [LP] represent the molar concentrations of the protein, ligand, and complex, respectively.
[0038] The present disclosure provides systems and methods useful for editing a target nucleic acid sequence. As used herein, "editing" is used interchangeably with "modification" and includes, but is not limited to, truncation, nicking, deletion, knock-in, knock-out, etc.
[0039] "Cleavage" refers to the disruption of the covalent backbone of a target nucleic acid molecule (e.g., RNA, DNA). Cleavage can be initiated by a variety of methods, including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-strand and double-strand breaks are possible, and double-strand breaks can occur as a result of two separate single-strand break events.
[0040] The term "knockout" refers to the elimination of a gene or the expression of a gene. For example, a gene can be knocked out by either deleting or adding a nucleotide sequence that results in a disruption of the reading frame. As another example, a gene can be knocked out by replacing a portion of the gene with an unrelated sequence. The term "knockdown," as used herein, refers to the reduction of the expression of a gene or its gene product. As a result of gene knockdown, protein activity or function can be attenuated, or protein levels can be reduced or eliminated.
[0041] As used herein, "homology-directed repair" (HDR) refers to a form of DNA repair that occurs during repair of double-strand breaks in cells. This process requires nucleotide sequence homology and uses a donor template to repair or knock out target DNA, resulting in the transfer of genetic information from the donor to the target. Homology-directed repair can result in sequence alterations of the target sequence through insertions, deletions, or mutations when the donor template differs from the target DNA sequence and some or all of the donor template's sequence is incorporated into the target DNA.
[0042] As used herein, "non-homologous end joining" (NHEJ) refers to the repair of a double-strand break in DNA by direct ligation of the broken ends to each other without the need for a homologous template (as opposed to homology-mediated repair, which requires homologous sequences to guide the repair). NHEJ often results in the loss (deletion) of nucleotide sequences near the double-strand break site.
[0043] As used herein, "microhomology-mediated end joining" (MMEJ) refers to a mutagenic DSB repair mechanism that does not require a homologous template (as opposed to homologous recombination repair, which requires a homologous sequence to guide repair) and is always associated with a deletion adjacent to the break site. MMEJ often results in the loss (deletion) of nucleotide sequences near the double-strand break site. A polynucleotide or polypeptide has a certain percent "sequence similarity" or "sequence identity" with another polynucleotide or polypeptide, which refers to the percentage of identical bases or amino acids in the same relative positions when two sequences are compared (aligned). Sequence similarity (also referred to as percent similarity, percent identity, or homology) can be determined in several different ways. To determine sequence similarity, sequences can be aligned using methods and computer programs known in the art, including BLAST, available on the World Wide Web at ncbi.nlm.nih.gov / BLAST. The percent complementarity between specific stretches of nucleic acid sequence within a nucleic acid can be determined using any convenient method. Exemplary methods include the BLAST program (Basic Local Alignment Search Tool) and PowerBLAST program (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656) (or by using the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), e.g., using default settings using the Smith and Waterman algorithm (Adv. Appl. Math., 1981, 2, 482-489)).
[0044] The terms "polypeptide" and "protein" are used interchangeably herein to refer to polymeric forms of amino acids of any length, which may include coded and non-coded amino acids, amino acids that have been chemically or biochemically modified or derivatized, and polypeptides with modified peptide backbones. This term encompasses fusion proteins, including, but not limited to, fusion proteins with heterologous amino acid sequences.
[0045] A "vector" or "expression vector" is a replicon, such as a plasmid, phage, virus, or cosmid, to which another DNA segment (i.e., an "insert") may be attached, so as to bring about the replication or expression of the attached segment in a cell.
[0046] As used herein, the terms "naturally occurring" or "unmodified" or "wild-type" when applied to a nucleic acid, polypeptide, cell, or organism, refer to a nucleic acid, polypeptide, cell, or organism that is found in nature.
[0047] As used herein, a "mutation" refers to an insertion, deletion, substitution, duplication, or inversion of one or more amino acids or nucleotides compared to a wild-type or reference amino acid sequence, or compared to a wild-type or reference nucleotide sequence.
[0048] As used herein, the term "isolated" is meant to refer to a polynucleotide, polypeptide, or cell that is in an environment that is different from the environment that the polynucleotide, polypeptide, or cell naturally occurs in. An isolated genetically modified host cell may be present in a mixed population of genetically modified host cells.
[0049] As used herein, a "host cell" means a eukaryotic cell, a prokaryotic cell, or a cell (e.g., a cell line) derived from a multicellular organism, and includes the progeny of the original cell that has been used as a recipient of a nucleic acid (e.g., an expression vector) and that has been genetically modified by the nucleic acid. It is understood that the progeny of a single cell may not necessarily be completely identical in morphology or in genomic or total DNA complement to the original parent due to natural, accidental, or deliberate mutation. A "recombinant host cell" (also called a "genetically modified host cell") is a host cell into which a heterologous nucleic acid (e.g., an expression vector) has been introduced.
[0050] As used herein, the term "tropism" refers to the preferential entry of a virus-like particle (XDP, sometimes referred to herein as XDP) into a particular cell or tissue type, and / or preferential interaction with the cell surface that facilitates entry into a particular cell or tissue type, optionally and preferably followed by expression (e.g., transcription and optionally translation) of sequences carried into the cell by the XDP.
[0051] As used herein, the term "pseudotype" or "pseudotyping" refers to a viral envelope protein being replaced with an envelope protein of another virus having favorable characteristics. For example, HIV can be pseudotyped with the vesicular stomatitis virus G protein (VSV-G) envelope protein (described herein below, among others), which allows HIV to infect a wider range of cells because the HIV envelope protein targets the virus primarily to CD4+ presenting cells.
[0052] As used herein, the term "tropism factor" refers to a moiety incorporated into the surface of an XDP that confers tropism for a particular cell or tissue type. Non-limiting examples of tropism factors include glycoproteins, antibody fragments (e.g., scFvs, nanobodies, linear antibodies, etc.), receptors, and ligands for target cell markers.
[0053] "Target cell marker" refers to a molecule expressed by a target cell, including, but not limited to, a cell surface receptor, cytokine receptor, antigen, tumor-associated antigen, glycoprotein, oligonucleotide, enzyme substrate, antigenic determinant, or binding site (which may be present on the surface of a target tissue or cell that can function as a ligand for an antibody fragment or glycoprotein tropism factor).
[0054] The term "conservative amino acid substitution" refers to the interchangeability of amino acid residues in proteins that have similar side chains. For example, the group of amino acids with aliphatic side chains consists of glycine, alanine, valine, leucine, and isoleucine; the group of amino acids with aliphatic hydroxyl side chains consists of serine and threonine; the group of amino acids with amide-containing side chains consists of asparagine and glutamine; the group of amino acids with aromatic side chains consists of phenylalanine, tyrosine, and tryptophan; the group of amino acids with basic side chains consists of lysine, arginine, and histidine; and the group of amino acids with sulfur-containing side chains consists of cysteine and methionine. Exemplary conservative amino acid substitution groups are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
[0055] The term "antibody" as used herein encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), nanobodies, single domain antibodies (e.g., VHH antibodies), and antibody fragments (as long as they exhibit the desired antigen-binding or immunological activity). Antibodies represent a large family of molecules that includes several types of molecules, such as IgD, IgG, IgA, IgM, and IgE.
[0056] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab'), diabodies, single-chain diabodies, linear antibodies, single-domain antibodies, single-domain camelid antibodies, single-chain variable fragment (scFv) antibody molecules, and multispecific antibodies (formed from antibody fragments).
[0057] As used herein, "treatment" or "treating" are used interchangeably herein and refer to an approach for obtaining a beneficial or desired result, including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. Therapeutic benefit refers to the eradication or amelioration of the underlying disorder or disease being treated. Therapeutic benefit can also be achieved by the eradication or amelioration of one or more symptoms associated with the underlying disease, or the improvement of one or more clinical parameters, such that an improvement is observed in a subject, even though the subject may still be afflicted with the underlying disease.
[0058] The terms "therapeutically effective amount" and "therapeutically effective dose," as used herein, refer to an amount of a drug or biologic, alone or as part of a composition, that, when administered in single or repeated doses to a subject (e.g., a human or experimental animal), can have any detectable beneficial effect on any symptom, aspect, measured parameter, or characteristic of a disease state or condition. Such effect need not be absolute to be beneficial.
[0059] As used herein, "administering" refers to the method of providing a dosage of a compound (e.g., a composition of the present disclosure) or composition (e.g., a pharmaceutical composition) to a subject.
[0060] A "subject" is a mammal, including, but not limited to, domestic animals, non-human primates, humans, dogs, rabbits, mice, rats, and other rodents.
[0061] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0062] I. General Methods The practice of the present invention will employ, unless otherwise indicated, prior art techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, including those described in standard textbooks such as Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., Harbor Laboratory Press 2001); Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999); Protein Methods (Bollag et al., John Wiley & Sons 1996); Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy eds., Academic Press 1995), Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997); and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998), the disclosures of which are incorporated herein by reference.
[0063] When a range of values is provided, it is understood that the endpoints are included, and that each intervening value between the upper and lower limit of that range, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, includes any other stated or intervening value in that stated range. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also included subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.
[0064] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials for which the publications are cited.
[0065] Please note that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include their plural referents unless the context clearly dictates otherwise.
[0066] It will be understood that certain features of the present disclosure that are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. In other cases, for brevity, various features of the present disclosure that are described in the context of a single embodiment may also be provided separately or in any suitable subcombination. All combinations of the embodiments related to the present disclosure are specifically embraced by the present disclosure and are intended to be disclosed herein as if each and every combination were individually and explicitly disclosed herein. In addition, all subcombinations of the various embodiments and elements thereof are also specifically embraced by the present disclosure and are intended to be disclosed herein as if each and every such subcombination were individually and explicitly disclosed herein.
[0067] II. Systems for Gene Editing and Gene Editing Pairs In a first aspect, the present disclosure provides a system, comprising a Class 2, Type V CRISPR nuclease protein and one or more guide nucleic acids (e.g., gRNAs) for use in modifying or editing a target nucleic acid (including coding and non-coding regions) of a gene. Generally, any portion of a gene can be targeted using the programmable systems and methods provided herein. As used herein, "system," such as a system comprising a CRISPR nuclease protein and one or more gRNAs of the present disclosure as a gene editing pair, a nucleic acid encoding the CRISPR nuclease protein and gRNA, and a vector comprising a nucleic acid or CRISPR nuclease protein and one or more gRNAs of the present disclosure, is used interchangeably with the term "composition."
[0068] In some embodiments, the present disclosure provides a system specifically designed to modify a target nucleic acid of a gene in a eukaryotic cell, either in vitro, ex vivo, or in vivo in a subject. Generally, any portion of a gene can be targeted using the programmable systems and methods provided herein. In some embodiments, the CRISPR nuclease is a class 2, type V nuclease. While there are differences among members of class 2 type V CRISPR-Cas nucleases, they share several common features that distinguish them from the Cas9 system. First, type V nucleases have an RNA-guided single effector containing a RuvC domain but no HNH domain, and recognize a PAM in a TC motif 5' upstream of the target region on the non-target strand. This differs from the Cas9 system, which relies on a G-rich PAM 3' to the target sequence. Unlike Cas9, which generates a blunt end at a proximal site close to the PAM, type V nucleases generate a double-strand break distal to the PAM sequence. Additionally, type V nucleases degrade ssDNA in trans when activated by target dsDNA or ssDNA binding in cis. In some embodiments, the present disclosure provides a class 2, type V nuclease selected from the group consisting of Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cas12k, C2c4, C2c8, C2c5, C2c10, C2c9, CasZ, and CasX. In some embodiments, the present disclosure provides a system comprising one or more CasX variant proteins and one or more guide nucleic acid (gRNA) variants as a CasX:gRNA system.
[0069] Provided herein is a system comprising a Class 2, Type V protein and a gRNA variant, referred to herein as a gene editing pair. In some embodiments, the Class 2, Type V variant is a CasX variant (e.g., but not limited to, the sequence of SEQ ID NO: 416). The terms CasX variant protein and CasX variant are used interchangeably herein. In some embodiments, the gRNA is a variant of another gRNA (e.g., but not limited to, the sequences of SEQ ID NOs: 2238 and 2239). The gRNA and CasX protein can bind together through non-covalent interactions to form a gene editing pair complex (referred to herein as a ribonucleoprotein (RNP) complex). In some embodiments, the use of a pre-complexed CasX:gRNA RNP confers advantages in the delivery of system components to a cell or target nucleic acid for editing of the target nucleic acid. In the RNP, the gRNA can provide target specificity to the RNP complex by including a targeting sequence (or "spacer") having a nucleotide sequence complementary to the sequence of the target nucleic acid sequence. In the RNP, the CasX protein of the pre-complexed CasX:gRNA provides specific activity and is directed to (e.g., further stabilized at) the target site within the target nucleic acid sequence to be modified by its association with the gRNA. The CasX variant protein of the RNP complex provides the site-specific activity of the complex, such as binding, cleaving, or nicking of the target sequence by the CasX protein. Provided herein are systems and cells comprising the CasX variant protein, gRNA variant, and CasX:gRNA gene editing pair of any combination of CasX variant and gRNA variant of the embodiments described herein, as well as a delivery modality comprising the CasX:gRNA. Each of these components and their use in editing genetic target nucleic acids is described herein below.
[0070] In some embodiments, the present disclosure provides a system of gene editing pairs comprising a CasX variant protein selected from any one of the CasX variant proteins in Table 3 (SEQ ID NOs: 247-592 and 1147-1231, or a sequence having at least about 85%, at least about 90%, or at least about 95%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto), while the gRNA is a gene editing protein selected from any one of the CasX variant proteins described herein. gRNA variants (e.g., SEQ ID NOS: 2101-2332 and 2353-2398 shown in Table 2), or sequence variants having at least 60%, or at least 70%, or at least about 80%, or at least about 90%, or at least about 95% sequence identity thereto, wherein the gRNA comprises a targeting sequence complementary to a target nucleic acid. In some embodiments, the present disclosure includes a CasX variant protein selected from any one of the CasX variant proteins in Table 3 (SEQ ID NOS: 270-592 and 1147-1231).
[0013] Provided are gene editing paired systems, wherein the gRNA is a gRNA variant described herein (e.g., SEQ ID NOS: 2238-2332 and 2353-2398), and wherein the gRNA comprises a targeting sequence complementary to a target nucleic acid. In some embodiments, the present disclosure provides gene editing paired systems comprising a CasX variant protein selected from any one of the CasX variant proteins in Table 3 (SEQ ID NOS: 415-592 and 1147-1231), wherein the gRNA is a gRNA variant described herein (e.g., SEQ ID NOS: Nos. 2281-2332 and 2353-2398), wherein the gRNA comprises a targeting sequence complementary to the target nucleic acid. In other embodiments, the present disclosure provides a gene editing pair system comprising a CasX variant protein, a first gRNA variant described herein having a targeting sequence (e.g., SEQ ID NOS: 2101-2332 or 2353-2398 shown in Table 2), and a second gRNA variant, wherein the second gRNA variant has a targeting sequence complementary to a different or overlapping portion of the target nucleic acid compared to the targeting sequence of the first gRNA.In other embodiments, the present disclosure provides a gene editing pair system comprising a CasX variant protein, a first gRNA variant described herein having a targeting sequence (e.g., SEQ ID NOs: 2101-2332 or 2353-2398), and a second gRNA variant, wherein the second gRNA variant has a targeting sequence that is complementary to a different or overlapping portion of the target nucleic acid compared to the targeting sequence of the first gRNA. In other embodiments, the present disclosure provides a gene editing pair system comprising a CasX variant protein, a first gRNA variant described herein having a targeting sequence (e.g., SEQ ID NOs: 2281-2332 or 2353-2398), and a second gRNA variant, wherein the second gRNA variant has a targeting sequence that is complementary to a different or overlapping portion of the target nucleic acid compared to the targeting sequence of the first gRNA. In some embodiments of the CasX:gRNA gene editing pairs of the present disclosure, the CasX variant protein is selected from the group consisting of CasX variant proteins 515, 528, 529, 534-539, 668, 672, and 678 (SEQ ID NOs:416, 428, 434-439, 567, 570, and 576) in Table 3, and the sgRNA variant is selected from the group consisting of gRNA variants 229-237 (SEQ ID NOs:2286-2294) in Table 2. In certain embodiments, the gene editing pair comprises a CasX variant protein selected from any one of CasX variant proteins 668 (SEQ ID NO:567), 672 (SEQ ID NO:570), or 676 (SEQ ID NO:574), and gRNA variant 235 (SEQ ID NO:2292).
[0071] In some embodiments, the gene editing pair can associate together to form a ribonucleoprotein complex (RNP). In other embodiments, the gene editing pair is associated together in a ribonucleoprotein complex (RNP). In some embodiments, the RNP of the gene editing pair can bind to and cleave double-stranded target nucleic acid, including coding sequences, complements of coding sequences, non-coding sequences, and regulatory elements. In some embodiments, the RNP of the gene editing pair can bind to the target nucleic acid and generate one or more single-stranded nicks in the target nucleic acid. In some embodiments, the RNP of the gene editing pair can bind to the target nucleic acid but cannot cleave the target nucleic acid.
[0072] In some embodiments, the variant gene editing pair has one or more improved characteristics compared to a reference gene editing pair comprising a reference CasX protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and a reference gRNA of SEQ ID NO: 5 or SEQ ID NO: 4. In other embodiments, the variant gene editing pair of a CasX variant and a gRNA variant has one or more improved characteristics compared to a gene editing pair comprising the CasX variant from which the variant was derived (e.g., CasX515, SEQ ID NO: 416) and the gRNA variant from which the variant was derived (e.g., gRNA scaffold 174 (SEQ ID NO: 2238) or 175 (SEQ ID NO: 2239)). In the foregoing embodiments, the one or more improved characteristics can be assayed in an in vitro assay under equivalent conditions for the gene editing pair and the reference CasX and reference gRNA. As described herein, exemplary improved characteristics can, in some embodiments, include stability of the CasX:gRNA RNP complex, increased binding affinity between CasX and gRNA, improved kinetics of RNP complex formation, a higher proportion of cleavage-competent RNPs, increased RNP binding affinity for the target nucleic acid, unwinding of the target nucleic acid, increased editing activity, increased editing efficiency, increased editing specificity for the target nucleic acid, reduced off-target editing or cleavage, increased activity of a nuclease, increased target strand loading for double-stranded cleavage, reduced target strand loading for single-stranded nicking, increased binding of the non-target strand of DNA, or increased resistance to nuclease activity. In the foregoing embodiments, the improvement is at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or at least about 100,000-fold compared to the characteristics of a reference CasX protein and reference gRNA pair, or the characteristics of the CasX variant and gRNA variant from which the gene editing pair was derived.In other cases, one or more of the improved characteristics may be about 1.1-100.00 fold, about 1.1-10.00 fold, about 1.1-1,000 fold, about 1.1-500 fold, about 1.1-100 fold, about 1.1-50 fold, about 1.1-20 fold, about 10-100.00 fold, about 10-10.00 fold, about 10-1,000 fold, about 10-500 fold, about 10-100 fold, about 10-50 fold, about 10-20 fold, about 2-70 fold, about 2-50 fold, about 2-30 fold, about 2-20 fold, about 2-70 fold, about 2-50 fold, about 2-30 fold, about 2-20 fold, about 2-3 ... 10 times, about 5 to 50 times, about 5 to 30 times, about 5 to 10 times, about 100 to 100,00 times, about 100 to 10,00 times, about 100 to 1,000 times, about 100~500x, approx. 500~100,00x, approx. 500~10,00x, approx. 500~1,000x, approx. 500~750x, approx. 1,000~ The improvement may be 100,00-fold, about 10,000 to 100,00-fold, about 20 to 500-fold, about 20 to 250-fold, about 20 to 200-fold, about 20 to 100-fold, about 20 to 50-fold, about 50 to 10,000-fold, about 50 to 1,000-fold, about 50 to 500-fold, about 50 to 200-fold, or about 50 to 100-fold. In other cases, one or more of the improved characteristics may be about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 30-fold, 40-fold, 45-fold, 50-fold, or more compared to the characteristics of the reference gene editing pair or the CasX variant and gRNA variant from which the gene editing pair was derived. The improvement may be 55-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold, 150-fold, 160-fold, 170-fold, 180-fold, 190-fold, 200-fold, 210-fold, 220-fold, 230-fold, 240-fold, 250-fold, 260-fold, 270-fold, 280-fold, 290-fold, 300-fold, 310-fold, 320-fold, 330-fold, 340-fold, 350-fold, 360-fold, 370-fold, 380-fold, 390-fold, 400-fold, 425-fold, 450-fold, 475-fold, or 500-fold or more.
[0073] In some embodiments, a gene editing pair includes both a CasX variant protein and a gRNA variant described herein, and one or more characteristics of the gene editing pair are improved beyond what could be achieved by altering the CasX protein or gRNA alone. In some embodiments, the CasX variant protein and the gRNA variant act additively to improve one or more characteristics of the gene editing pair. In some embodiments, the CasX variant protein and the gRNA variant act synergistically to improve one or more characteristics of the gene editing pair. In the foregoing embodiments, the improvement is at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or at least about 100,000-fold compared to the characteristics of a reference CasX protein and reference gRNA pair, or the characteristics of the CasX variant and gRNA variant from which the gene editing pair was derived.
[0074] In some embodiments, the present disclosure provides a composition of the gene editing pair of any of the embodiments disclosed herein for use as a medicament for the treatment of a subject having a disease.
[0075] In other embodiments, the disclosed system includes one or more CasX variant proteins, one or more guide nucleic acids (gRNAs), and one or more donor template nucleic acids that include a nucleic acid encoding a portion of a gene, wherein the donor template nucleic acid includes a wild-type sequence to correct a mutation or includes a deletion, insertion, or mutation of one or more nucleotides compared to the wild-type genomic nucleic acid sequence to knock down or knock out a gene.
[0076] In other embodiments, the present disclosure provides vectors encoding or comprising CasX variants, gRNA variants, and optionally donor templates for the production and / or delivery of the CasX:gRNA system. Also provided herein are methods of making and using the CasX variant proteins and gRNA variants, including gene editing and therapeutic methods. The CasX variant protein and gRNA variant components of the CasX:gRNA system, and their characteristics, as well as delivery modes and methods of using the system, are described in more detail below.
[0077] The donor template for the CasX:gRNA system is designed depending on whether it is being used to correct a mutation in a target gene, to insert ("knock in") a transgene at a different locus in the genome, or to disrupt ("knock down" or "knock out") expression of an aberrant gene product (e.g., containing one or more mutations that reduce expression of the gene product or render the protein nonfunctional). In some embodiments, the donor template is a single-stranded DNA template or a single-stranded RNA template. In other embodiments, the donor template is a double-stranded DNA template. In some embodiments, the CasX:gRNA system used in editing a target nucleic acid includes a donor template having all or at least a portion of the open reading frame of a gene in the target nucleic acid for insertion of a corrected wild-type sequence to correct the defective protein. In other cases, the donor template includes all or a portion of the wild-type gene for insertion at a different locus in the genome for expression of the gene product. In still other cases, a portion of a gene can be inserted upstream ('5) of a mutation in the target nucleic acid, with the donor template gene portion extending to the C-terminus of the gene or the 3' end of the sequence bearing the mutation, resulting in expression of a functional gene product upon its insertion into the target nucleic acid.
[0078] In some embodiments, the donor template sequence contains a non-homologous sequence flanked by two homologous regions (i.e., homology arms) 5' and 3' to the cleavage site of the target nucleic acid, facilitating insertion of the non-homologous sequence at the target region, which may be mediated by homology-directed repair (HDR) or homology-independent targeted integration (HITI). The exogenous donor template inserted by HITI can be a relatively short sequence of any length, e.g., 10-50 nucleotides in length, or a longer sequence of about 50-1000 nucleotides in length. The lack of homology can be, for example, 20-50% or less sequence identity and / or lack of specific hybridization at low stringency. In other cases, the lack of homology can further include the criteria of having no more than 5, 6, 7, 8, or 9 bp of identity. In such cases, the use of homology arms facilitates insertion of the non-homologous sequence at the cleavage site introduced by the nuclease. In some embodiments, the donor template polynucleotide comprises at least about 10, at least about 50, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 10,000, or at least about 15,000 nucleotides. In other embodiments, the donor template comprises at least about 10 to about 15,000 nucleotides, at least about 100 to about 10,000 nucleotides, at least about 400 to about 8,000 nucleotides, at least about 600 to about 5000 nucleotides, or at least about 1000 to about 2000 nucleotides. The donor template sequence may contain differences compared to the genomic sequence, such as specific sequences, e.g., restriction sites, nucleotide polymorphisms, selectable markers (e.g., drug resistance genes, fluorescent proteins, enzymes, etc.), which can be used to assess successful insertion of the donor nucleic acid at the cleavage site, or, in some cases, for other purposes (e.g., to indicate expression at the target genomic locus).Alternatively, these sequence differences may include flanking recombination sequences (eg, FLP sequences, loxP sequences, etc.) that can be subsequently activated to remove the marker sequence.
[0079] III. Nucleic Acid Guide Systems for Gene Editing In another aspect, the present disclosure relates to a specially designed guide ribonucleic acid (gRNA) that includes a targeting sequence (also referred to herein as a spacer) that is complementary to (and therefore capable of hybridizing with) a target nucleic acid sequence of a gene, which, when complexed with a CRISPR nuclease, is useful for genome editing of a target nucleic acid in a cell. In some embodiments, it is envisioned that multiple gRNAs are delivered in a system for modifying a target nucleic acid. For example, a pair of gRNAs with targeting sequences directed to different or overlapping regions of the target nucleic acid sequence can be used, each complexed with a CRISPR nuclease to bind and cleave at two different or overlapping sites within a gene, and the gene is then edited by non-homologous end joining (NHEJ), homology-directed repair (HDR), homology-independent targeted integration (HITI), microhomology-mediated end joining (MMEJ), single-strand annealing (SSA), or base excision repair (BER).
[0080] In some embodiments, the present disclosure provides a gRNA utilized in the system, which has utility in genome editing of genes in eukaryotic cells. In certain embodiments, the gRNA of the system can form a complex with CRISPR nuclease (ribonucleoprotein (RNP) complex), which will be described in more detail below.
[0081] a. Reference gRNA and gRNA variants As used herein, a "reference gRNA" refers to a CRISPR guide nucleic acid that comprises the wild-type sequence of a naturally occurring gRNA. In some embodiments, a reference gRNA of the present disclosure may be subjected to one or more mutagenesis methods, such as those described herein in the Examples (e.g., Example 13, and International Application Nos. PCT / US20 / 36506 and WO2020247883(A2), which are incorporated herein by reference), to generate one or more guide nucleic acid variants (referred to herein as "gRNA variants") that have enhanced or altered properties compared to the reference gRNA, including deep mutational evolution (DME), deep mutational scanning (DMS), error-prone PCR, cassette mutagenesis, random mutagenesis, staggered extension PCR, gene shuffling, or domain swapping. gRNA variants also include variants that contain one or more exogenous sequences, for example, fused to either the 5' or 3' end or inserted internally. The activity of a reference gRNA or a variant from which it is derived may be used as a benchmark against which the activity of a gRNA variant is compared, thereby measuring improvement in function or other characteristics of the gRNA variant. In other embodiments, the reference gRNA or gRNA variant may be subjected to one or more deliberate, specifically targeted mutations to produce a gRNA variant (e.g., a rationally designed variant).
[0082] The gRNA of the present disclosure comprises two segments: a targeting sequence and a protein-binding segment. The targeting segment of a gRNA comprises a nucleotide sequence (interchangeably referred to as a guide sequence, spacer, targeter, or targeting sequence) that is complementary to (and therefore hybridizes with) a specific sequence (target site) within a target nucleic acid sequence (e.g., a target ssRNA, a target ssDNA, a strand of a double-stranded target DNA, etc.), as described in more detail below. The targeting sequence of a gRNA can bind to a target nucleic acid sequence (including a coding sequence, a complement of a coding sequence, or a non-coding sequence) and a regulatory element. The protein-binding segment (or "activator" or "protein-binding sequence") interacts with (e.g., binds to) the CasX protein as a complex forming an RNP (described in more detail below). Alternatively, the protein-binding segment is referred to herein as a "scaffold," which is composed of several regions (described in more detail below).
[0083] In the case of a dual guide RNA (dgRNA), the targeter and activator portions each have a duplex-forming segment, and the targeter duplex-forming segment and the activator duplex-forming segment are complementary to each other and hybridize to each other to form a double-stranded duplex (a dsRNA duplex for a gRNA). When the gRNA is a gRNA, the term "targeter" or "targeter RNA" is used herein to refer to the crRNA-like molecule (crRNA: "CRISPR RNA") of a CasX dual guide RNA (and thus of a CasX single guide RNA when the "activator" and "targeter" are linked together, e.g., by an intervening nucleotide). The crRNA has a 5' region that anneals to the tracrRNA, followed by nucleotides of the targeting sequence. Thus, for example, a guide RNA (dgRNA or sgRNA) comprises a guide sequence and a duplex-forming segment of the crRNA (which may also be referred to as a crRNA repeat). The corresponding tracrRNA-like molecule (activator) also contains a duplex-forming stretch of nucleotides that forms the other half of the dsRNA duplex of the protein-binding segment of the guide RNA. Thus, the targeter and activator hybridize as a matched pair to form a dual guide RNA (referred to herein as a "dual-molecule gRNA," "dgRNA," "dual-molecule guide RNA," or "binary guide RNA"). Site-specific binding and / or cleavage of a target nucleic acid sequence (e.g., genomic DNA) by the CasX protein can occur at one or more positions (e.g., the sequence of the target nucleic acid) determined by base-pairing complementarity between the targeting sequence of the gRNA and the target nucleic acid sequence. Thus, for example, a gRNA of the present disclosure has a sequence complementary to a target nucleic acid adjacent to a TC PAM motif or a sequence complementary to a PAM sequence (such as ATC, CTC, GTC, or TTC), and is therefore capable of hybridizing to the target nucleic acid. Because the targeting sequence of the guide sequence hybridizes to a sequence in the target nucleic acid sequence, the user can modify the targeter to hybridize to a specific target nucleic acid sequence, as long as the location of the PAM sequence is taken into consideration.Thus, in some cases, the targeter sequence may be complementary to a non-naturally occurring sequence. In other cases, the targeter sequence may be a naturally occurring sequence derived from the complement of the gene to be edited. In other embodiments, the activator and targeter of a gRNA are covalently linked to each other (rather than hybridizing to each other) and comprise a single molecule (referred to herein as a "single-molecule gRNA," "single guide RNA," "single-molecule guide RNA," "one-molecule guide RNA," or "sgRNA"). In some embodiments, the sgRNA comprises an "activator" or a "targeter," and thus may be an "activator RNA" and a "targeter RNA," respectively. In some embodiments, the gRNA is a ribonucleic acid molecule ("gRNA"); in other embodiments, the gRNA is chimeric and comprises both DNA and RNA. As used herein, the term gRNA encompasses naturally occurring molecules as well as sequence variants (e.g., non-naturally occurring modified nucleotides).
[0084] In summary, the constructed gRNA of the present disclosure comprises four distinct regions or domains: an RNA triplex, a scaffold stem, an extension stem, and a targeting sequence (which in embodiments of the present disclosure is specific to the target nucleic acid and located at the 3' end of the gRNA). The RNA triplex, scaffold stem, and extension stem are collectively referred to as the "scaffold" of the gRNA (gRNA scaffold). The gRNA scaffold of the present disclosure may comprise RNA, or RNA and DNA. The gRNA scaffold may comprise uracil (U), and one or more uracils may be replaced by thymine (T).
[0085] b.RNA triplex In some embodiments of the guide RNAs provided herein, the gRNA comprises an RNA triplex, optionally consisting of a UUU-N sequence ending in AAAG after two intervening stem-loops (a scaffold stem-loop and an extension stem-loop). XThe gRNA comprises a (approximately 4-15)-UUU stem-loop (SEQ ID NO: 241) sequence, forming a pseudoknot that may extend across the triplex into a double-stranded pseudoknot. The triplex UU-UUU-AAA sequence forms a nexus between the targeting sequence, the scaffold stem, and the extension stem. In an exemplary gRNA, the UUU-loop-UUU region is encoded first, followed by the scaffold stem-loop, followed by the extension stem-loop connected by the tetraloop, followed by AAAG to close the triplex before the targeting sequence.
[0086] c. Scaffold stem loop In some embodiments of gRNAs of the present disclosure, the triplex region is followed by a scaffold stem-loop. The scaffold stem-loop is the region of the gRNA to which a CasX protein (e.g., a reference or CasX variant protein) binds when RNPs are formed. In some embodiments, the scaffold stem-loop is a fairly short and stable stem-loop, increasing the overall stability of the gRNA. In some cases, the scaffold stem-loop does not tolerate much variation and requires some form of RNA bubble. In some embodiments, the scaffold stem is necessary for gRNA function. While this is similar to the nexus stem of the Cas9 guide, which is likely a critical stem-loop, the scaffold stem of a gRNA in some embodiments possesses a necessary bulge (RNA bubble), which differs from many other stem-loops found in CRISPR / Cas systems. In some embodiments, the presence of this bulge is conserved across gRNAs that interact with different CasX proteins. An exemplary sequence of a gRNA scaffold stem-loop sequence comprises the sequence CCAGCGACUAUGUCGUAUGG (SEQ ID NO: 242).
[0087] d. extended stem loop In some embodiments of gRNAs of the present disclosure, the scaffold stem-loop is followed by an extended stem-loop. In some embodiments, the extended stem primarily comprises a synthetic tracrRNA and crRNA fusion without the CasX protein bound. In some embodiments, the extended stem-loop can be highly malleable. In some embodiments, single-guide gRNAs are generated using a GAAA tetraloop or GAGAAA linker between the tracrRNA and crRNA in the extended stem-loop. In some cases, the targeter and activator of the sgRNA are linked to each other by an intervening nucleotide, and the linker can have a length of 3 to 20 nucleotides. In some embodiments of sgRNAs of the present disclosure, the extended stem is a large 32-bp loop located outside the CasX protein in the ribonucleoprotein complex. An exemplary sequence of an extended stem-loop sequence of a reference gRNA includes the sequence GCGCUUAUUUAUCGGAGAGAAAUCCGAUAAAUAAGAAGC (SEQ ID NO: 15).
[0088] e. Targeting Sequence In some embodiments of gRNAs of the present disclosure, the extended stem-loop is followed by a region that forms part of a triplex, followed by a targeting sequence (or "spacer") at the 3' end of the gRNA. The targeting sequence targets the CasX ribonucleoprotein holocomplex to a specific region of the target nucleic acid sequence of the gene to be modified. Thus, for example, a gRNA targeting sequence of the present disclosure has, as a component of an RNP, a sequence that is complementary to (and therefore capable of hybridizing to) a portion of a gene in a eukaryotic target nucleic acid (e.g., a eukaryotic chromosome, chromosomal sequence, etc.) when the TC PAM motif or any one of the PAM sequences TTC, ATC, GTC, or CTC is located one nucleotide 5' to the non-target strand sequence that is complementary to the target sequence. The targeting sequence of a gRNA can be modified to enable the gRNA to target a desired sequence of any desired target nucleic acid sequence, as long as the position of the PAM sequence is taken into consideration. In some embodiments, the gRNA scaffold is 5' to the target sequence and the targeting sequence is at the 3' end of the gRNA. In some embodiments, the PAM motif sequence recognized by the RNP nuclease is TC. In other embodiments, the PAM sequence recognized by the RNP nuclease is NTC (i.e., ATC, CTC, GTC, or TTC).
[0089] In some embodiments, the present disclosure provides a gRNA, wherein the targeting sequence of the gRNA is complementary to the target nucleic acid sequence of the gene to be modified. In some embodiments, the targeting sequence of the gRNA is complementary to the target nucleic acid sequence of the gene and contains one or more mutations compared to the wild-type gene sequence, for the purpose of editing the mutation-containing sequence with the CasX:gRNA system of the present disclosure. In such cases, the modification effected by the CasX:gRNA system can correct or compensate for the mutation, or can knock down or knock out expression of the mutant gene product. In other embodiments, the targeting sequence of the gRNA is complementary to the target nucleic acid sequence of the wild-type gene, for the purpose of editing the sequence to introduce a mutation with the CasX:gRNA system of the present disclosure to knock down or knock out the gene. In some embodiments, the targeting sequence of the gRNA is designed to be specific to an exon of the gene of the target nucleic acid. In other embodiments, the targeting sequence of the gRNA is designed to be specific to an intron of the gene of the target nucleic acid. In other embodiments, the targeting sequence of the gRNA is designed to be specific to an intron-exon junction of the gene of the target nucleic acid. In some embodiments, the targeting sequence of the gRNA is designed to be specific to a regulatory element of a gene. In some embodiments, the targeting sequence of the gRNA is designed to be complementary to a sequence containing one or more single nucleotide polymorphisms (SNPs) in a gene. SNPs in coding or non-coding sequences are both within the scope of the present disclosure. In other embodiments, the targeting sequence of the gRNA is designed to be complementary to a sequence in an intergenic region of the gene of the target nucleic acid.
[0090] In some embodiments, the targeting sequence is designed to be specific for regulatory elements that regulate the expression of a gene product. Such regulatory elements include, but are not limited to, promoter regions, enhancer regions, intergenic regions, 5' untranslated regions (5'UTRs), 3' untranslated regions (3'UTRs), conserved elements, and regions containing cis-regulatory elements. A promoter region is intended to encompass nucleotides within 5 kb of the start of a coding sequence, or in the case of a gene enhancer element or conserved element, may be thousands, hundreds of thousands, or even millions of bp away from the coding sequence of the gene of the target nucleic acid. In the foregoing, the target is one whose coding gene is intended to be knocked out or knocked down so that the gene product is not expressed or expressed at a lower level in the cell.
[0091] In some embodiments, the targeting sequence of the gRNA comprises 14-35 contiguous nucleotides. In some embodiments, the targeting sequence of the gRNA comprises 10-30 contiguous nucleotides. In some embodiments, the targeting sequence comprises 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides. In other embodiments, the targeting sequence of the gRNA comprises 20 contiguous nucleotides. In some embodiments, the targeting sequence comprises 19 contiguous nucleotides. In some embodiments, the targeting sequence comprises 18 contiguous nucleotides. In some embodiments, the targeting sequence comprises 17 contiguous nucleotides. In some embodiments, the targeting sequence comprises 16 contiguous nucleotides. In some embodiments, the targeting sequence comprises 15 contiguous nucleotides. In some embodiments, the targeting sequence has 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotides, and the targeting sequence can contain 0 to 5, 0 to 4, 0 to 3, or 0 to 2 mismatches to the target nucleic acid sequence and retain sufficient binding specificity such that an RNP containing a gRNA that includes the targeting sequence can form a complementary bond to the target nucleic acid.
[0092] In some embodiments, the CasX:gRNA system includes a first gRNA and further includes a second (and optionally, a third, fourth, fifth, or more) gRNA, where the second or additional gRNA has a targeting sequence complementary to a different or overlapping portion of the target nucleic acid sequence compared to the targeting sequence of the first gRNA, resulting in multiple points being targeted in the target nucleic acid, e.g., multiple cleavages being introduced in the target nucleic acid by CasX. In such cases, it will be understood that the second or additional gRNA is complexed with additional copies of the CasX protein. Depending on the selection of the gRNA targeting sequence, defined regions of the target nucleic acid sequence surrounding a mutation can be modified or edited using the CasX:gRNA system described herein, including, for example, facilitating excision of DNA between the insertion or cleavage sites of the donor template where a mutation repeat occurs, or, in some cases, where removal of the exon containing the mutation still results in expression of a functional gene product.
[0093] f. gRNA scaffold Except for the targeting sequence region, the remaining region of the gRNA is referred to herein as the scaffold. In some embodiments, the gRNA scaffold is derived from a naturally occurring sequence, described below as a reference gRNA. In other embodiments, the gRNA scaffold is a variant of another gRNA variant, in which mutations, insertions, deletions, or domain substitutions are introduced to confer desirable properties to the gRNA.
[0094] In some embodiments, the reference gRNA comprises a sequence isolated or derived from Deltaproteobacteria. In some embodiments, the sequence is a CasX tracrRNA sequence. Exemplary reference tracrRNA sequences isolated or derived from Deltaproteobacteria may include ACAUCUGGCGCGUUUAUUCCAUUACUUUGGAGCCAGUCCCAGCGACUAUGUCGUAUGGACGAAGCGCUUAUUUAUCGGAGA (SEQ ID NO: 6) and ACAUCUGGCGCGUUUAUUCCAUUACUUUGGAGCCAGUCCCAGCGACUAUGUCGUAUGGACGAAGCGCUUAUUUAUCGG (SEQ ID NO: 7). An exemplary crRNA sequence isolated or derived from Deltaproteobacteria may comprise the sequence CCGAUAAGUAAAACGCAUCAAAG (SEQ ID NO: 243).
[0095] In some embodiments, the reference guide RNA comprises a sequence isolated or derived from Planctomycetes. In some embodiments, the sequence is a tracrRNA. Exemplary reference tracrRNA sequences isolated or derived from Planctomycetes are UACUGGCGCUUUUAUCUCAUUACUUUGAGAGCCAUCACCAGCGACUAUGUCGUAUGGGUAAAGCGCUUAUUUAUCGGAGA (SEQ ID NO: 8) and An exemplary crRNA sequence isolated or derived from Planctomycetes may include the sequence UCUCCGAUAAAUAAGAAGCAUCAAAG (SEQ ID NO: 244).
[0096] In some embodiments, the reference gRNA comprises a sequence isolated or derived from Candidatus Sungbacteria. Exemplary CasX reference tracrRNA sequences isolated or derived from Candidatus Sungbacteria may include the sequences GUUUACACACUCCCUCUCAUAGGGU (SEQ ID NO: 10), GUUUACACACUCCCUCUCAUGAGGU (SEQ ID NO: 11), UUUUACAUACCCCCUCUCAUGGGAU (SEQ ID NO: 12), and GUUUACACACUCCCUCUCAUGGGGG (SEQ ID NO: 13).
[0097] Table 1 provides the sequences of the reference gRNAs tracr, cr, and scaffold sequences. In some embodiments, the present disclosure provides gRNA variant sequences, wherein the gRNA has a scaffold comprising a sequence having at least one nucleotide alteration compared to a reference gRNA sequence having the sequence of any one of SEQ ID NOS: 4-16 in Table 1. In embodiments in which the vector comprises DNA encoding the sequence of the gRNA or the gRNA is a chimera of RNA and DNA, it will be understood that thymine (T) bases can be substituted for uracil (U) bases in any of the gRNA sequence embodiments described herein.
[0098] [Table 1]
[0099] g.gRNA variants In another aspect, the present disclosure relates to gRNA variants that contain one or more modifications relative to a reference gRNA scaffold or are derived from another gRNA variant. As used herein, "scaffold" refers to all portions of a gRNA that are necessary for gRNA function, excluding the targeting sequence.
[0100] In some embodiments, gRNA variants comprise one or more nucleotide substitutions, insertions, deletions, or swapped or substituted regions compared to a reference gRNA sequence of the present disclosure. In some embodiments, mutations can be made in any region of a reference gRNA scaffold to generate a gRNA variant. In some embodiments, the scaffold of the gRNA variant sequence has at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, at least 80%, at least 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the sequence of SEQ ID NO: 4 or SEQ ID NO: 5. In other embodiments, gRNA variants comprise one or more nucleotide substitutions, insertions, deletions, or swapped or substituted regions compared to a gRNA variant sequence of the present disclosure. In some embodiments, the scaffold of the gRNA variant sequence has at least 50%, at least 60%, or at least 70%, at least 80%, at least 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the sequence of SEQ ID NO:2238 or SEQ ID NO:2239.
[0101] In some embodiments, a gRNA variant comprises one or more nucleotide changes within one or more regions of a reference gRNA scaffold that improve the characteristics of the reference gRNA. In other embodiments, a gRNA variant comprises one or more nucleotide changes within one or more regions of the gRNA variant scaffold from which it is derived that improve the characteristics compared to the gRNA. Exemplary regions include RNA triplexes, pseudoknots, scaffold stem-loops, and extended stem-loops. In some cases, the variant scaffold stem further comprises a bubble. In other cases, the variant scaffold further comprises a triplex loop region. In still other cases, the variant scaffold further comprises a 5' unstructured region. In some embodiments, the gRNA variant scaffold comprises a scaffold stem-loop that has at least 60% sequence identity, at least 70% sequence identity, at least 80% sequence identity, at least 90% sequence identity, at least 95% sequence identity, or at least 99% sequence identity to SEQ ID NO: 14. In other embodiments, the gRNA variant comprises a scaffold stem-loop having the sequence CCAGCGACUAUGUCGUAGUGG (SEQ ID NO: 245). In other embodiments, the disclosure provides a C18G substitution, a G55 insertion, a U1 deletion, and an altered extended stem-loop relative to SEQ ID NO: 5, in which the original 6-nt loop and 13 most-loop-proximal base pairs (32 nucleotides total) are replaced by a Uvsx hairpin (4-nt loop and 5 most-loop-proximal base pairs; 14 nucleotides total), and the loop-distal bases of the extended stem are converted into a perfectly base-paired stem adjacent to the new Uvsx hairpin by an A99 deletion and a G65U substitution. In the foregoing embodiment, the gRNA scaffold is gRNA variant 174 and comprises the sequence ACUGGCGCUUUUAUCUGAUUACUUUGAGAGCCAUCACCAGCGACUAUGUCGUAGUGGGUAAAGCUCCCUCUUCGGAGGGAGCAUCAAAG (SEQ ID NO: 2238).
[0102] All gRNA variants that have one or more improved characteristics or add one or more new functions when compared to a reference gRNA or a gRNA variant that has been mutagenized to generate the new gRNA variant described herein are contemplated within the scope of this disclosure. A representative example of such a gRNA variant is guide 235 (SEQ ID NO: 2292), the design of which is described in the Examples. In some embodiments, the gRNA variant adds a new function to the RNP that contains the gRNA variant. In some embodiments, the gRNA variant has an improved characteristic selected from the following: increased stability, increased transcription of the gRNA, increased resistance to nuclease activity, increased folding rate of the gRNA, reduced by-product formation during folding, increased productive folding, increased binding affinity for the CasX protein, increased binding affinity for the target nucleic acid when complexed with the CasX protein, increased gene editing when complexed with the CasX protein, increased specificity of editing of the target nucleic acid when complexed with the CasX protein, reduced off-target editing when complexed with the CasX protein, and an increased ability to utilize one or more broader PAM sequences including ATC, CTC, GTC, or TTC in editing of the target nucleic acid when complexed with the CasX protein, or any combination thereof. In some cases, one or more of the improved characteristics of the gRNA variant is increased by at least about 1.1 to about 100,000-fold compared to the reference gRNA of SEQ ID NO: 4 or SEQ ID NO: 5 or gRNA variant 174 or 175. In other cases, one or more improved characteristics of the gRNA variant are increased by at least about 1.1-fold, at least about 10-fold, at least about 100-fold, at least about 1000-fold, at least about 10,000-fold, at least about 100,000-fold, or more compared to the reference gRNA of SEQ ID NO: 4 or SEQ ID NO: 5 or gRNA variant 174 or 175.In other cases, one or more of the improved characteristics of the gRNA variant may be about 1.1 to 100,00 fold, about 1.1 to 10,00 fold, about 1.1 to 1,000 fold, about 1.1 to 500 fold, about 1.1 to 100 fold, about 1.1 to 50 fold, about 1.1 to 20 fold, about 10 to 100,00 fold, about 10 to 10,00 fold, about 10 to 1,000 fold, about 10 to 500 fold, about 10 to 100 fold, about 10 to 50 fold, about 10 to 20 fold, about 2 to 70 fold, about 2 to 50 fold, about 2 to 30 fold, about 2 to 20 fold, about 2 to 20 fold, about 2 to 3 ... ~10 times, about 5 to 50 times, about 5 to 30 times, about 5 to 10 times, about 100 to 100,00 times, about 100 to 10,00 times, about 100 to 1,000 times, Approximately 100 to 500 times, approximately 500 to 100,00 times, approximately 500 to 10,00 times, approximately 500 to 1,000 times, approximately 500 to 750 times, approximately 1,000 about 10,000 to 100,00 times, about 20 to 500 times, about 20 to 250 times, about 20 to 200 times, about 20 to 100 times, about 20 to 50 times, about 50 to 10,000 times, about 50 to 1,000 times, about 50 to 500 times, about 50 to 200 times, or about 50 to 100 times. In other cases, the one or more improved characteristics of the gRNA variant may be about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 30-fold, 40-fold, 45-fold, 46-fold, 47-fold, 48-fold, 49-fold, 50-fold, 51-fold, 52-fold, 53-fold, 54-fold, 55-fold, 56-fold, 57-fold, 58-fold, 59-fold, 60-fold, 61-fold, 62-fold, 63-fold, 64-fold, 65-fold, 66-fold, 67-fold, 68-fold, 69-fold, 70-fold, 71-fold, 72-fold, 73-fold, 74-fold, 75-fold, 76-fold, 77-fold, 78-fold, 79-fold, 80-fold, 81-fold, 82-fold, 83-fold, 84-fold, 85-fold, 86-fold, 87-fold, 88-fold, 89-fold, 90-fold, 91-fold, 92-fold, 93-fold, 94-fold, 95-fold, A 50-fold, 55-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold, 150-fold, 160-fold, 170-fold, 180-fold, 190-fold, 200-fold, 210-fold, 220-fold, 230-fold, 240-fold, 250-fold, 260-fold, 270-fold, 280-fold, 290-fold, 300-fold, 310-fold, 320-fold, 330-fold, 340-fold, 350-fold, 360-fold, 370-fold, 380-fold, 390-fold, 400-fold, 425-fold, 450-fold, 475-fold, or 500-fold increase.
[0103] In some embodiments, new gRNA variants can be generated by subjecting a reference gRNA or gRNA variant to one or more mutagenesis methods, such as those described herein in the Examples below, which may include comprehensive mutational evolution (DME), comprehensive mutation scanning (DMS), error-prone PCR, cassette mutagenesis, random mutagenesis, tethered extension PCR, gene shuffling, or domain swapping, to generate gRNA variants of the present disclosure. The activity of the reference gRNA or the activity of a gRNA variant subjected to mutagenesis can be used as a benchmark for the activity of the gRNA variant, thereby measuring the improvement in the function of the gRNA variant. In other embodiments, a reference gRNA or gRNA can be subjected to one or more deliberately targeted mutations, substitutions, or domain swaps to produce gRNA variants (e.g., rationally designed variants). Exemplary gRNA variants produced by such methods are described in the Examples, and representative sequences of gRNA scaffolds are provided in Table 2.
[0104] In some embodiments, the gRNA variant comprises one or more modifications compared to a reference gRNA or gRNA variant scaffold sequence, the one or more modifications being selected from the following: at least one nucleotide substitution in a region of the gRNA, at least one nucleotide deletion in a region of the gRNA, at least one nucleotide insertion in a region of the gRNA, a substitution of all or part of a region of the gRNA, a deletion of all or part of a region of the gRNA, or any combination of the above. In some cases, the modification is a substitution of 1 to 15 contiguous or non-contiguous nucleotides in one or more regions of the gRNA. In other cases, the modification is a deletion of 1 to 10 contiguous or non-contiguous nucleotides in one or more regions of the gRNA. In other cases, the modification is an insertion of 1 to 10 contiguous or non-contiguous nucleotides in one or more regions of the gRNA. In other cases, the modification is a replacement of the scaffold stem-loop or extended stem-loop with an RNA stem-loop sequence from a heterologous RNA source having proximal 5' and 3' ends. In some cases, gRNA variants of the present disclosure contain two or more modifications in one region compared to a reference gRNA or gRNA variant. In other cases, gRNA variants of the present disclosure contain modifications in two or more regions. In other cases, gRNA variants contain any combination of the foregoing modifications described in this paragraph.
[0105] In some embodiments, a 5' G is added to the gRNA variant sequence compared to the original gRNA for in vivo expression because transcription from the U6 promoter is more efficient and more consistent with respect to the start site when the +1 nucleotide is G. In other embodiments, two 5' Gs are added to the gRNA variant sequence to increase production efficiency during in vitro transcription because T7 polymerase strongly prefers a G at the +1 position and a purine at the +2 position. In some cases, a 5' G base is added to the reference scaffold in Table 1. In other cases, a 5' G base is added to the variant scaffold in Table 2.
[0106] Table 2 provides exemplary gRNA variant scaffold sequences. In some embodiments, the gRNA variant scaffold comprises any one of the sequences listed in Table 2 as SEQ ID NOs: 2101-2332 or 2353-2398, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the gRNA variant scaffold comprises any one of the sequences set forth in SEQ ID NOs: 2238-2332 or 2353-2398, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the gRNA variant scaffold comprises any one of the sequences set forth in SEQ ID NOs: 2281-2332 or 2353-2398, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In embodiments in which the vector comprises DNA encoding the sequence of a gRNA or the gRNA is a chimera of RNA and DNA, it will be understood that thymine (T) bases can be substituted for uracil (U) bases in any of the gRNA sequence embodiments described herein.
[0107] [Table 2-1]
[0108] [Table 2-2]
[0109] [Table 2-3]
[0110] Table 2-4
[0111] Table 2-5
[0112] Table 2-6
[0113] Table 2-7
[0114] Table 2-8
[0115] Table 2-9
[0116] Table 2-10
[0117] Table 2-11
[0118] In some embodiments, the sgRNA variant comprises one or more additional modifications to the sequence of SEQ ID NO:2238, SEQ ID NO:2239, SEQ ID NO:2240, SEQ ID NO:2241, SEQ ID NO:2243, SEQ ID NO:2256, SEQ ID NO:2274, SEQ ID NO:2275, SEQ ID NO:2279, SEQ ID NO:2281, SEQ ID NO:2285, SEQ ID NO:2289, SEQ ID NO:2292, or SEQ ID NO:2308 in Table 2.
[0119] In some embodiments of the gRNA variants of the present disclosure, the gRNA variant comprises at least one modification compared to the reference guide scaffold of SEQ ID NO: 5, wherein the at least one modification is selected from one or more of the following: (a) a C18G substitution within the triple-stranded loop; (b) a G55 insertion in the stem bubble; (c) a U1 deletion; (d) a modification of the extended stem-loop in which (i) the 6 nt loop and 13 base pairs proximal to the loop are replaced by a Uvsx hairpin, and (ii) the base distal to the loop is perfectly base-paired due to the deletion of A99 and substitution of G65U.
[0120] In some embodiments, the gRNA variant comprises an exogenous stem-loop with a long non-coding RNA (lncRNA). As used herein, lncRNA refers to a non-coding RNA that is greater than about 200 bp in length. In some embodiments, the 5' and 3' ends of the exogenous stem-loop are base-paired (i.e., interact to form a region of double-stranded RNA). In some embodiments, the 5' and 3' ends of the exogenous stem-loop are base-paired, and one or more regions between the 5' and 3' ends of the exogenous stem-loop are not base-paired, forming a loop.
[0121] In some embodiments, the present disclosure provides gRNA variants having nucleotide modifications compared to a reference gRNA, including (a) a substitution of 1 to 15 consecutive or non-consecutive nucleotides in one or more regions of the gRNA variant, (b) a deletion of 1 to 10 consecutive or non-consecutive nucleotides in one or more regions of the gRNA variant, (c) an insertion of 1 to 10 consecutive or non-consecutive nucleotides in one or more regions of the gRNA variant, (d) a replacement of the scaffold stem-loop or extended stem-loop with an RNA stem-loop sequence from a heterologous RNA source having proximal 5' and 3' ends, or any combination of (a)-(d). Any of the substitutions, insertions, and deletions described herein can be combined to generate gRNA variants of the present disclosure. For example, a gRNA variant can include at least one substitution and at least one deletion compared to a reference gRNA, at least one substitution and at least one insertion compared to a reference gRNA, at least one insertion and at least one deletion compared to a reference gRNA, or at least one substitution, one insertion, and one deletion compared to a reference gRNA.
[0122] In some embodiments, sgRNA variants of the present disclosure contain one or more modifications to the sequence of a previously generated variant, with the previously generated variant itself serving as the sequence to be modified. In some cases, one or more modifications are introduced into the pseudoknot region of the scaffold. In other cases, one or more modifications are introduced into the triplex region of the scaffold. In other cases, one or more modifications are introduced into the scaffold bubble. In other cases, one or more modifications are introduced into the extended stem region of the scaffold. In still other cases, one of the modifications is introduced into two or more of the aforementioned regions. Such modifications may include the insertion, deletion, or substitution of one or more nucleotides in the aforementioned regions, or any combination thereof. Exemplary methods for generating and evaluating modifications are described in Example 15.
[0123] In some embodiments, the sgRNA variant comprises one or more modifications to the sequence of SEQ ID NO:2238, SEQ ID NO:2239, SEQ ID NO:2240, SEQ ID NO:2241, SEQ ID NO:2241, SEQ ID NO:2274, SEQ ID NO:2275, SEQ ID NO:2279, or SEQ ID NO:2285, SEQ ID NO:2289, SEQ ID NO:2292, or SEQ ID NO:2308.
[0124] In exemplary embodiments, gRNA variants comprise one or more modifications to gRNA scaffold variant 174 (SEQ ID NO: 2238), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 174 when evaluated in in vitro or in vivo assays under comparable conditions. In other exemplary embodiments, gRNA variants comprise one or more modifications to gRNA scaffold variant 175 (SEQ ID NO: 2239), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 175 when evaluated in in vitro or in vivo assays under comparable conditions. For example, variants with modifications to the triple loop of gRNA variant 175, particularly mutations to C15 or C17, show high enrichment compared to the 175 scaffold. Additionally, changes to either member of the predicted pair in the pseudoknot stem between G7 and A29 are both highly enriched compared to the 175 scaffold, converting A29 to a C or T to form a canonical Watson-Crick pair (G7:C29), the second of which forms a GU wobble pair (G7:U29), both of which can be expected to increase helix stability compared to the G:A pair. In addition, the insertion of a C at position 54 in guide scaffold 175 results in an enriched modification.
[0125] In some embodiments, the present disclosure provides gRNA variants comprising one or more modifications to gRNA scaffold variant 174 (SEQ ID NO: 2238) selected from the group consisting of the modifications in Table 19, wherein the resulting gRNA variant exhibits improved functional characteristics compared to parent 174 when assessed in in vitro or in vivo assays under comparable conditions. In some embodiments, the improved functional characteristics are one or more functional properties selected from the group consisting of increased editing activity, increased pseudoknot stem stability, increased triplex region stability, increased scaffold stem stability, extended stem stability, reduced off-target folding intermediates, and increased binding affinity for Class 2, Type V CRISPR proteins. In the foregoing embodiments, a gRNA (having an attached targeting sequence and complexing with a Class 2, type V CRISPR protein) comprising one or more modifications to gRNA scaffold variant 174 selected from the group consisting of the modifications in Table 16 exhibits an improved enrichment score (log2) in an in vitro assay that is at least about 2.0, at least about 2.5, at least about 3, or at least about 3.5 greater than the score for the gRNA scaffold of SEQ ID NO: 2238.
[0126] In some embodiments, the present disclosure provides gRNA variants comprising one or more modifications to gRNA scaffold variant 175 (SEQ ID NO: 2239) selected from the group consisting of the modifications in Table 20, wherein the resulting gRNA variant exhibits improved functional characteristics compared to parent 175 when assessed in in vitro or in vivo assays under comparable conditions. In some embodiments, the improved functional characteristics are one or more functional properties selected from the group consisting of increased editing activity, increased pseudoknot stem stability, increased triplex region stability, increased scaffold stem stability, extended stem stability, reduced off-target folding intermediates, and increased binding affinity for Class 2, Type V CRISPR proteins. In the foregoing embodiments, a gRNA (having an attached targeting sequence and complexing with a Class 2, type V CRISPR protein) comprising one or more modifications to gRNA scaffold variant 175 selected from the group consisting of the modifications in Table 16 exhibits an improved enrichment score (log2) in an in vitro assay that is at least about 1.2, at least about 1.5, at least about 2.0, at least about 2.5, at least about 3, or at least about 3.5 greater than the score for the gRNA scaffold of SEQ ID NO: 2239.
[0127] In certain embodiments, one or more modifications of gRNA scaffold variant 174 are selected from the group consisting of nucleotide positions U11, U24, A29, U65, C66, C68, A69, U76, G77, A79, and A87. In certain embodiments, the modifications of gRNA scaffold variant 174 are U11C, U24C, A29C, U65C, C66G, C68U, an insertion of ACGGA at position 69, an insertion of UCCGU at position 76, G77A, an insertion of GA at position 79, A87G. In another specific embodiment, the modifications of gRNA scaffold variant 175 are selected from the group consisting of nucleotide positions C9, U11, C17, U24, A29, G54, C65, A89, and A96. In certain embodiments, the modifications of gRNA scaffold variant 174 are C9U, U11C, C17G, U24C, A29C, an insertion of G at position 54, an insertion of C at position 65, A89G, and A96G.
[0128] In exemplary embodiments, gRNA variants comprise one or more modifications to gRNA scaffold variant 215 (SEQ ID NO: 2275), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 215 when evaluated in in vitro or in vivo assays under comparable conditions.
[0129] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 221 (SEQ ID NO: 2281), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 221 when assessed in in vitro or in vivo assays under comparable conditions.
[0130] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 225 (SEQ ID NO: 2285), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 225 when evaluated in in vitro or in vivo assays under comparable conditions.
[0131] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 235 (SEQ ID NO: 2292), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 225 when evaluated in in vitro or in vivo assays under comparable conditions.
[0132] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 251 (SEQ ID NO: 2308), and the resulting gRNA variants exhibit improved functional characteristics compared to parent 251 when evaluated in in vitro or in vivo assays under comparable conditions.
[0133] In the foregoing embodiments, the improved functional characteristics include, but are not limited to, one or more of: increased stability, increased transcription of the gRNA, increased resistance to nuclease activity, increased folding rate of the gRNA, reduced by-product formation during folding, increased productive folding, increased binding affinity for the CasX protein, increased binding affinity for the target nucleic acid when complexed with the CasX protein, increased gene editing when complexed with the CasX protein, increased editing specificity when complexed with the CasX protein, reduced off-target editing when complexed with the CasX protein, and increased ability to utilize one or more broader PAM sequences, including ATC, CTC, GTC, or TTC, in modifying the target nucleic acid when complexed with the CasX protein. In some cases, one or more of the improved characteristics of the gRNA variant is improved by at least about 1.1 to about 100,000-fold compared to the gRNA from which it is derived. In other cases, one or more improved characteristics of the gRNA variant is improved by at least about 1.1-fold, at least about 10-fold, at least about 100-fold, at least about 1000-fold, at least about 10,000-fold, at least about 100,000-fold, or more compared to the gRNA from which it is derived.In other cases, one or more of the improved characteristics of the gRNA variant, compared to the gRNA from which it is derived, is about 1.1-100,00 fold, about 1.1-10,00 fold, about 1.1-1,000 fold, about 1.1-500 fold, about 1.1-100 fold, about 1.1-50 fold, about 1.1-20 fold, about 10-100,00 fold, about 10-10,00 fold, about 10-1,000 fold, about 10-500 fold, about 10-100 fold, about 10-50 fold, about 10-20 fold, about 2-70 fold, about 2-50 fold, about 2-30 fold, about 2-20 fold, about 2-10 fold, about 5-50 fold, about 5-60 fold, about 5-70 fold, about 5-80 fold, about 5-90 fold, about 5-10 ... The improvement is 30-fold, about 5 to 10-fold, about 100 to 100,00-fold, about 100 to 10,00-fold, about 100 to 1,000-fold, about 100 to 500-fold, about 500 to 100,00-fold, about 500 to 10,000-fold, about 500 to 1,000-fold, about 500 to 750-fold, about 1,000 to 100,00-fold, about 10,000 to 100,00-fold, about 20 to 500-fold, about 20 to 250-fold, about 20 to 200-fold, about 20 to 100-fold, about 20 to 50-fold, about 50 to 10,000-fold, about 50 to 1,000-fold, about 50 to 500-fold, about 50 to 200-fold, or about 50 to 100-fold. In other cases, one or more improved characteristics of the gRNA variant may be about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 30-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, or 70-fold improved compared to the gRNA from which it is derived. , 80x, 90x, 100x, 110x, 120x, 130x, 140x, 150x, 160x, 170x, 180x, 190x, 200x, 210x, 220x, 230x, 240x, 250x, 260x, 270x, 280x, 290x, 300x, 310x, 320x, 330x, 340x, 350x, 360x, 370x, 380x, 390x, 400x, 425x, 450x, 475x, or 500x improvement.
[0134] In some embodiments, the gRNA variant comprises an exogenous extended stem-loop, and such differences from the reference gRNA are as follows: In some embodiments, the exogenous extended stem-loop has little or no identity to the reference stem-loop region disclosed herein (e.g., SEQ ID NO: 15). In some embodiments, the exogenous stem loop is at least 10 bp, at least 20 bp, at least 30 bp, at least 40 bp, at least 50 bp, at least 60 bp, at least 70 bp, at least 80 bp, at least 90 bp, at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp, at least 700 bp, at least 800 bp, at least 900 bp, at least 1,000 bp, at least 2,000 bp, at least 3,000 bp, at least 4,000 bp, at least 5,000 bp, at least 6,000 bp, at least 7,000 bp, at least 8,000 bp, at least 9,000 bp, at least 10,000 bp, at least 12,000 bp, at least 15,000 bp, or at least 20,000 bp. In some embodiments, the gRNA variant comprises an extended stem-loop region comprising at least 10, at least 100, at least 500, at least 1000, or at least 10,000 nucleotides. In some embodiments, the heterologous stem-loop increases the stability of the gRNA. In some embodiments, the heterologous RNA stem-loop is capable of binding to proteins, RNA structures, DNA sequences, or small molecules. In some embodiments, the exogenous stem-loop region replacing the stem-loop comprises an RNA stem-loop or hairpin, and the resulting gRNA has increased stability and can interact with specific cellular proteins or RNAs, depending on the loop selection.Such exogenous extended stem loops include, for example, thermostable RNAs, such as MS2 hairpin (ACAUGAGGAUCACCCAUGU (SEQ ID NO: 1137)), Qβ hairpin (UGCAUGUCUAAGACAGCA (SEQ ID NO: 32)), U1 hairpin II (AAUCCAUUGCACUCCGGAUU (SEQ ID NO: 33)), Uvsx (CCUCUUCGGAGG (SEQ ID NO: 34)), PP7 hairpin (AGGAGUUUCUAUGGAAACCCU (SEQ ID NO: 35)), phage replication loop (AGGUGGGACGACCUCUCGGUCGUCCUAUCU (SEQ ID NO: 36)), kissing loop_a (UGCUCGCUCCGUUCGAGCA (SEQ ID NO: 37)), kissing loop It may comprise loop_b1 (UGCUCGACGCGUCCUCGAGCA (SEQ ID NO: 38)), kissing loop_b2 (UGCUCGUUUGCGGCUACGAGCA (SEQ ID NO: 39)), G triplex M3q (AGGGAGGGAGGGAGAGG (SEQ ID NO: 40)), G quadruplex telomere basket (GGUUAGGGUUAGGGUUAGG (SEQ ID NO: 41)), sarcin-ricin loop (CUGCUCAGUACGAGAGGAACCGCAG (SEQ ID NO: 42)), or pseudoknot (UACACUGGGAUCGCUGAAUUAGAGAUCGGCGUCCUUUCAUUCUAUAUACUUUGGAGUUUUAAAAUGUCUCUAAGUACA (SEQ ID NO: 43)). In some embodiments, one of the aforementioned hairpin sequences is incorporated into the stem-loop to aid in transporting the incorporation of the gRNA (and associated CasX in the RNP complex) into the budding XDP when the corresponding ligand is incorporated into the Gag polyprotein of the XDP (described in more detail below).
[0135] In some embodiments, gRNA variants include terminal fusion partners. The term gRNA variant encompasses variants that include exogenous sequences, such as terminal fusions or internal insertions. Exemplary terminal fusions may include fusion of a gRNA to a self-cleaving ribozyme or a protein-binding motif. As used herein, "ribozyme" refers to an RNA or a segment thereof that possesses one or more catalytic activities similar to protein enzymes. Exemplary catalytic activities of ribozymes may include, for example, RNA cleavage and / or ligation, DNA cleavage and / or ligation, or peptide bond formation. In some embodiments, such fusions may improve scaffold folding or recruit DNA repair mechanisms. For example, in some embodiments, gRNAs can be fused to hepatitis delta virus (HDV) antigenome ribozyme, HDV genomic ribozyme, hatchet ribozyme (from metagenomic data), env25 pistol ribozyme (representative from Aliistipes putredinis), HH15 minimal hammerhead ribozyme, tobacco ring mottle virus (TRSV) ribozyme, WT virus hammerhead ribozyme (and rational variants), or Twisted Sister 1 or RBMX recruitment motifs. Hammerhead ribozymes are RNA motifs that catalyze reversible cleavage and ligation reactions at specific sites within RNA molecules. Hammerhead ribozymes include type I, type II, and type III hammerhead ribozymes. HDV, pistol, and hatchet ribozymes possess self-cleaving activity. A gRNA variant containing one or more ribozymes may enable expanded gRNA function compared to a reference gRNA. For example, a gRNA containing a self-cleaving ribozyme can, in some embodiments, be transcribed and processed into a mature gRNA as part of a polycistronic transcript. Such fusions can occur at either the 5' or 3' end of the gRNA. In some embodiments, a gRNA variant contains fusions at both the 5' and 3' ends, each fusion independently as described herein.
[0136] In embodiments of gRNA variants, the gRNA variants further comprise a spacer (or targeting sequence) region located at the 3' end of the gRNA that can hybridize to a target nucleic acid, wherein the spacer comprises at least 14 to about 35 nucleotides and is designed with a sequence complementary to the target nucleic acid. In some embodiments, the encoded gRNA variant comprises a targeting sequence of at least 10 to 20 nucleotides that is complementary to the target nucleic acid. In some embodiments, the targeting sequence has 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the encoded gRNA variant comprises a targeting sequence having 20 nucleotides. In some embodiments, the targeting sequence has 25 nucleotides. In some embodiments, the targeting sequence has 24 nucleotides. In some embodiments, the targeting sequence has 23 nucleotides. In some embodiments, the targeting sequence has 22 nucleotides. In some embodiments, the targeting sequence has 21 nucleotides. In some embodiments, the targeting sequence has 20 nucleotides. In some embodiments, the targeting sequence has 19 nucleotides. In some embodiments, the targeting sequence has 18 nucleotides. In some embodiments, the targeting sequence has 17 nucleotides. In some embodiments, the targeting sequence has 16 nucleotides. In some embodiments, the targeting sequence has 15 nucleotides. In some embodiments, the targeting sequence has 14 nucleotides.
[0137] h. Complex formation with class 2 and V proteins In some embodiments, upon expression, the gRNA variant is complexed as an RNP with a Class 2, Type V protein, including a CasX variant protein comprising any one of the sequences set forth in SEQ ID NOs: 247-592 or 1147-1231 of Table 3, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity thereto. In some embodiments, upon expression, the gRNA variant is complexed as an RNP with a CasX variant protein comprising any one of the sequences of SEQ ID NOs: 270-592 or 1147-1231, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity thereto. In some embodiments, upon expression, the gRNA variant is complexed as an RNP with a CasX variant protein comprising any one of the sequences of SEQ ID NOs: 415-592 or 1147-1231, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity thereto.
[0138] In some embodiments, the gRNA variant has an improved ability to form a complex with a CasX variant protein compared to a reference gRNA, thereby improving its ability to form a cleavage-competent ribonucleoprotein (RNP) complex with the CasX protein, as described in the Examples. Improving the formation of a ribonucleoprotein complex can, in some embodiments, improve the efficiency with which functional RNPs are assembled. In some embodiments, more than 90%, more than 93%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99% of RNPs comprising the gRNA variant and its targeting sequence are competent for gene editing of the target nucleic acid.
[0139] An exemplary nucleotide change that can improve the ability of a gRNA variant to form a complex with a CasX protein may, in some embodiments, include replacing the scaffold stem with a thermostable stem-loop. Without wishing to be bound by any theory, replacing the scaffold stem with a thermostable stem-loop can increase the overall binding stability of the gRNA variant with the CasX protein. Alternatively, or additionally, removing a large portion of the stem-loop can alter the folding kinetics of the gRNA variant, e.g., by reducing the extent to which the gRNA variant can "tangle" with itself, allowing for easier and more rapid structural assembly of a functionally folded gRNA. In some embodiments, the selection of the scaffold stem-loop sequence can vary depending on the different targeting sequences utilized for the gRNA. In some embodiments, the scaffold sequence can be tailored to the targeting sequence, and thus the target sequence. Biochemical assays, including those in the Examples, can be used to assess the binding affinity of the CasX protein to a gRNA variant to form an RNP. For example, one skilled in the art can measure changes in the amount of fluorescently tagged gRNA bound to immobilized CasX protein in response to increasing concentrations of an additional unlabeled "cold competitor" gRNA. Alternatively, or additionally, one can monitor or observe how the fluorescent signal changes as different amounts of fluorescently labeled gRNA are flowed over the immobilized CasX protein. Alternatively, the ability to form RNPs can be assessed using an in vitro cleavage assay against a defined target nucleic acid sequence, as described in the Examples.
[0140] i. Chemically modified gRNA In some embodiments, the present disclosure provides chemically modified gRNAs. In some embodiments, the present disclosure provides chemically modified gRNAs that have guide NA functionality and reduced susceptibility to cleavage by nucleases. A gRNA that includes any nucleotide or deoxynucleotide other than the four canonical ribonucleotides (A, C, G, and U) is a chemically modified gRNA. In some cases, a chemically modified gRNA includes any backbone or internucleotide linkage other than a natural phosphodiester internucleotide linkage. In certain embodiments, the retained functionality includes the ability of the modified gRNA to bind to a CasX of any of the embodiments described herein. In certain embodiments, the retained functionality includes the ability of the modified gRNA to bind to a target nucleic acid sequence. In certain embodiments, the retained functionality includes the ability to target a CasX protein or the ability of a pre-complexed RNP to bind to a target nucleic acid sequence. In certain embodiments, the retained functionality includes the ability of the CasX-gRNA to nick a target polynucleotide. In certain embodiments, the retained functionality includes the ability of the CasX-gRNA to cleave a target nucleic acid sequence. In certain embodiments, the retained functionality is any other known function of a gRNA in a recombination system having a CasX chimeric protein of an embodiment of the present disclosure.
[0141] In some embodiments, the present disclosure provides chemically modified gRNAs, 1~4 Alkyl, e.g., 2'-O-methyl (2'-OMe), 2'-deoxy (2'-H), 2'-OC 1-3 Alkyl-OC 1-3Nucleotide sugar modifications selected from the group consisting of alkyl, e.g., 2'-methoxyethyl ("2'-MOE"), 2'-fluoro ("2'-F"), 2'-amino ("2'-NH"), 2'-arabinosyl ("2'-arabino") nucleotides, 2'-F-arabinosyl ("2'-F-arabino") nucleotides, 2'-locked nucleic acid ("LNA") nucleotides, 2'-unlocked nucleic acid ("ULNA") nucleotides, L-form sugars ("L-sugars"), and 4'-thioribosyl nucleotides are incorporated into the gRNA. In other embodiments, phosphorothioate "P(S)" (P(S)), phosphonocarboxylate (P(CH)), phosphonothioate ... n COOR), e.g., phosphonoacetate "PACE" (P(CHCOO - )), thiophosphonocarboxylate ((S)P(CH2) n COOR), e.g., thiophosphonoacetate "thioPACE" ((S)P(CH2) n COO - )), alkyl phosphonates (P(C 1-3 Modifications of the internucleotide linkages selected from the group consisting of alkyl (e.g., methylphosphonate-P(CH), boranophosphonate (P(BH)), and phosphorodithioate (P(S)) are incorporated into the guide RNA.
[0142] In certain embodiments, the present disclosure provides chemically modified gRNAs, and includes 2-thiouracil ("2-thioU"), 2-thiocytosine ("2-thioC"), 4-thiouracil ("4-thioU"), 6-thioguanine ("6-thioG"), 2-aminoadenine ("2-aminoA"), 2-aminopurine, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-methylcytosine ("5-methylC"), 5-methyluracil ("5-methylU"), 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydro ... Nucleobase ("base") modifications selected from the group consisting of uracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allyluracil ("5-allylU"), 5-allylcytosine ("5-allylC"), 5-aminoallyluracil ("5-aminoallylU"), 5-aminoallyl-cytosine ("5-aminoallylC"), abasic nucleotides, Z bases, P bases, amorphous nucleic acids ("UNA"), isoguanine ("isoG"), isocytosine ("isoC"), 5-methyl-2-pyrimidine, x (A, G, C, T), and y (A, G, C, T) are incorporated into the gRNA.
[0143] In other embodiments, the present disclosure provides chemically modified gRNAs, comprising one or more 15 N, 13 C. 14 C, deuterium, 3 H, 32 P, 125 I, 131 One or more isotopic modifications are introduced into the nucleotide sugar, nucleobase, phosphodiester bond, and / or nucleotide phosphate, including nucleotides containing an I atom or other atom or element used as a tracer.
[0144] In some embodiments, the "terminal" modification incorporated into the gRNA is selected from the group consisting of PEG (polyethylene glycol), hydrocarbon linkers (heteroatom (O,S,N)-substituted hydrocarbon spacers, halo-substituted hydrocarbon spacers, keto-, carboxyl-, amido-, thionyl-, carbamoyl-, thionocarbamaoyl-containing hydrocarbon spacers), spermine linkers, dyes such as fluorescent dyes (e.g., fluorescein, rhodamine, cyanine) attached to a linker, e.g., 6-fluorescein-hexyl, quenchers (e.g., dabcyl, BHQ), and other labels (e.g., biotin, digoxigenin, acridine, streptavidin, avidin, peptides, and / or proteins). In some embodiments, the "terminal" modification comprises conjugation (or ligation) of the gRNA to another molecule, including deoxynucleotide and / or ribonucleotide oligonucleotides, peptides, proteins, sugars, oligosaccharides, steroids, lipids, folate, vitamins, and / or other molecules. In certain embodiments, the present disclosure provides chemically modified gRNAs in which the "terminal" modifications (described above) are located internal to the gRNA sequence via a linker, such as, for example, a 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linker, which is incorporated as a phosphodiester bond and can be incorporated anywhere between two nucleotides in the gRNA.
[0145] In some embodiments, the present disclosure provides chemically modified gRNAs with terminal modifications, including terminal functional groups such as amine, thiol (or sulfhydryl), hydroxyl, carboxyl, carbonyl, thionyl, thiocarbonyl, carbamoyl, thiocarbamoyl, phosphoryl, alkene, alkyne, halogen, or functional terminal linkers, which can subsequently be linked to fluorescent dyes, non-fluorescent labels, tags (e.g., 14 For C, for example, biotin, avidin, streptavidin, or 15 N, 13 C, deuterium, 3 H, 32 P, 125The conjugation can be performed using standard chemistries well known in the art, including, but not limited to, coupling via N-hydroxysuccinimide, isothiocyanate, DCC (or DCI), and / or any other standard method (see, for example, "Bioconjugate Techniques" by Greg T. Hermanson, Publisher Essevier Science, 3003, the contents of which are incorporated herein by reference in their entirety). rd (ed. (2013)).
[0146] IV. Class 2, Type V CRISPR Proteins for Modifying Target Nucleic Acids The present disclosure provides a system comprising a CRISPR nuclease useful for genome editing in eukaryotic cells. In some embodiments, the CRISPR nuclease used in the genome editing system is a class 2, type V nuclease. Although there are differences between members of class 2, type V CRISPR-Cas systems, they share several common features that distinguish them from the Cas9 system. First, class 2, type V nucleases have a single RNA-guided RuvC domain-containing effector but lack an HNH domain and recognize a PAM in a TC motif 5' upstream of the target region on the non-target strand, which differs from the Cas9 system, which relies on a G-rich PAM 3' to the target sequence. Unlike Cas9, which generates blunt ends at proximal sites close to the PAM, type V nucleases generate double-strand breaks distal to the PAM sequence. Additionally, type V nucleases degrade ssDNA in trans when activated by target dsDNA or ssDNA binding in cis. In some embodiments, the type V nuclease of the present embodiments recognizes a 5'-TC PAM motif and generates sticky ends that are cleaved only by the RuvC domain. In some embodiments, the type V nuclease is selected from the group consisting of Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cas12k, C2c4, C2c8, C2c5, C2c10, C2c9, CasZ, and CasX. In some embodiments, the present disclosure provides a system comprising a CasX variant protein and one or more gRNA variants (CasX:gRNA system), which is specifically designed to modify a target nucleic acid sequence in a eukaryotic cell.
[0147] As used herein, the term "CasX protein" refers to a family of proteins and includes all naturally occurring CasX proteins, proteins that share at least 50% identity with a naturally occurring CasX protein, and CasX variants that have one or more improved characteristics compared to a naturally occurring reference CasX protein or another CasX variant from which it is derived.
[0148] The CasX proteins of the present disclosure comprise at least one of the following domains: a non-target strand binding (NTSB) domain, a target strand loading (TSL) domain, a helix I domain (further divided into helix II and I-II subdomains), a helix II domain, an oligonucleotide binding domain (further divided into OBD, OBD-I, and OBD-II subdomains), and a RuvC DNA cleavage domain (further divided into RuvC-I and II subdomains). The RuvC domain can be modified or deleted in catalytically-dead CasX variants, which are described in more detail below.
[0149] In some embodiments, a CasX protein can bind to and / or modify (e.g., nick, catalyze double-stranded cleavage, methylate, demethylate, etc.) a target nucleic acid at a specific sequence targeted by an associated gRNA that hybridizes to a sequence within the target nucleic acid sequence.
[0150] a. Reference CasX protein The present disclosure provides naturally occurring CasX proteins (herein referred to as "reference CasX proteins") that were subsequently modified to generate the CasX variants of the present disclosure. For example, the reference CasX protein can be isolated from a naturally occurring prokaryote, such as a Deltaproteobacteria, Planctomycetes, or Candidatus Sungbacteria species. The reference CasX protein is a type II CRISPR / Cas endonuclease that belongs to the CasX (interchangeably referred to as Cas12e) family of proteins that interact with guide RNAs to form ribonucleoprotein (RNP) complexes.
[0151] In some cases, the reference CasX protein is isolated or derived from Deltaproteobacter and has the following sequence: 1 MEKRINKIRK KLSADNATKP VSRSGPMKTL LVRVMTDDLK KRLEKRRKKP EVMPQVISNN 61 AANNLRMLLD DYTKMKEAIL QVYWQEFKDD HVGLMCKFAQ PASKKIDQNK LKPEMDEKGN 121 LTTAGFACSQ CGQPLFVYKL EQVSEKGKAY TNYFGRCNVA EHEKLILLAQ LKPEKDSDEA 181 VTYSLGKFGQ RALDFYSIHV TKESTHPVKP LAQIAGNRYA SGPVGKALSD ACMGTIASFL 241 SKYQDIIIEH QKVVKGNQKR LESLRELAGK ENLEYPSVTL PPQPHTKEGV DAYNEVIARV 301 RMWVNLNLWQ KLKLSRDDAK PLLRLKGFPS FPVVERRENE VDWWNTINEV KKLIDAKRDM 361 GRVFWSGVTA EKRNTILEGY NYLPNENDHK KREGSLENPK KPAKRQFGDL LLYLEKKYAG 421 DWGKVFDEAW ERIDKKIAGL TSHIEREEAR NAEDAQSKAV LTDWLRAKAS FVLERLKEMD 481 EKEFYACEIQ LQKWYGDLRG NPFAVEAENR VVDISGFSIG SDGHSIQYRN LLAWKYLENG 541 KREFYLLMNY GKKGRIRFTD GTDIKKSGKW QGLLYGGGKA KVIDLTFDPD DEQLIILPLA 601 FGTRQGREFI WNDLLSLETG LIKLANGRVI EKTIYNKKIG RDEPALFVAL TFERREVVDP 661 SNIKPVNLIG VDRGENIPAV IALTDPEGCP LPEFKDSSGG PTDILRIGEG YKEKQRAIQA 721 AKEVEQRRAG GYSRKFASKS RNLADDMVRN SARDLFYHAV THDAVLVFEN LSRGFGRQGK 781 RTFMTERQYT KMEDWLTAKL AYEGLTSKTY LSKTLAQYTS KTCSNCGFTI TTADYDGMLV 841 RLKKTSDGWA TTLNNKELKA EGQITYYNRY KRQTVEKELS AELDRLSEES GNNDISKWTK 901 GRRDEALFLL KKRFSHRPVQ EQFVCLDCGH EVHADEQAAL NIARSWLFLN SNSTEFKSYK 961 SGKQPFVGAW QAFYKRRLKE VWKPNA (SEQ ID NO: 1).
[0152] In some cases, the reference CasX protein is isolated or derived from a Planctomycetes and has the following sequence: 1 MQEIKRINKI RRRLVKDSNT KKAGKTGPMK TLLVRVMTPD LRERLENLRK KPENIPQPIS 61 NTSRANLNKL LTDYTEMKKA ILHVYWEEFQ KDPVGLMSRV AQPAPKNIDQ RKLIPVKDGN 121 ERLTSSGFAC SQCCQPLYVY KLEQVNDKGK PHTNYFGRCN VSEHERLILL SPHKPEANDE 181 LVTYSLGKFG QRALDFYSIH VTRESNHPVK PLEQIGGNSC ASGPVGKALS DACMGAVASF 241 LTKYQDIILE HQKVIKKNEK RLANLKDIAS ANGLAFPKIT LPPQPHTKEG IEAYNNVVAQ 301 IVIWVNLNLW QKLKIGRDEA KPLQRLKGFP SFPLVERQAN EVDWWDMVCN VKKLINEKKE 361 DGKVFWQNLA GYKRQEALLP YLSSEEDRKK GKKFARYQFG DLLLHLEKKH GEDWGKVYDE 421 AWERIDKKVE GLSKHIKLEE ERRSEDAQSK AALTDWLRAK ASFVIEGLKE ADKDEFCRCE 481 LKLQKWYGDL RGKPFAIEAE NSILDISGFS KQYNCAFIWQ KDGVKKLNLY LIINYFKGGK 541 LRFKKIKPEA FEANRFYTVI NKKSGEIVPM EVNFNFDDPN LIILPLAFGK RQGREFIWND 601 LLSLETGSLK LANGRVIEKT LYNRRTRQDE PALFVALTFE RREVLDSSNI KPMNLIGIDR 661 GENIPAVIAL TDPEGCPLSR FKDSLGNPTH ILRIGESYKE KQRTIQAAKE VEQRRAGGYS 721 RKYASKAKNL ADDMVRNTAR DLLYYAVTQD AMLIFENLSR GFGRQGKRTF MAERQYTRME 781 DWLTAKLAYE GLPSKTYLSK TLAQYTSKTC SNCGFTITSA DYDRVLEKLK KTATGWMTTI 841 NGKELKVEGQ ITYYNRYKRQ NVVKDLSVEL DRLSEESVNN DISSWTKGRS GEALSLLKKR 901 FSHRPVQEKF VCLNCGFETH ADEQAALNIA RSWLFLRSQE YKKYQTNKTT GNTDKRAFVE 961 TWQSFYRKKL KEVWKPAV (SEQ ID NO: 2).
[0153] In some cases, the reference CasX protein is isolated or derived from Candidatus Sungbacteria and has the following sequence: 1 MDNANKPSTK SLVNTTRISD HFGVTPGQVT RVFSFGIIPT KRQYAIIERW FAAVEAARER 61 LYGMLYAHFQ ENPPAYLKEK FSYETFKGR PVNLGLRDID PTIMTSAVFT ALRHKAEGAM 121 AAFHTNHRRL FEEARKKMRE YAECLKANEA LLRGAADIDW DKIVNALRTR LNTCLAPEYD 181 AVIADFGALC AFRALIAETN ALKGAYNHAL NQMLPALVKV DEPEEAEESP RLRFFNGRIN 241 DLPKFPVAER ETPPDTETII RQLEDMARVI PDTAEILGYI HRIRHKAARR KPGSAVPLPQ 301 RVALYCAIRM ERNPEEDPST VAGHFLGEID RVCEKRRQGL VRTPFDSQIR ARYMDIISFR 361 ATLAHPDRWT EIQFLRSNAA SRRVRAETIS APFEGFSWTS NRTNPAPQYG MALAKDANAP 421 ADAPELCICL SPSSAAFSVR EKGGDLIYMR PTGGRRGKDN PGKEITWVPG SFDEYPASGV 481 ALKLRLYFGR SQARRMLTNK TWGLLSDNPR VFAANAELVG KKRNPQDRWK LFFHMVISGP 541 PPVEYLDFSS DVRSRARTVI GINRGEVNPL AYAVVSVEDG QVLEEGLLGK KEYIDQLIET 601 RRRISEYQSR EQTPPRDLRQ RVRHLQDTVL GSARAKIHSL IAFWKGILAI ERLDDQFHGR 661 EQKIIPKKTY LANKTGFMNA LSFSGAVRVD KKGNPWGGMI EIYPGGISRT CTQCGTVWLA 721 RRPKNPGHRD AMVVIPDIVD DAAATGFDNV DCDAGTVDYG ELFTLSREWV RLTPRYSRVM 781 RGTLGDLERA IRQGDDRKSR QMLELALEPQ PQWGQFFCHR CGFNGQSDVL AATNLARRAI 841 SLIRRLPDTD TPPTP (SEQ ID NO: 3).
[0154] b. Class 2, type V CasX variant proteins The present disclosure provides variants derived from class 2, type V, CasX variants of a reference CasX protein or other CasX variants (see, e.g., Figure 44) (interchangeably referred to herein as "class 2, type V CasX variants," "CasX variants," or "CasX variant proteins"). Class 2, type V CasX variants contain at least one modification in at least one domain compared to a reference CasX protein (including, but not limited to, the sequences of SEQ ID NOS: 1-3) or another CasX variant. Any change in the amino acid sequence of a reference CasX protein or another CasX variant protein that results in improved characteristics of the CasX protein is considered a CasX variant protein of the present disclosure. For example, a CasX variant can contain one or more amino acid substitutions, insertions, deletions, or swapped domains, or any combination thereof, compared to the reference CasX protein sequence.
[0155] The CasX variants of the present disclosure have one or more improved characteristics compared to the reference CasX protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or the variant from which it is derived (e.g., CasX491 (SEQ ID NO: 336) or CasX515 (SEQ ID NO: 416). Exemplary improved characteristics of CasX variant embodiments include improved folding of the variant, increased binding affinity for a gRNA, increased binding affinity for a target nucleic acid, improved ability to utilize a wider range of PAM sequences in editing and / or binding to a target nucleic acid, improved target DNA unwinding, increased editing activity, improved editing efficiency, improved editing specificity for a target nucleic acid, reduced off-target editing or cleavage, an increased proportion of eukaryotic genomes that can be efficiently edited, increased nuclease activity, increased target strand loading for double-stranded cleavage, reduced target strand loading for single-stranded nicking, increased binding of non-target strands of DNA, improved protein stability, and / or improved protein reactivity. These include, but are not limited to, improved stability of the gRNA (RNP) complex and improved fusion characteristics. In the foregoing embodiments, one or more of the improved characteristics of the CasX variant are improved by at least about 1.1 to about 100,000-fold compared to the reference CasX protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or CasX491 (SEQ ID NO: 336) or CasX515 (SEQ ID NO: 416), when assayed in a comparable manner. In other embodiments, the improvement is at least about 1.1-fold, at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or at least about 100,000-fold compared to the reference CasX protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or CasX491 or CasX515, when assayed in a comparable manner.In other cases, one or more improved characteristics of the RNP of the CasX variant and gRNA variant are improved by at least about 1.1, at least about 10, at least about 100, at least about 1000, at least about 10,000, at least about 100,000 times, or more compared to the RNP of a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 and a gRNA of Table 1, or the RNP of CasX491 or CasX515 and gRNA174. In other cases, one or more of the improved characteristics of the RNP of the CasX variant and gRNA variant are about 1.1 to 100,00 fold, about 1.1 to 10,00 fold, about 1.1 to 1,000 fold, about 1.1 to 500 fold, about 1.1 to 100 fold, about 1.1 to 50 fold, about 1.1 to 20 fold, about 10 to 100,00 fold, about 10 to 10,00 fold, about 10 to 1,000 fold, about 10 to 500 fold, about 10 to 100 fold, about 10 to 50 fold, about 10 to 20 fold, compared to the RNP of a reference CasX protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and a gRNA of Table 1, or CasX491 or CasX515 and gRNA174, when assayed in an equivalent manner. , about 2-70 times, about 2-50 times, about 2-30 times, about 2-20 times, about 2-10 times, about 5-50 times, about 5-30 times, about 5-10 times, about 100-100,00 times, about 100~10,00x, approx. 100~1,000x, approx. 100~500x, approx. 500~100,00x, approx. 500~10,00x, approx. 500~1,000x, approx. The improvement is 500 to 750 times, about 1,000 to 100,00 times, about 10,000 to 100,00 times, about 20 to 500 times, about 20 to 250 times, about 20 to 200 times, about 20 to 100 times, about 20 to 50 times, about 50 to 10,000 times, about 50 to 1,000 times, about 50 to 500 times, about 50 to 200 times, or about 50 to 100 times.In other cases, the one or more improved characteristics of the RNP of the CasX variant and gRNA variant may be about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 26-fold, 27-fold, 28-fold, 29-fold, 30-fold, 31-fold, 32-fold, 33-fold, 34-fold, 35-fold, 36-fold, 37-fold, 38-fold, 39-fold, 40-fold, 41-fold, 42-fold, 43-fold, 44-fold, 45-fold, 46-fold, 47-fold, 48-fold, 49-fold, 50-fold, 51-fold, 52-fold, 53-fold, 54-fold, 55-fold, 56-fold, 57-fold, 58-fold, 59-fold, 60-fold, 61-fold, 62-fold, 63-fold, 64-fold, 65-fold, 66-fold, 67-fold, 68-fold, 69-fold, 70-fold, 71-fold, 72-fold, 73- fold, 17x, 18x, 19x, 20x, 25x, 30x, 40x, 45x, 50x, 55x, 60x, 70x, 80x, 90x, 100x, 110x, 120x, 130x, 140x, 150x, 160x, 170x, 180x, 190x, 200x, 210x, 220x, 230x, 240x, 250x, 260x, 270x, 280x, 290x, 300x, 310x, 320x, 330x, 340x, 350x, 360x, 370x, 380x, 390x, 400x, 425x, 450x, 475x, or 500x improvement.
[0156] In some embodiments, the modification of the CasX variant is a mutation in one or more amino acids of the reference CasX. In other embodiments, the modification includes the insertion or substitution of part or all of a domain from a different CasX protein. In certain embodiments, the CasX variants of SEQ ID NOs: 415-592 and 1147-1231 have the NTSB and helix 1B domains of SEQ ID NO: 1, in addition to individual modifications in select domains described herein, while other domains are derived from SEQ ID NO: 2. Mutations can be introduced into any one or more domains of the reference CasX protein or CasX variant, including, for example, deletion of part or all of one or more domains, or substitution, deletion, or insertion of one or more amino acids in any domain of the reference CasX protein or the CasX variant from which it is derived. Domains of the CasX protein include the non-target strand binding (NTSB) domain, the target strand loading (TSL) domain, the helix I domain, the helix II domain, the oligonucleotide binding domain (OBD), and the RuvC DNA cleavage domain. Without being bound by theory or mechanism, the NTSB domain in CasX may enable binding to a non-target nucleic acid strand and assist in unwinding the non-target and target strands. The NTSB domain is presumed to be involved in unwinding or capturing the unwound non-target nucleic acid strand. An exemplary NTSB domain includes amino acids 100-190 of SEQ ID NO:1 or amino acids 102-191 of SEQ ID NO:2. In some embodiments, the NTSB domain of a reference CasX protein includes a four-stranded β-sheet. In some embodiments, the TSL acts to position or capture the target strand in a folded state, positioning the scissile phosphate of the target strand DNA backbone in the RuvC active site. An exemplary TSL includes amino acids 824-933 of SEQ ID NO:1 or amino acids 811-920 of SEQ ID NO:2. Without wishing to be bound by theory, it is believed that in some cases, the Helix I domain may contribute to protospacer adjacent motif (PAM) binding. In some embodiments, the helix I domain of the reference CasX protein comprises one or more alpha helices.Exemplary helix II and I-II domains include amino acids 56-99 and 191-331 of SEQ ID NO: 1, respectively, or amino acids 58-101 and 192-332 of SEQ ID NO: 2, respectively. The helix II domain is involved in binding to the guide RNA scaffold stem-loop and the bound DNA. Exemplary helix II domains include amino acids 332-508 of SEQ ID NO: 1, or amino acids 333-500 of SEQ ID NO: 2. The OBD primarily binds to the RNA triplex of the guide RNA scaffold. The OBD may also be involved in binding to the protospacer adjacent motif (PAM). Exemplary OBD I and II domains include amino acids 1-55 and 509-659 of SEQ ID NO: 1, respectively, or amino acids 1-57 and 501-646 of SEQ ID NO: 2, respectively. RuvC possesses a DED motif active site that is responsible for cleaving both strands of DNA (one at a time, most likely first cleaving the non-target strand 11-14 nucleotides (nt) into the target sequence, and then cleaving the target strand 2-4 nucleotides after the target sequence, resulting in staggered cleavage). CasX is particularly unique in that the RuvC domain is also responsible for binding the guide RNA scaffold stem-loop, which is critical for CasX function. Exemplary RuvC I and II domains include amino acids 660-823 and 934-986 of SEQ ID NO:1, respectively, or amino acids 647-810 and 921-978 of SEQ ID NO:2, respectively, while CasX variants can include mutations at positions I658 and A708 relative to SEQ ID NO:2, or the CasX515 mutation described below.
[0157] In some embodiments, the CasX variant protein comprises at least one modification in at least one domain, in each of at least two domains, in each of at least three domains, in each of at least four domains, or in each of at least five domains of a reference CasX protein comprising a sequence of SEQ ID NOs: 1-3. In some embodiments, the CasX variant protein comprises two or more modifications in at least one domain of a reference CasX protein. In some embodiments, the CasX variant protein comprises at least two modifications in at least one domain of a reference CasX protein, at least three modifications in at least one domain of a reference CasX protein, or at least four or more modifications in at least one domain of a reference CasX protein. In some embodiments, the CasX variant comprises two or more modifications compared to the reference CasX, each modification independently occurring in a domain selected from the group consisting of NTSB, TSL, helix I domain, helix II domain, OBD, and RuvC DNA cleavage domain. In some embodiments, the CasX variant comprises two or more modifications compared to a reference CasX protein, the modifications being in two or more domains. In some embodiments, at least one modification of the CasX variant protein comprises a deletion of at least a portion of one domain of the reference CasX protein of SEQ ID NOs: 1-3. In some embodiments, the deletion is in the NTSB domain, the TSL domain, the Helix I domain, the Helix II domain, the OBD, or the RuvC DNA cleavage domain.
[0158] In some cases, the CasX variants of the present disclosure contain modifications in structural regions that may encompass one or more domains. In some embodiments, the CasX variant contains at least one modification in a region of non-contiguous amino acid residues of the CasX variant that forms a channel through which gRNA:target nucleic acid complexation with the CasX variant occurs. In other embodiments, the CasX variant contains at least one modification in a region of non-contiguous amino acid residues of the CasX variant that forms an interface that binds with the gRNA. In other embodiments, the CasX variant contains at least one modification in a region of non-contiguous amino acid residues of the CasX variant that forms a channel that binds with non-target strand DNA. In other embodiments, the CasX variant contains at least one modification in a region of non-contiguous amino acid residues of the CasX variant that forms an interface that binds with the protospacer adjacent motif (PAM) of the target nucleic acid. In other embodiments, the CasX variant contains at least one modification in a region of non-contiguous surface-exposed amino acid residues of the CasX variant. In other embodiments, the CasX variant comprises at least one modification of a region of non-adjacent amino acid residues that form a core through hydrophobic packing in the domain of the CasX variant. In the foregoing embodiments of this paragraph, the modification of the region can comprise one or more of a deletion, insertion, or substitution of one or more amino acids in the region, or a substitution of 2 to 15 amino acid residues in the region of the CasX variant with charged amino acids, or a substitution of 2 to 15 amino acid residues in the region of the CasX variant with polar amino acids, or a substitution of 2 to 15 amino acid residues in the region of the CasX variant with amino acids that stack with or have affinity for bases in DNA or RNA.
[0159] In other embodiments, the present disclosure provides CasX variants that contain at least one modification compared to another CasX variant. For example, CasX variants 515 and 527 are variants of CasX variant 491, and CasX variants 668 and 672 are variants of CasX535 (see Figure 44). In some embodiments, the at least one modification is selected from the group consisting of an amino acid insertion, deletion, or substitution. All variants that improve one or more functions or characteristics of the CasX variant protein when compared to a reference CasX protein described herein or the variant from which it is derived are contemplated within the scope of the present disclosure. As described in the Examples, CasX variants can be mutagenized to generate additional CasX variants. In certain embodiments, the present disclosure provides a variant of CasX515 (SEQ ID NO: 416) generated by introducing modifications into the coding sequence that result in amino acid substitutions, deletions, or insertions at one or more positions in one or more domains, as described in Example 14.
[0160] Suitable mutagenesis methods for generating the disclosed CasX variant proteins can include, for example, comprehensive mutational evolution (DME), comprehensive mutation scanning (DMS), error-prone PCR, cassette mutagenesis, random mutagenesis, tethered extension PCR, gene shuffling, or domain swapping (described in International Application No. PCT / US20 / 36506 and International Publication No. WO2020247883(A2), which are incorporated herein by reference). In some embodiments, CasX variants are designed by selecting multiple desired mutations in a CasX variant identified, for example, using the assays described in the Examples. In certain embodiments, the activity of a reference CasX or CasX variant protein is used as a benchmark, prior to mutagenesis, against which the activity of one or more resulting CasX variants is compared, thereby measuring the improved function of the new CasX variant.
[0161] In some embodiments of the CasX variants described herein, at least one modification comprises: (a) a substitution of 1 to 100 contiguous or non-contiguous amino acids in the CasX variant compared to the reference CasX of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, CasX variant 491 (SEQ ID NO: 336), or CasX variant 515 (SEQ ID NO: 416); (b) a deletion of 1 to 100 contiguous or non-contiguous amino acids in the CasX variant compared to the reference CasX or the variant from which it is derived; (c) an insertion of 1 to 100 contiguous or non-contiguous amino acids in the CasX compared to the reference CasX or the variant from which it is derived; or (d) any combination of (a)-(c). In some embodiments, at least one modification comprises: (a) a substitution of 1 to 10 consecutive or non-consecutive amino acids in the CasX variant compared to a reference CasX of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or the variant from which it is derived; (b) a deletion of 1 to 5 consecutive or non-consecutive amino acids in the CasX variant compared to the reference CasX or the variant from which it is derived; (c) an insertion of 1 to 5 consecutive or non-consecutive amino acids in the CasX compared to the reference CasX or the variant from which it is derived; or (d) any combination of (a)-(c).
[0162] In some embodiments, the CasX variant protein comprises or consists of a sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 modifications compared to the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, CasX491, or CasX515. In some embodiments, the CasX variant protein comprises one or more substitutions compared to CasX491 or SEQ ID NO:336. In some embodiments, the CasX variant protein comprises one or more substitutions compared to CasX515 or SEQ ID NO:416. These modifications can be amino acid insertions, deletions, substitutions, or any combination thereof. The modifications can be in one domain of the CasX variant, or in either domain, or in any combination of domains. In the substitutions described herein, any amino acid can be substituted for any other amino acid. Substitutions can be conservative (e.g., a basic amino acid is substituted for another basic amino acid). Substitutions can also be non-conservative (e.g., a basic amino acid is substituted for an acidic amino acid, or vice versa). For example, a proline in a reference CasX protein can be substituted with any of arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, glycine, alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, or valine to generate a CasX variant protein of the disclosure.
[0163] Any permutation of the substitutions, insertions, and deletions of the embodiments described herein can be combined to generate a CasX variant protein of the present disclosure. For example, a CasX variant protein can include at least one substitution and at least one deletion compared to a reference CasX protein sequence or the sequence of CasX491 or CasX515, can include at least one substitution and at least one insertion compared to a reference CasX protein sequence or the sequence of CasX491 or CasX515, can include at least one insertion and at least one deletion compared to a reference CasX protein sequence or the sequence of CasX491 or CasX515, or can include at least one substitution, at least one insertion, and at least one deletion compared to a reference CasX protein sequence or the sequence of CasX491 or CasX515.
[0164] In some embodiments, the CasX variant protein comprises 400 to 2000 amino acids, 500 to 1500 amino acids, 700 to 1200 amino acids, 800 to 1100 amino acids, or 900 to 1000 amino acids.
[0165] In some embodiments, the CasX variant protein comprises the sequence of SEQ ID NO: 247-592 or 1147-1231 shown in Table 3. In some embodiments, the CasX variant protein consists of the sequence of SEQ ID NO: 247-592 or 1147-1231 shown in Table 3. In other embodiments, the CasX variant protein comprises a sequence at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to the sequence of SEQ ID NOs:247-592 and 1147-1231 shown in Table 3. In some embodiments, the CasX variant protein comprises or consists of the sequence of SEQ ID NOs:270-592 or 1147-1231. In other embodiments, the CasX variant protein comprises a sequence at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to the sequence of SEQ ID NOs: 270-592 or 1147-1231. In some embodiments, the CasX variant protein comprises or consists of the sequence of SEQ ID NOs: 415-592 or 1147-1231.In other embodiments, the CasX variant protein comprises a sequence at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to the sequence of SEQ ID NOs: 416-592 or 1147-1231 (ND = not listed or otherwise provided).
[0166] [Table 3-1]
[0167] [Table 3-2]
[0168] [Table 3-3]
[0169] [Table 3-4]
[0170] [Table 3-5]
[0171] [Table 3-6]
[0172] [Table 3-7]
[0173] c. CasX variant proteins with domains derived from multiple protein sources In certain embodiments, the present disclosure provides chimeric CasX proteins comprising protein domains from two or more different CasX proteins (e.g., two or more naturally occurring CasX proteins or two or more CasX variant protein sequences described herein). As used herein, "chimeric CasX protein" refers to a CasX comprising at least two domains isolated or derived from different sources (e.g., two naturally occurring proteins), which in some embodiments may be isolated from different species. For example, in some embodiments, a chimeric CasX protein comprises a first domain from a first CasX protein and a second domain from a second, different CasX protein. In some embodiments, the first domain may be selected from the group consisting of NTSB, TSL, helix I, helix II, OBD, and RuvC domains. In some embodiments, the second domain is selected from the group consisting of NTSB, TSL, helix I, helix II, OBD, and RuvC domains, and the second domain is different from said first domain. In certain embodiments, CasX variants 514-791 (SEQ ID NOs: 415-592 and 1147-1231) have the NTSB and helix 1B domains derived from the sequence of SEQ ID NO: 1, while the other domains are derived from SEQ ID NO: 2, with the understanding that this variant has additional amino acid changes at selected positions.
[0174] d. Protein affinity for gRNA In some embodiments, the CasX variant protein has improved affinity for gRNA compared to a reference CasX protein, resulting in the formation of a ribonucleoprotein complex (RNP). The increased affinity of the CasX variant protein for gRNA can result in, for example, a lower K for the formation of the RNP complex. d This may result in the formation of a more stable ribonucleoprotein complex, in some cases. In some embodiments, increased affinity of the CasX variant protein for gRNA results in increased stability of the ribonucleoprotein complex when delivered to human cells. This increased stability may affect the function and utility of the complex in the subject's cells and may result in improved pharmacokinetic properties in the blood when delivered to a subject. In some embodiments, increased affinity of the CasX variant protein and the resulting increased stability of the ribonucleoprotein complex allow for lower doses of the CasX variant protein to be delivered to a subject or cell while still having the desired activity, e.g., gene editing in vivo or in vitro. In some embodiments, higher affinity (stronger binding) of the CasX variant protein for gRNA allows for more editing events when both the CasX variant protein and gRNA remain in the RNP complex. The increase in editing events can be assessed using an editing assay, such as the tdTom editing assay described herein. In some embodiments, the K of the CasX variant protein for gRNA is measured. dis increased by at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100-fold compared to a reference CasX protein. In some embodiments, the CasX variant has an increased binding affinity for the gRNA by about 1.1 to about 10-fold compared to a reference CasX protein of SEQ ID NO:2.
[0175] In some embodiments, increased affinity of the CasX variant protein for gRNA results in increased stability of the ribonucleoprotein complex when delivered to mammalian cells, including in vivo delivery to a subject. This increased stability can affect the function and utility of the complex in the subject's cells and can result in improved pharmacokinetic properties in the blood when delivered to a subject. In some embodiments, increased affinity of the CasX variant protein and the resulting increased stability of the ribonucleoprotein complex allow lower doses of the CasX variant protein to be delivered to a subject or cell while still having the desired activity (e.g., in vivo or in vitro gene editing). The increased ability to form RNPs and maintain them in a stable form can be assessed using assays (e.g., the in vitro cleavage assay described in the Examples herein). In some embodiments, RNPs containing the disclosed CasX variants, when complexed as RNPs, have at least two-fold, at least five-fold, or at least ten-fold higher kappa activity than RNPs containing the reference CasXs of SEQ ID NOS: 1-3. 切断 Speed can be achieved.
[0176] In some embodiments, the higher affinity (tighter binding) of the CasX variant protein for the gRNA allows for more editing events when both the CasX variant protein and the gRNA remain in the RNP complex, which can be assessed using an editing assay such as those described herein.
[0177] Without wishing to be bound by theory, in some embodiments, amino acid changes in the helix I domain can increase the binding affinity of the CasX variant protein to the gRNA targeting sequence, changes in the helix II domain can increase the binding affinity of the CasX variant protein to the gRNA scaffold stem-loop, and changes in the oligonucleotide binding domain (OBD) increase the binding affinity of the CasX variant protein to the gRNA triplex.
[0178] Methods for measuring the binding affinity of a CasX protein to a gRNA include in vitro methods using purified CasX protein and gRNA. Binding affinity to the reference CasX and variant proteins can be measured by fluorescence polarization if the gRNA or CasX protein is tagged with a fluorophore. Alternatively, or additionally, binding affinity can be measured by biolayer interferometry, electrophoretic mobility shift assay (EMSA), or membrane binding. Further standard techniques for quantifying the absolute affinity of an RNA-binding protein, such as a reference CasX and variant proteins of the present disclosure, to a particular gRNA, such as a reference gRNA and its variants, include, but are not limited to, isothermal calorimetry (ITC) and surface plasmon resonance (SPR), as well as methods in the Examples.
[0179] In some catalytically inactive embodiments, the CasX variant protein comprises one or more modifications in a region of non-contiguous residues that form the channel through which gRNA:target nucleic acid complexing occurs. In some embodiments, the CasX variant protein comprises one or more modifications comprising a region of non-contiguous residues that form the interface that binds to the gRNA. For example, in some embodiments of a reference CasX protein, the helix I, helix II, and OBD domains are all in contact with or close to the gRNA:target nucleic acid complex, and one or more modifications to non-contiguous residues within any of these domains can improve the function of the CasX variant protein.
[0180] In some embodiments, the CasX variant protein contains one or more modifications in a region of non-contiguous residues that form a channel that binds to non-target strand DNA. For example, the CasX variant protein can contain one or more modifications to non-contiguous residues in the NTSB domain. In some embodiments, the CasX variant protein contains one or more modifications in a region of non-contiguous residues that form an interface that binds to PAM. For example, the CasX variant protein can contain one or more modifications to non-contiguous residues in the helix I domain or the OBD. In some embodiments, the CasX variant protein contains one or more modifications that include a region of non-contiguous surface-exposed residues. As used herein, "surface-exposed residue" refers to an amino acid on the surface of the CasX protein or an amino acid where at least a portion of the amino acid (e.g., part of the backbone or side chain) is on the surface of the protein. Surface-exposed residues of cellular proteins (e.g., CasX) exposed to the aqueous intracellular environment are often selected from positively charged hydrophilic amino acids, such as arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, and threonine. Thus, for example, in some embodiments of the variants provided herein, the region of surface-exposed residues comprises one or more insertions, deletions, or substitutions compared to a reference CasX protein. In some embodiments, one or more positively charged residues are replaced with one or more other positively charged residues, or negatively charged residues, or uncharged residues, or any combination thereof. In some embodiments, one or more amino acid residues for substitution are in a nearby bound nucleic acid (e.g., residues in the RuvC domain or helix I domain that contact the target nucleic acid, or residues in the OBD or helix II domain that binds to the gRNA) and may be replaced with one or more positively charged or polar amino acids.
[0181] In some embodiments, the CasX variant protein contains one or more modifications in a region of non-contiguous residues that form a core through hydrophobic packing in a domain of a reference CasX protein. Without wishing to be bound by any theory, the region that forms the core through hydrophobic packing is rich in hydrophobic amino acids (e.g., valine, isoleucine, leucine, methionine, phenylalanine, tryptophan, and cysteine). For example, in some reference CasX proteins, the RuvC domain contains a hydrophobic pocket adjacent to the active site. In some embodiments, 2 to 15 residues in the region are charged, polar, or base-stacking residues. Charged amino acids (sometimes referred to herein as residues) can include, for example, arginine, lysine, aspartic acid, and glutamic acid, whose side chains can form salt bridges, provided a cross-linking partner is also present (see Figure 14). Polar amino acids can include, for example, glutamine, asparagine, histidine, serine, threonine, tyrosine, and cysteine. Polar amino acids, in some embodiments, can form hydrogen bonds as proton donors or acceptors, depending on the identity of their side chains. As used herein, "base stacking" refers to the interaction of aromatic side chains of amino acid residues (such as tryptophan, tyrosine, phenylalanine, or histidine) with stacked nucleotide bases in nucleic acids. Any modification to a region of non-contiguous amino acids that are spatially proximal to form a functional portion of a CasX variant protein is contemplated within the scope of this disclosure.
[0182] e. CasX variant proteins with domains derived from multiple protein sources In certain embodiments, the present disclosure provides chimeric CasX variant proteins comprising protein domains from two or more different CasX proteins (e.g., two or more naturally occurring CasX proteins or two or more CasX variant protein sequences described herein). As used herein, "chimeric CasX protein" refers to a CasX comprising at least two domains isolated or derived from different sources (e.g., two naturally occurring proteins), which in some embodiments may be isolated from different species. For example, in some embodiments, a chimeric CasX protein comprises a first domain from a first CasX protein and a second domain from a second, different CasX protein. In some embodiments, the first domain may be selected from the group consisting of NTSB, TSL, helix I, helix II, OBD, and RuvC domains. In some embodiments, the second domain is selected from the group consisting of NTSB, TSL, helix I, helix II, OBD, and RuvC domains, and the second domain is different from said first domain. For example, a chimeric CasX protein can comprise the NTSB, TSL, helix I, helix II, and OBD domains from the CasX protein of SEQ ID NO: 2 and the RuvC domain from the CasX protein of SEQ ID NO: 1, or vice versa. As a further example, a chimeric CasX protein can comprise the NTSB, TSL, helix II, OBD, and RuvC domains from the CasX protein of SEQ ID NO: 2 and the helix I domain from the CasX protein of SEQ ID NO: 1, or vice versa. Thus, in certain embodiments, a chimeric CasX protein can comprise the NTSB, TSL, helix II, OBD, and RuvC domains from a first CasX protein and the helix I domain from a second CasX protein. In some embodiments of the chimeric CasX protein, a domain of a first CasX protein is derived from the sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, and a domain of a second CasX protein is derived from the sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, and the first and second CasX proteins are not the same.In some embodiments, a domain of a first CasX protein comprises a sequence derived from SEQ ID NO:1, and a domain of a second CasX protein comprises a sequence derived from SEQ ID NO:2. In some embodiments, a domain of a first CasX protein comprises a sequence derived from SEQ ID NO:1, and a domain of a third CasX protein comprises a sequence derived from SEQ ID NO:2. In some embodiments, a domain of a second CasX protein comprises a sequence derived from SEQ ID NO:1, and a domain of a third CasX protein comprises a sequence derived from SEQ ID NO:2. As an example of the foregoing, a chimeric RuvC domain comprises amino acids 660-823 of SEQ ID NO:1 and amino acids 921-978 of SEQ ID NO:2. As an alternative example of the foregoing, a chimeric RuvC domain comprises amino acids 647-810 of SEQ ID NO:2 and amino acids 934-986 of SEQ ID NO:1. In some embodiments, at least one chimeric domain comprises a chimeric helix I domain, wherein the chimeric helix I domain comprises amino acids 56-99 of SEQ ID NO:1 and amino acids 192-332 of SEQ ID NO:2. In some embodiments, the chimeric CasX variant is further modified to include a CasX variant selected from the group consisting of the sequences of SEQ ID NO:270, SEQ ID NO:328, SEQ ID NO:336, SEQ ID NO:780, SEQ ID NO:412, SEQ ID NO:413, SEQ ID NO:414, SEQ ID NO:416, SEQ ID NO:435, SEQ ID NO:329, SEQ ID NO:781, SEQ ID NO:330, SEQ ID NO:782, SEQ ID NO:331, SEQ ID NO:783, SEQ ID NO:332, SEQ ID NO:784, SEQ ID NO:333, SEQ ID NO:785, SEQ ID NO:334, SEQ ID NO:786, SEQ ID NO:335, SEQ ID NO:567, SEQ ID NO:570, SEQ ID NO:574, SEQ ID NO:787, and SEQ ID NO:788. In some embodiments, the one or more additional modifications comprise an insertion, substitution, or deletion as described herein.
[0183] In the case of split or non-contiguous domains, such as helix I, RuvC, and OBD, portions of the non-contiguous domains can be replaced with corresponding portions from any other source. For example, the helix II domain (sometimes referred to as helix Ia) in SEQ ID NO:2 can be replaced with the corresponding helix II sequence from SEQ ID NO:1, etc. Table 4 lists domain sequences and their coordinates from reference CasX proteins. Representative examples of chimeric CasX proteins include variants of CasX472-483, 485-491, and 515, the sequences of which are listed in Table 3.
[0184] [Table 4] * OBDI and II, helices II and I-II, and RuvC I and II are also referred to herein as OBDa and b, helices Ia and b, and RuvCa and b.
[0185] Exemplary domain sequences are provided in Table 5 below.
[0186] [Table 5]
[0187] A further exemplary Helix II domain sequence is provided as SEQ ID NO:2351, and a further exemplary RuvCa domain sequence is provided as SEQ ID NO:2352.
[0188] In other embodiments, the CasX variant protein comprises the sequence of SEQ ID NOs:247-592 or 1147-1231 shown in Table 3 and further comprises one or more NLSs disclosed herein at or near either the N-terminus, C-terminus, or both. In other embodiments, the CasX variant protein comprises the sequence of SEQ ID NOs:270-592 and 1147-1231 and further comprises one or more NLSs disclosed herein at or near either the N-terminus, C-terminus, or both. In other embodiments, the CasX variant protein comprises the sequence of SEQ ID NOs:415-592 and 1147-1231 and further comprises one or more NLSs disclosed herein at or near either the N-terminus, C-terminus, or both. It will be understood that in some cases, the N-terminal methionine of the CasX variants in the tables is removed from the expressed CasX variant during post-translational modification. One of skill in the art will understand that an NLS near the N- or C-terminus of a protein can be within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, or 20 amino acids of the N- or C-terminus.
[0189] f. CasX variants derived from other CasX variants In further iterations of variant protein generation, the variant proteins can be utilized to generate additional CasX variants of the present disclosure. For example, as shown in Figure 44, CasX119 (SEQ ID NO:270), CasX491 (SEQ ID NO:336), and CasX515 (SEQ ID NO:416) are exemplary variant proteins that have been modified to generate additional CasX variants of the present disclosure with improved or additional properties compared to the reference CasX or CasX variant from which they were derived. CasX119 contains the L379R substitution, the A708K substitution, and a deletion of P at position 793 of SEQ ID NO:2. CasX491 contains an NTSB and helix 1B swap from SEQ ID NO:1. CasX515 was derived from CasX491 by inserting P at position 793 (relative to SEQ ID NO:2) and was used to generate the CasX variants described in Examples 13 and 14. For example, CasX668 has an R insertion at position 26 and a G223S substitution compared to CasX515. CasX672 has an L169K and a G223S substitution compared to CasX515. CasX676 has an L169K and a G223S substitution and an R insertion at position 26 compared to CasX515.
[0190] Exemplary methods used to generate and evaluate CasX variants derived from other CasX variants are described in the Examples, which were generated by introducing modifications into the coding sequence that resulted in amino acid substitutions, deletions, or insertions at one or more positions in one or more domains of the CasX variant. In particular, Examples 14 and 15 describe methods used to generate variants of CasX515 (SEQ ID NO: 416), which were then assayed to determine positions in the sequence that, when modified by amino acid insertion, deletion, or substitution, resulted in enrichment or improvement in the assay. In some cases, the results of the assays were used to generate the heat maps in Figures 34-36, which provide qualitative and quantitative data at given amino acid positions that were modified by the methods. For purposes of this disclosure, the sequences of CasX515 domains are provided in Table 4, including the OBD-I domain having the sequence of SEQ ID NO:2342, the OBD-II domain having the sequence of SEQ ID NO:2347, the NTSB domain having the sequence of SEQ ID NO:2335, the Helix II domain having the sequence of SEQ ID NO:2343, the Helix I-II domain having the sequence of SEQ ID NO:2336, the Helix II domain having the sequence of SEQ ID NO:2351, the RuvC-I domain having the sequence of SEQ ID NO:2352, the RuvC-II domain having the sequence of SEQ ID NO:2350, and the TSL domain having the sequence of SEQ ID NO:2349. By the methods of this disclosure, individual positions in the domains of CasX515 are modified and assayed, and compared to those positions in each domain or subdomain to provide exemplary modifications that result in the resulting positions and subsequent enrichment or improvement. In some cases, such positions are disclosed in Tables 21-24 in the Examples. In some embodiments, the disclosure provides a CasX variant derived from CasX515 and comprises one or more modifications (i.e., insertions, deletions, or substitutions) at one or more amino acid positions in the NTSB domain selected from the group consisting of P2, S4, Q9, E15, G20, G33, L41, Y51, F55, L68, A70, E75, K88, and G90 relative to SEQ ID NO: 2335, wherein the modifications result in improved characteristics relative to CasX515.In certain embodiments, the one or more modifications at one or more amino acid positions in the NTSB domain relative to SEQ ID NO: 2335 are selected from the group consisting of ^G2, ^I4, ^L4, Q9P, E15S, G20D, [S30], G33T, L41A, Y51T, F55V, L68D, L68E, L68K, A70Y, A70S, E75A, E75D, E75P, K88Q, and G90Q (where "^" represents an insertion at that position and "[ ]" represents a deletion at that position). In some embodiments, the disclosure provides a CasX variant derived from CasX515, comprising one or more modifications at one or more amino acid positions in the helix I-II domain selected from the group consisting of I24, A25, Y29, G32, G44, S48, S51, Q54, I56, V63, S73, L74, K97, V100, M112, L116, G137, F138, and S140 relative to SEQ ID NO: 2336, wherein the modifications result in improved characteristics relative to CasX515. In certain embodiments, the one or more modifications at one or more amino acid positions in the helix I-II domain are selected from the group consisting of ^T24, ^C25, Y29F,G32Y, G32N, G32H, G32S, G32T, G32A, G32V, [G32], G32S, G32T, G44L, G44H, S48H, S48T, S51T, Q54H, I56T, V63T, S73H, L74Y, K97G, K97S, K97D, K97E, V100L, M112T, M112W, M112R, M112K, L116K, G137R, G137K, G137N, ^Q138, and S140Q.In some embodiments, the disclosure provides CasX variants derived from CasX515, and have the following sequence details relative to SEQ ID NO: 2351: L2, V3, E4, R5, Q6, A7, E9, V10, D11, W12, W13, D14, M15, V16, C17, N18, V19, K20, L22, I23, E25, K26, K31, Q35, L37, A38, K41, R42, Q43, E44, L46, K57, Y65, G68, L70, L71, L72, E75, G79, D81, W82, K84, V85, Y86, D87, I93, K95, K96, E98, L100, K10 2, I104, K105, E109, R110, D114, K118, A120, L121, W124, L125, R126, A127, A129, I133, E134, G135, L136, E138, D140, K141, D142, E143, F144, C145, C147, E148, L149, K150, L151, Q152, K153, L158, E166, and A167, wherein the modifications result in improved characteristics compared to CasX515.In certain embodiments, the one or more modifications at one or more amino acid positions in the helix II domain are ^A2, ^H2, [L2]+[V3], V3E, V3Q, V3F, [V3], ^D3, V3P, E4P, [E4], E4D, E4L, E4R, R5N, Q6V, ^Q6, ^G7, ^H9, ^A9, VD10, ^T10, [V10], ^F10, ^D11, [D11], D11S, [W12], W12T, W12H, ^P12, ^Q13, ^G12, ^R13, W13P, W13D, ^D13, W13L, ^P14, ^D1 4, [D14]+[M15], [M15], ^T16, ^P17, N18I, V19N, V19H, K20D, L22D, I23S , E25C, E25P, ^G25, K26T, K27E, K31L, K31Y, Q35D, Q35P, ^S37, [L37]+[A 38], K41L, ^R42, [Q43]+[E44], L46N, K57Q, Y65T, G68M, L70V, L71C, L72 D, L72N, L72W, L72Y, E75F, E75L, E75Y, G79P, ^E79, ^T81, ^R81, ^W81, ^Y 81, ^W82, ^Y82, W82G, W82R, K84D, K84H, K84P, K84T, V85L, V85A, ^L85, Y 86C, D87G, D87M, D87P, I93C, K95T, K96R, E98G, L100A, K102H, I104T, I1 04S, I104Q, K105D, ^K109, E109L, R110D, [R110], D114E, ^D114, K118P, A120R, L121T, W124L, L125C, R126D, A127E, A127L, A129T, A129K, I133E , ^C133, ^S134, ^G134, ^R135, G135P, L136K, L136D, L136S, L136H, [E138], D140R, ^D140, ^P141, ^D142, [E143]+[F144], ^Q143, F144K, [F144], [F144]+[C145], C145R, ^G145, C145K, C147D, ^V148, E148D, ^H149, L149R, K150R, L151H, Q152C, K153P, L158S, E166L, and ^F167.In some embodiments, the disclosure provides a CasX variant derived from CasX515 and comprises one or more modifications at one or more amino acid positions in the RuvC-I domain selected from the group consisting of I4, K5, P6, M7, N8, L9, V12, G49, K63, K80, N83, R90, M125, and L146 relative to SEQ ID NO: 2352, wherein the modifications result in improved characteristics relative to CasX515. In certain embodiments, the one or more modifications at one or more amino acid positions in the RuvC-I domain are ^I4, ^S5, ^T6, ^N6, ^R7, ^K7, ^H8, ^S8, V12L, G49W, G49R, S51R, S51K, K62S, K62T, K62E, V65A, K80E, N83G, R90H, R90G, M125S, M125A, L137Y, ^P137, [L141], L141R, L141D, ^Q142 , ^R143, ^N143, E144N, ^P146, L146F, P147A, K149Q, T150V, ^R152, ^H153, T155Q, ^H155, ^R155, ^L156, [L156], ^W156, ^A157, ^F157, A157S, Q158K, [Y159], T160Y, T160F, ^I161, S161P, T163P, ^N163, C164K, and C164M. In some embodiments, the disclosure provides a CasX variant derived from CasX515 and comprises one or more modifications at one or more amino acid positions in the OBD-I domain selected from the group consisting of I4, K5, P6, M7, N8, L9, V12, G49, K63, K80, N83, R90, M125, and L146 relative to SEQ ID NO: 2342, wherein the modifications result in improved characteristics relative to CasX515.In certain embodiments, the one or more modifications at one or more amino acid positions in the OBD-I domain are selected from the group consisting of ^G3, I3G, I3E, ^G4, K4G, K4P, K4S, K4W, K4W, R5P, ^P5, ^G5, R5S, ^S5, R5A, R5P, R5G, R5L, I6A, I6L, ^G6, N7Q, N7L, N7S, K8G, K15F, D16W, ^F16, ^F18, ^P27, M28P, M28H, V33T, R34P, M36Y, R41P, L47P, ^P48, E52P, ^P55, [P55]+[Q56], Q56S, Q56P, ^D56, ^T56, and Q56P. In some embodiments, the disclosure provides a CasX variant derived from CasX515 and comprises one or more modifications at one or more amino acid positions in the OBD-II domain selected from the group consisting of I4, K5, P6, M7, N8, L9, V12, G49, K63, K80, N83, R90, M125, and L146 relative to SEQ ID NO: 2347, wherein the modifications result in improved characteristics relative to CasX515. In certain embodiments, the one or more modifications at one or more amino acid positions in the OBD-I domain are selected from the group consisting of: [S2], I3R, I3K, [I3]+[L4], [L4], K11T, ^P24, K37G, R42E, ^S53, ^R58, [K63], M70T, I82T, Q92I, Q92F, Q92V, Q92A, ^A93, K110Q, R115Q, L121T, ^A124, ^R141, ^D143, ^A143, ^W144, and ^A145. In some embodiments, the disclosure provides a CasX variant derived from CasX515 and comprises one or more modifications at one or more amino acid positions in the TSL domain selected from the group consisting of S1, N2, C3, G4, F5, 17, K18, V58, S67, T76, G78, S80, G81, E82, S85, V96, and E98 relative to SEQ ID NO: 2349, wherein the modifications result in improved characteristics relative to CasX515.In certain embodiments, the one or more modifications at one or more amino acid positions in the OBD-I domain are selected from the group consisting of M1, [N2], V2, C3S, G4, W4, F5P, W7, K18G, V58D, A67, T76E, T76D, T76N, G78D, S80, G81, E82, N82, S85I, V96C, V96T, and E98D. It will be understood that any combination of the aforementioned modifications in the same paragraph can be similarly introduced into the CasX variants of the present disclosure, resulting in a CasX variant with improved characteristics. For example, in one embodiment, the present disclosure provides CasX variant 535 (SEQ ID NO: 435), which has a single mutation, G223S, compared to CasX 515. In another embodiment, In one embodiment, the disclosure provides CasX variant 668 (SEQ ID NO: 567) with an R insertion and a G223S substitution at position 26 relative to CasX515. In another embodiment, the disclosure provides CasX672 (SEQ ID NO: 570) with an L169K and G223S substitution compared to CasX515. In another embodiment, the disclosure provides CasX676 (SEQ ID NO: 574) with an L169K and G223S substitution and an R insertion at position 26 relative to CasX515. CasX variants with improved characteristics relative to CasX515 include the variants in Table 3.
[0191] Exemplary characteristics that may be improved in CasX variant proteins compared to the same characteristics in a reference CasX protein or compared to the CasX variant from which they are derived include, but are not limited to, improved folding of the variant, improved binding affinity for gRNA, improved binding affinity for target nucleic acids, improved ability to utilize a wider range of PAM sequences in editing and / or binding to target nucleic acids, improved unwinding of target DNA, increased editing activity, improved editing efficiency, improved editing specificity for target nucleic acids, reduced off-target editing or cleavage, an increase in the proportion of eukaryotic genomes that can be efficiently edited, increased nuclease activity, increased target strand loading for double-stranded cleavage, reduced target strand loading for single-stranded nicking, improved binding of non-target strands of DNA, improved protein stability, improved stability of the protein:gRNA (RNP) complex, and improved fusion characteristics. In certain embodiments, as described in the Examples, such improved characteristics may include, but are not limited to, improved cleavage activity at target nucleic acids having TTC, ATC, and CTC PAM sequences, increased specificity for cleavage of target nucleic acid sequences, and reduced off-target cleavage of target nucleic acids.
[0192] [Table 6]
[0193] The CasX variants of the embodiments described herein are capable of forming an RNP complex with a gRNA disclosed herein. In some embodiments, an RNP comprising a CasX variant protein and a gRNA of the present disclosure can cleave a double-stranded DNA target with at least 80% efficiency at a concentration of 20 pM or less. In some embodiments, an RNP at a concentration of 20 pM or less can cleave a double-stranded DNA target with at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% efficiency. In some embodiments, an RNP at a concentration of 50 pM or less, 40 pM or less, 30 pM or less, 20 pM or less, 10 pM or less, or 5 pM or less can cleave a double-stranded DNA target with at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% efficiency. These improved features are described in more detail below.
[0194] g. Protein stability In some embodiments, the present disclosure provides CasX variant proteins with improved stability compared to a reference CasX protein. In some embodiments, improved stability of a CasX variant protein results in higher steady-state protein expression, improving editing efficiency. In some embodiments, improved stability of a CasX variant protein results in a greater proportion of the CasX protein remaining folded into a functional conformation, improving editing efficiency or improving purifability for manufacturing purposes. As used herein, "functional conformation" refers to a CasX protein in a conformation that allows the protein to bind to a gRNA and a target nucleic acid. In embodiments in which the CasX variant does not have one or more mutations that render it catalytically inactive, the CasX variant can cleave, nick, or otherwise modify a target nucleic acid when complexed with a gRNA having a targeting sequence that can hybridize to the target nucleic acid. A functional conformation of CasX refers to a "cleavage competent" conformation. In some embodiments, including those embodiments in which the CasX variant protein results in a greater proportion of the CasX protein remaining folded in a functional conformation, lower concentrations of the CasX variant are required for applications such as gene editing compared to a reference CasX protein. Thus, in some embodiments, a CasX variant with improved stability has improved efficiency compared to a reference CasX in one or more gene editing contexts.
[0195] In some embodiments, the present disclosure provides CasX variant proteins that have improved stability of the CasX variant protein:gRNA RNP complex compared to a reference CasX protein:gRNA complex, such that the RNP remains in a functional form. Improved stability may include increased thermal stability, resistance to proteolysis, enhanced pharmacokinetic properties, stability across a range of pH conditions, salt conditions, and tonicity. Improved complex stability may, in some embodiments, result in improved editing efficiency. In some embodiments, the RNPs of the CasX variant and gRNA variant have at least a two-fold, at least a three-fold, or at least a four-fold higher percentage of cleavage-competent RNPs compared to the RNPs of the reference CasX of SEQ ID NOS: 1-3 and gRNA of SEQ ID NOS: 4 or 5 in Table 1. Exemplary data for increased cleavage-competent RNPs are provided in the Examples.
[0196] In some embodiments, the improved stability of the CasX variant protein comprises improved folding kinetics of the CasX variant protein relative to a reference CasX protein, ie, the folding kinetics of the CasX variant protein are improved by at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1,000-fold, at least about 2,000-fold, at least about 3,000-fold, at least about 4,000-fold, at least about 5,000-fold, or at least about 10,000-fold relative to a reference CasX protein. In some embodiments, the folding kinetics of the CasX variant protein is improved by at least about 1 kJ / mol, at least about 5 kJ / mol, at least about 10 kJ / mol, at least about 20 kJ / mol, at least about 30 kJ / mol, at least about 40 kJ / mol, at least about 50 kJ / mol, at least about 60 kJ / mol, at least about 70 kJ / mol, at least about 80 kJ / mol, at least about 90 kJ / mol, at least about 100 kJ / mol, at least about 150 kJ / mol, at least about 200 kJ / mol, at least about 250 kJ / mol, at least about 300 kJ / mol, at least about 350 kJ / mol, at least about 400 kJ / mol, at least about 450 kJ / mol, or at least about 500 kJ / mol compared to a reference CasX protein.
[0197] Exemplary amino acid changes that can increase the stability of a CasX variant protein relative to a reference CasX protein include, but are not limited to, amino acid changes that increase the number of hydrogen bonds in the CasX variant protein, increase the number of disulfide bridges in the CasX variant protein, increase the number of salt bridges in the CasX variant protein, strengthen interactions between portions of the CasX variant protein, increase the buried hydrophobic surface of the CasX variant protein, or any combination thereof.
[0198] h. Protein affinity for gRNA In some embodiments, the CasX variant protein has improved affinity for a gRNA compared to a reference CasX protein or another CasX variant from which it is derived, resulting in the formation of a ribonucleoprotein complex. The increased affinity of the CasX variant protein for a gRNA can result, for example, in a lower K for the formation of an RNP complex. d This can result in, in some cases, more stable RNP complex formation. In some embodiments, increasing the affinity of the CasX variant protein for the gRNA results in increased stability of the RNP complex when delivered to human cells. This increased stability can affect the function and utility of the complex in a subject's cells and can result in improved pharmacokinetic properties in the blood when delivered to a subject. In some embodiments, increasing the affinity of the CasX variant protein and the resulting increased stability of the RNP complex allows for lower doses of the CasX variant protein to be delivered to a subject or cell while still having the desired activity, e.g., gene editing in vivo or in vitro.
[0199] In some embodiments, the higher affinity (tighter binding) of the CasX variant protein for the gRNA allows for more editing events when both the CasX variant protein and the gRNA remain in the RNP complex. This increase in editing events can be assessed using the editing assays described herein.
[0200] In some embodiments, the K of the CasX variant protein relative to the gRNA dis increased by at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100-fold compared to the reference CasX protein or another CasX variant from which it is derived. In some embodiments, the CasX variant has an increased binding affinity for the gRNA by about 1.1 to about 10-fold compared to the reference CasX protein of SEQ ID NO:2.
[0201] Without wishing to be bound by theory, in some embodiments, amino acid changes in the helix I domain can increase the binding affinity of the CasX variant protein to the gRNA targeting sequence, changes in the helix II domain can increase the binding affinity of the CasX variant protein to the gRNA scaffold stem-loop, and changes in the oligonucleotide binding domain (OBD) increase the binding affinity of the CasX variant protein to the gRNA triplex.
[0202] Methods for measuring the binding affinity of a CasX protein to a gRNA include in vitro methods using purified CasX protein and gRNA. Binding affinity to the reference CasX and variant proteins can be measured by fluorescence polarization if the gRNA or CasX protein is tagged with a fluorophore. Alternatively, or additionally, binding affinity can be measured by biolayer interferometry, electrophoretic mobility shift assay (EMSA), or membrane binding. Further standard techniques for quantifying the absolute affinity of an RNA-binding protein, such as a reference CasX and variant proteins of the present disclosure, for a particular gRNA, such as a reference gRNA and its variants, include, but are not limited to, isothermal calorimetry (ITC) and surface plasmon resonance (SPR), as well as the methods in the Examples.
[0203] i. affinity for target nucleic acid In some embodiments, a CasX variant protein has improved binding affinity for a target nucleic acid compared to the affinity of a reference CasX protein or another CasX variant from which it is derived for that target nucleic acid. CasX variants with higher affinity for their target nucleic acids can, in some embodiments, cleave a target nucleic acid sequence more rapidly than a reference CasX protein that does not have increased affinity for the target nucleic acid.
[0204] In some embodiments, improved affinity for a target nucleic acid includes improved affinity for the target sequence or protospacer sequence of the target nucleic acid, improved affinity for the PAM sequence, improved ability to search DNA for the target sequence, or any combination thereof. Without wishing to be bound by theory, it is believed that proteins of the CRISPR / Cas system, such as CasX, can find their target sequence by one-dimensional diffusion along the DNA molecule. This process is believed to involve (1) binding of the ribonucleoprotein to the DNA molecule, followed by (2) termination at the target sequence, both of which, in some embodiments, can be affected by improved affinity of the CasX protein for the target nucleic acid sequence, thereby improving the function of the CasX variant protein compared to a reference CasX protein.
[0205] In some embodiments, CasX variant proteins with improved target nucleic acid affinity have increased affinity for or ability to utilize specific PAM sequences other than the canonical TTC PAM recognized by the reference CasX protein of SEQ ID NO: 2, including PAM sequences selected from the group consisting of TTC, ATC, GTC, and CTC, thereby increasing the amount of target nucleic acid that can be edited compared to wild-type CasX nuclease or CasX199 or 491 nuclease. Without wishing to be bound by theory, it is possible that these protein variants may interact more strongly with DNA overall and have an increased ability to access and edit sequences within target nucleic acids due to their ability to utilize additional PAM sequences beyond those of the wild-type reference CasX or CasX199 or 491 nuclease, thereby enabling a more efficient search process for the CasX protein for target sequences. A higher overall affinity for DNA can also, in some embodiments, increase the frequency with which the CasX protein can effectively initiate and complete the binding and unwinding steps, thereby facilitating target strand invasion and R-loop formation, and ultimately cleavage of the target nucleic acid sequence.
[0206] Without being bound by theory, amino acid changes in the NTSB domain may increase the efficiency of unwinding or capturing non-target nucleic acid strands in the unwound state, thereby increasing the affinity of the CasX variant protein for the target nucleic acid. Alternatively, or additionally, amino acid changes in the NTSB domain may increase the ability of the NTSB domain to stabilize DNA during unwinding, thereby increasing the affinity of the CasX variant protein for the target nucleic acid. Alternatively, or additionally, amino acid changes in the OBD may increase the affinity of the CasX variant protein binding to the protospacer adjacent motif (PAM), thereby increasing the affinity of the CasX variant protein for the target nucleic acid. Alternatively, or additionally, amino acid changes in helix I and / or helix II, RuvC, and TSL domains may increase the affinity of the CasX variant protein for the target nucleic acid strand, thereby increasing the affinity of the CasX variant protein for the target nucleic acid.
[0207] In some embodiments, the binding affinity of a CasX variant protein of the present disclosure for a target nucleic acid molecule is increased by at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100-fold compared to a reference CasX protein or another CasX variant from which it is derived. In some embodiments, the CasX variant protein has about a 1.1 to about 100-fold increased binding affinity for the target nucleic acid compared to the reference protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or the CasX491 and 515 variants.
[0208] In some embodiments, the CasX variant protein has increased binding affinity for the non-target strand of the target nucleic acid. As used herein, the term "non-target strand" refers to the strand of the DNA target nucleic acid sequence that does not form Watson-Crick base pairs with the targeting sequence in the gRNA and is complementary to the target nucleic acid strand. In some embodiments, the CasX variant protein has an increased binding affinity for the non-target strand of the target nucleic acid of about 1.1 to about 100-fold compared to the reference protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or the CasX variant of SEQ ID NO: 270 or SEQ ID NO: 336.
[0209] Methods for measuring the affinity of a CasX protein (e.g., a reference or variant) for a target nucleic acid molecule and / or a non-target nucleic acid molecule can include electrophoretic mobility shift assays (EMSA), membrane binding, isothermal calorimetry (ITC), and surface plasmon resonance (SPR), fluorescence polarization, and biolayer interferometry (BLI). Additional methods for measuring the affinity of a CasX protein for a target include in vitro biochemical assays that measure DNA cleavage events over time.
[0210] j. Improved specificity for the target site In some embodiments, a CasX variant protein has improved specificity for a target nucleic acid sequence compared to a reference CasX protein or another CasX variant from which it is derived. As used herein, "specificity" (sometimes interchangeably referred to as "target specificity") refers to the degree to which a CRISPR / Cas system ribonucleoprotein complex cleaves off-target sequences that are similar, but not identical, to the target nucleic acid sequence. For example, a CasX variant RNP with a higher degree of specificity exhibits reduced off-target cleavage of sequences compared to a reference CasX protein. The specificity of a CRISPR / Cas system protein, and the reduction of potentially deleterious off-target effects, can be crucial for achieving an acceptable therapeutic index for use in mammalian subjects.
[0211] In some embodiments, the CasX variant protein has improved specificity for target sites within a target sequence that are complementary to the targeting sequence of a gRNA. As noted above, improved specificity correlates with reduced off-target editing. In some embodiments, the CasX variant protein exhibits reduced off-target editing or cleavage for target sites within a target sequence that are not 100% complementary to the targeting sequence of a gRNA complexed with the CasX variant as an RNP. Without wishing to be bound by theory, it is possible that amino acid changes in the helix I and II domains that increase the specificity of the CasX variant protein for a target nucleic acid strand can increase the specificity of the CasX variant protein for the entire target nucleic acid. In some embodiments, amino acid changes that increase the specificity of the CasX variant protein for a target nucleic acid can also result in a decreased affinity of the CasX variant protein for DNA.
[0212] Methods for testing the target specificity of a CasX protein (e.g., variant or reference) can include Circularization for In Vitro Reporting of Cleavage Effects by Sequencing (CIRCLE-seq) or similar methods. Briefly, in CIRCLE-seq technology, genomic DNA is sheared and circularized by ligation of stem-loop adapters, nicking the stem-loop region and exposing a 4-nucleotide palindromic overhang. This is followed by intramolecular ligation and degradation of the remaining linear DNA. The circular DNA molecule containing the CasX cleavage site is then linearized with CasX, and adapter-adapters are ligated to the exposed ends, followed by high-throughput sequencing to generate paired-end reads containing information about off-target sites. Additional assays that can be used to detect off-target events (and thus the specificity of the CasX protein) include assays used to detect and quantify indels (insertions and deletions) formed at their selected off-target sites (e.g., mismatch-detection nuclease assays and next-generation sequencing (NGS)). Exemplary mismatch-detection assays include nuclease assays, in which genomic DNA from cells treated with CasX and sgRNA is PCR-amplified, denatured, and rehybridized to form heteroduplex DNA containing one wild-type strand and one strand with an indel. Mismatches are recognized and cleaved by a mismatch-detection nuclease, such as Surveyor nuclease or T7 endonuclease I. Methods for assessing the specificity of CasX variants, along with supporting data demonstrating the improved specificity of CasX variant embodiments, are described in the Examples.
[0213] k. Protospacer and PAM sequence As used herein, a protospacer is defined as a DNA sequence complementary to the targeting sequence of a guide RNA and a DNA sequence complementary to that sequence, referred to as the target strand and non-target strand, respectively. As used herein, a PAM is a nucleotide sequence proximal to the protospacer that, in conjunction with the targeting sequence of a gRNA, helps orient and position CasX for potential cleavage of the protospacer strand.
[0214] PAM sequences may be degenerate, and particular RNP constructs may have different preferred and accepted PAM sequences that support different cleavage efficiencies. By convention, unless otherwise noted, this disclosure refers to both the PAM and protospacer sequences and their orientation relative to the orientation of the non-target strand. This does not imply that the PAM sequence of the non-target strand, rather than the target strand, is determinative of cleavage or is mechanistically involved in target recognition. For example, when referring to a TTC PAM, it may actually be the complementary GAA sequence required for target cleavage, or some combination of nucleotides from both strands. In the CasX proteins disclosed herein, the PAM is located 5' to the protospacer, with a single nucleotide separating the PAM from the first nucleotide of the protospacer. Thus, for the reference CasX, a TTC PAM should be understood to mean a sequence according to the formula 5'-...NNTTCN(protospacer)NNNNNN...3' (SEQ ID NO: 19), where "N" is any DNA nucleotide and "(protospacer)" is a DNA sequence having identity to the targeting sequence of a guide RNA. For CasX variants with extended PAM recognition, a TTC, CTC, GTC, or ATC PAM should be understood to mean a sequence according to the following formula: 5'-...NNTTCN(protospacer)NNNNNN...3' (SEQ ID NO: 19), 5'-...NNCTCN(protospacer)NNNNNN...3' (SEQ ID NO: 20); 5'-...NNGTCN(protospacer)NNNNNN...3' (SEQ ID NO: 21); or 5'-...NNATCN(protospacer)NNNNNN...3' (SEQ ID NO: 22). Alternatively, TC PAM should be understood to mean a sequence according to the formula 5'-...NNNTCN(protospacer)NNNNNN...3' (SEQ ID NO: 23).
[0215] Additionally, the disclosed CasX variant proteins utilize a PAM TC motif containing a PAM sequence selected from TTC, ATC, GTC, or CTC (in the 5' to 3' orientation) to enhance their ability to efficiently edit and / or bind to a target nucleic acid when complexed with a gRNA as an RNP, compared to the RNP of a reference CasX protein and reference gRNA, or the RNP of another CasX variant from which it is derived (e.g., CasX491 and gRNA174). In the foregoing, the PAM sequence is located at least one nucleotide 5' to the non-target strand of a protospacer that shares identity with the targeting sequence of a gRNA in an assay system, compared to the editing efficiency and / or binding of an RNP containing a reference CasX protein and reference gRNA in a comparable assay system. In one embodiment, the RNPs of the CasX variant and gRNA variant exhibit higher editing efficiency and / or binding of the target sequence in the target nucleic acid compared to an RNP comprising a reference CasX protein and a reference gRNA (or an RNP of another CasX variant from which it is derived, e.g., CasX491 and gRNA174) in an equivalent assay system in which the PAM sequence of the target DNA is TTC. In another embodiment, the RNPs of the CasX variant and gRNA variant exhibit higher editing efficiency and / or binding of the target sequence in the target nucleic acid compared to an RNP comprising a reference CasX protein and a reference gRNA (or an RNP of another CasX variant from which it is derived, e.g., CasX491 and gRNA174) in an equivalent assay system in which the PAM sequence of the target DNA is ATC. In the specific embodiment described above in which the CasX variant exhibits enhanced editing with an ATC PAM, the CasX variant is 528 (SEQ ID NO: 428). In another embodiment, the RNP of the CasX variant and gRNA variant exhibits higher editing efficiency and / or binding of the target sequence in the target nucleic acid compared to an RNP containing a reference CasX protein and a reference gRNA (or an RNP of another CasX variant from which it is derived, e.g., CasX491 and gRNA174) in an equivalent assay system in which the PAM sequence of the target DNA is CTC.In another embodiment, the RNP of the CasX variant and gRNA variant exhibits higher editing efficiency and / or binding of the target sequence in the target nucleic acid compared to an RNP containing a reference CasX protein and a reference gRNA (or an RNP of another CasX variant and gRNA174 from which it is derived) in an equivalent assay system in which the PAM sequence of the target DNA is GTC. In the foregoing embodiment, the increased editing efficiency and / or binding affinity for one or more PAM sequences is at least 1.5-fold, at least 2-fold, at least 4-fold, at least 10-fold, at least 20-fold, at least 30-fold, or at least 40-fold, or more, greater than the editing efficiency and / or binding affinity of an RNP containing a CasX protein of any one of SEQ ID NOS: 1-3 and a gRNA of Table 1 for the PAM sequence. Exemplary assays demonstrating improved editing are described in the Examples section herein (see, e.g., Figure 41). In some embodiments, the CasX protein is capable of binding to and / or modifying (e.g., cleaving, nicking, methylating, demethylating, etc.) target nucleic acids and / or polypeptides associated with target nucleic acids (e.g., methylating or acetylating histone tails). In some embodiments, the CasX protein is catalytically inactive (dCasX) but retains the ability to bind to target nucleic acids.
[0216] l. DNA unwinding In some embodiments, CasX variant proteins have improved DNA unwinding ability compared to reference CasX proteins. It has previously been shown that insufficient dsDNA unwinding impairs or prevents the ability of the CRISPR / Cas system proteins AnaCas9 or Cas14 to cleave DNA. Therefore, without wishing to be bound by any theory, the increased DNA cleavage activity of some CasX variant proteins disclosed herein is likely due, at least in part, to their increased ability to find and unwind dsDNA at target sites. Methods for measuring the DNA unwinding ability of a CasX protein (e.g., variant or reference) include, but are not limited to, in vitro assays that observe increased on-rates of dsDNA targets in fluorescence polarization or biolayer interferometry.
[0217] Without wishing to be bound by theory, it is believed that amino acid changes in the NTSB domain can produce CasX variant proteins with increased DNA unwinding characteristics. Alternatively, or in addition, amino acid changes in the helical domain regions that interact with the OBD or PAM can also produce CasX variant proteins with increased DNA unwinding characteristics.
[0218] Methods for measuring the ability of a CasX protein (e.g., variant or reference) to unwind DNA include, but are not limited to, in vitro assays that observe the increase in on-rate of a dsDNA target in fluorescence polarization or biolayer interferometry.
[0219] m.Catalytic activity The ribonucleoprotein complex of the CasX:gRNA system disclosed herein comprises a CasX variant complexed with a gRNA variant that binds to and, optionally, cleaves a target nucleic acid. In some embodiments, the CasX variant protein has improved catalytic activity compared to a reference CasX protein or another CasX variant from which it is derived. Without wishing to be bound by theory, it is believed that, in some cases, cleavage of the target strand may be the limiting factor for Cas12-like molecules in generating dsDNA breaks. In some embodiments, the CasX variant protein improves bending of the target strand of DNA and cleavage of this strand, resulting in improved overall efficiency of dsDNA cleavage by the CasX ribonucleoprotein complex.
[0220] In some embodiments, a CasX variant protein has increased nuclease activity relative to a reference CasX protein or relative to another CasX variant from which it is derived. Variants with increased nuclease activity can be generated, for example, through amino acid changes in the RuvC nuclease domain. In some embodiments, the CasX variant comprises a RuvC nuclease domain with nickase activity. In the foregoing, the CasX nickase in the CasX:gRNA system generates a single-strand break within 10-18 nucleotides 3' of the PAM site on the non-target strand. In other embodiments, the CasX variant comprises a RuvC nuclease domain with double-strand cleavage activity. In the foregoing, the CasX in the CasX:gRNA system generates a double-strand break within 18-26 nucleotides 5' of the PAM site on the target strand and within 10-18 nucleotides 3' of the PAM site on the non-target strand. Nuclease activity can be assayed by various methods, including those described in the Examples. In some embodiments, the CasX variant has a k that is at least 2-fold, or at least 3-fold, or at least 4-fold, or at least 5-fold, or at least 6-fold, or at least 7-fold, or at least 8-fold, or at least 9-fold, or at least 10-fold greater than the reference CasX. 切断 It has a constant.
[0221] In some embodiments, the CasX variant protein has improved RNP formation characteristics with a gRNA, resulting in a higher percentage of cleavage-competent RNPs compared to the RNPs of a reference CasX protein and gRNA of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, as described in the Examples. Cleavage competent means that the RNPs formed have the ability to cleave a target nucleic acid. In some embodiments, the RNPs of the CasX variant and gRNA exhibit at least two-fold, or at least three-fold, or at least four-fold, or at least five-fold, or at least ten-fold faster cleavage rates compared to the RNPs of a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 and a gRNA of Table 2. In the foregoing embodiments, the improved competency rate can be demonstrated in in vitro assays such as those described in the Examples.
[0222] In some embodiments, the CasX variant protein has increased target strand loading for double-strand cleavage compared to a reference CasX. Variants with increased target strand loading activity can be generated, for example, through amino acid changes in the TLS domain. Without wishing to be bound by theory, amino acid changes in the TLS domain can result in CasX variant proteins with improved catalytic activity. Alternatively, or additionally, amino acid changes around the binding channel of the RNA:DNA duplex can also improve the catalytic activity of the CasX variant protein.
[0223] In some embodiments, the CasX variant protein has increased incidental cleavage activity compared to a reference CasX protein. As used herein, "incidental cleavage activity" refers to the additional non-targeted cleavage of nucleic acids following recognition and cleavage of a target nucleic acid sequence. In some embodiments, the CasX variant protein has decreased incidental cleavage activity compared to a reference CasX protein.
[0224] Exemplary methods for characterizing the catalytic activity of a CasX protein can include, but are not limited to, in vitro cleavage assays, including those in the Examples below. In some embodiments, electrophoresis of DNA products on an agarose gel can examine the kinetics of strand scission.
[0225] n. affinity for target RNA In some embodiments, a ribonucleoprotein complex comprising a reference CasX protein or a variant thereof binds to a target RNA and cleaves the target nucleic acid. In some embodiments, a variant of a reference CasX protein increases the specificity of the CasX variant protein for the target RNA or increases the activity of the CasX variant protein for the target RNA when compared to the reference CasX protein. For example, the CasX variant protein can exhibit increased binding affinity for the target RNA or increased cleavage of the target RNA when compared to the reference CasX protein. In some embodiments, a ribonucleoprotein complex comprising a CasX variant protein binds to and / or cleaves the target RNA. In some embodiments, the CasX variant has at least about a 2-fold to about a 10-fold increased binding affinity for the target nucleic acid when compared to the reference protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or the CasX variant of SEQ ID NO: 270 or SEQ ID NO: 336.
[0226] o. catalytically inactive CasX variants In some embodiments, e.g., embodiments involving applications in which cleavage of a target nucleic acid sequence is not a desired outcome, improving the catalytic activity of a CasX variant protein includes altering, reducing, or eliminating the catalytic activity of the CasX variant protein. In some embodiments, the present disclosure provides catalytically inactive CasX variant proteins that can bind to a target nucleic acid but cannot cleave the target nucleic acid when complexed with a gRNA having a targeting sequence complementary to the target nucleic acid. Exemplary catalytically inactive CasX proteins contain one or more mutations in the active site of the RuvC domain of the CasX protein. In some embodiments, the catalytically inactive CasX variant protein contains substitutions at residues 672, 769, and / or 935 compared to SEQ ID NO:1. In one embodiment, the catalytically inactive CasX variant protein contains substitutions D672A, E769A, and / or D935A compared to the reference CasX protein of SEQ ID NO:1. In other embodiments, catalytically inactive CasX variant proteins contain substitutions at amino acids 659, 756, and / or 922 relative to the reference CasX protein of SEQ ID NO: 2. In some embodiments, catalytically inactive CasX variant proteins contain D659A, E756A, and / or D922A substitutions relative to the reference CasX protein of SEQ ID NO: 2. In some embodiments, catalytically inactive CasX variants 527, 668, and 676 proteins contain D660A, E757A, and D922A modifications that abolish endonuclease activity. In further embodiments, catalytically inactive CasX proteins contain a deletion of all or part of the RuvC domain of the CasX protein. It will be understood that the same aforementioned substitutions can be similarly introduced into the CasX variants of the present disclosure, resulting in catalytically inactive CasX (dCasX) variants. In one embodiment, all or part of the RuvC domain is deleted from a CasX variant, resulting in a dCasX variant. The catalytically inactive dCasX variant protein can, in some embodiments, be used for base editing or epigenetic modification.In some embodiments, catalytically inactive dCasX variant proteins with higher affinity for DNA may find their target nucleic acid faster, remain bound to the target nucleic acid for a longer period of time, bind to the target nucleic acid in a more stable manner, or a combination thereof, compared to catalytically active CasX, thereby improving these functions of the catalytically inactive CasX variant protein compared to a CasX variant that retains its cleavage ability. Exemplary dCasX variant sequences are disclosed as SEQ ID NOS: 44-62 and 1232-1235 in Table 7. In some embodiments, the dCasX variant is at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the sequence of SEQ ID NOS: 44-62 or 1232-1235 and retains the functional properties of the dCasX variant protein. In some embodiments, the dCasX variant comprises a sequence of SEQ ID NO: 44-62 or 1232-1235.
[0227] [Table 7]
[0228] p.CasX fusion protein In some embodiments, the disclosure provides a CasX variant protein comprising a heterologous protein fused to CasX, including any of the CasX variant embodiments described herein, including CasX variants comprising an N-terminal, C-terminal, or internal fusion of CasX to a heterologous protein or domain thereof.
[0229] In some embodiments, a CasX fusion protein comprises a variant of SEQ ID NOs: 247-592 or 1147-1231, or any one of the sequences in Table 3, fused to one or more proteins or domains thereof with different activities of interest, resulting in a fusion protein. In some embodiments, a CasX fusion protein comprises a variant of SEQ ID NOs: 270-592 or 1147-1231 fused to one or more proteins or domains thereof with different activities of interest. In some embodiments, a CasX fusion protein comprises a variant of SEQ ID NOs: 415-592 or 1147-1231 fused to one or more proteins or domains thereof with different activities of interest. For example, in some embodiments, a CasX variant protein is fused to a protein (or domain thereof) that inhibits transcription, modifies a target nucleic acid, or modifies a polypeptide associated with a nucleic acid (e.g., a histone modifying protein).
[0230] In some embodiments, a heterologous polypeptide (or heterologous amino acid, such as a cysteine residue or an unnatural amino acid) can be inserted at one or more positions within a CasX protein to generate a CasX fusion protein. In other embodiments, a cysteine residue can be inserted at one or more positions within a CasX protein, followed by conjugation of a heterologous polypeptide, as described below. In some alternative embodiments, a heterologous polypeptide or heterologous amino acid can be added to the N-terminus or C-terminus of a reference or CasX variant protein. In other embodiments, a heterologous polypeptide or heterologous amino acid can be inserted internally within the sequence of a CasX protein.
[0231] In some embodiments, the CasX variant fusion protein retains RNA-guided, sequence-specific target nucleic acid binding and cleavage activity. In some embodiments, the CasX variant fusion protein retains 50% or more of the activity (e.g., cleavage and / or binding activity) of a corresponding CasX variant protein without the heterologous protein insertion. In some embodiments, the CasX variant fusion protein retains at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 92%, or at least about 95%, or at least about 98%, or at least about 100% of the activity (e.g., cleavage and / or binding activity) of a corresponding CasX protein without the heterologous protein insertion.
[0232] In some cases, the reference CasX or CasX variant fusion protein retains (has) target nucleic acid binding activity compared to the activity of the CasX protein without the inserted heterologous amino acid or polypeptide. In some cases, the reference CasX or CasX variant fusion protein retains at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 92%, or at least about 95%, or at least about 98%, or about 100% of the binding activity of the corresponding CasX protein without the inserted heterologous protein.
[0233] In some cases, the CasX variant fusion protein retains (has) target nucleic acid binding and / or cleavage activity compared to the activity of the parent CasX protein without the inserted heterologous amino acid or polypeptide. For example, in some cases, the CasX variant fusion protein retains (has) 50% or more of the binding and / or cleavage activity of the corresponding parent CasX protein (the CasX protein without the insertion). For example, in some cases, the CasX variant fusion protein retains (has) 60% or more (70% or more, 80% or more, 90% or more, 92% or more, 95% or more, 98% or more, or 100%) of the binding and / or cleavage activity of the corresponding parent CasX protein (the CasX protein without the insertion). Methods for measuring the cleavage and / or binding activity of CasX proteins and / or CasX fusion proteins are known to those of skill in the art, and any convenient method can be used.
[0234] A variety of heterologous polypeptides are suitable for inclusion in the CasX variant fusion proteins of the present disclosure. In some cases, the fusion partner can modulate transcription of a target nucleic acid (e.g., inhibit transcription, increase transcription). For example, in some cases, the fusion partner is a protein (or a domain derived from a protein) that represses transcription (e.g., a protein that functions via a transcriptional repressor, recruitment of a transcriptional repressor protein, modification of a target nucleic acid such as methylation, recruitment of a DNA modifier, regulation of histones associated with the target nucleic acid, recruitment of histone modifiers such as those that modify histone acetylation and / or methylation, etc.). In some cases, the fusion partner is a protein (or a domain derived from a protein) that increases transcription (e.g., a protein that functions via a transcriptional activator, recruitment of a transcriptional activator protein, modification of a target nucleic acid such as demethylation, recruitment of a DNA modifier, regulation of histones associated with the target nucleic acid, recruitment of histone modifiers such as those that modify histone acetylation and / or methylation, etc.).
[0235] In some cases, the fusion partner has an enzymatic activity that modifies a target nucleic acid sequence, such as a nuclease activity, a methyltransferase activity, a demethylase activity, a DNA repair activity, a DNA damaging activity, a deaminating activity, a dismutase activity, an alkylating activity, a depurinating activity, an oxidizing activity, a pyrimidine dimer forming activity, an integrase activity, a transposase activity, a recombinase activity, a polymerase activity, a ligase activity, a helicase activity, a photolyase activity, or a glycosylase activity. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 247-592 or 1147-1231 and a polypeptide having methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylating activity, deadenylating activity, sumoylating activity, desumoylating activity, ribosylation activity, deribosylation activity, myristoylating activity, or demyristoylating activity. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 270-592 or 1147-1231 and the above polypeptide. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 415-592 or 1147-1231 and the above polypeptide.
[0236] Examples of proteins (or fragments thereof) that can be used as fusion partners to increase transcription include transcription activators (e.g., VP16, VP64, VP48, VP160, p65 subdomains (e.g., from NFkB), and the activation domain of EDLL and / or TAL activation domains (e.g., active in plants); histone lysine methyltransferases (e.g., SET1A, SET1B, MLL1-5, ASH1, SYMD2, NSD1, etc.); histone lysine demethylases (e.g., JHDM2a / b, UTX, JMJD3, etc.); histone acetyltransferases (e.g., GCN5, PCAF, CBP, p300, TAF1, TIP60 / PLIP, MOZ / MYST3, MORF / MYST4, SRC1, ACTR, P160, CLOCK, etc.); and DNA demethylases (e.g., Ten-Eleven Translocation (TET) dioxygenase 1 (TET1CD), TET1, DME, DML1, DML2, ROS1, etc.
[0237] Examples of proteins (or fragments thereof) that can be used as fusion partners to reduce transcription include, but are not limited to, transcriptional repressors (e.g., Kruppel-associated box (KRAB or SKD)); KOX1 repression domain; Mad mSIN3-interacting domain (SID); ERF repressor domain (ERF repressor domain, ERD), SRDX repression domain (e.g., for repression in plants), etc.; histone lysine methyltransferases (e.g., Pr-SET7 / 8, SUV4-20H1, RIZ1, etc.); histone lysine demethylases (e.g., JMJD2A / JHDM3A, JMJD2B, JMJD2C / GASC1, JMJD2D, JARID1A / RBP2, JARID1B / PLU-1, JARID1C / SMCX, JARID1D / SMCY, etc.); histone lysine deacetylases (e.g., HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC7, HDAC9, SIRT1, SIRT2, HDAC11, etc.); DNA methylases (e.g., HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3 (plants), ZMET2, CMT1, CMT2 (plants), etc.); and peripheral mobilization elements (e.g., Lamin A, Lamin B, etc.).
[0238] In some cases, the fusion partner to the CasX variant has an enzymatic activity that modifies a target nucleic acid (e.g., ssRNA, dsRNA, ssDNA, dsDNA). Examples of enzymatic activities that can be provided by the fusion partner include nuclease activity (e.g., that provided by a restriction enzyme (e.g., FokI nuclease)), methyltransferase activity (e.g., that provided by a methyltransferase (e.g., HhaI DNA m5c-methyltransferase (M.Hhal), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3 (plants), ZMET2, CMT1, CMT2 (plants), etc.), demethylase activity (e.g., a demethylase (e.g., Ten-Eleven Translocation (TET) dioxygenase 1 (TET1)), etc.), and the like. CD), TET1, DME, DML1, DML2, ROS1, etc.), DNA repair activity, DNA damage activity, deamination activity (e.g., provided by deaminases (e.g., cytosine deaminase enzymes, e.g., rat apolipoprotein B mRNA editing enzymes, APOBEC proteins such as catalytic peptide 1 {APOBEC1}), dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity (e.g., integrase and / or Examples of such activities include, but are not limited to, resolvase activity (e.g., that provided by a Gin invertase (e.g., a high-activity mutant of Gin invertase GinH106Y)), human immunodeficiency virus type 1 integrase (IN), Tn3 resolvase, etc.), transposase activity, recombinase activity (e.g., that provided by a recombinase (e.g., the catalytic domain of Gin recombinase)), polymerase activity, ligase activity, helicase activity, photolyase activity, and glycosylase activity.
[0239] In some cases, the CasX variant proteins of the present disclosure are fused to a polypeptide selected from a domain for increasing transcription (e.g., a VP16 domain, a VP64 domain), a domain for decreasing transcription (e.g., a KRAB domain (e.g., from the Kox1 protein)), a core catalytic domain of a histone acetyltransferase (e.g., histone acetyltransferase p300), a protein / domain that provides a detectable signal (e.g., a fluorescent protein such as GFP), a nuclease domain (e.g., a FokI nuclease), or a base editor (e.g., a cytidine deaminase such as APOBEC1).
[0240] In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 247-592 or 1147-1231, or any one of SEQ ID NOs: 270-592 or 1147-1231, or any one of SEQ ID NOs: 415-592 or 1147-1231, or a sequence in Table 3, fused to a polypeptide selected from the group consisting of a domain for reducing transcription, a domain with enzymatic activity, a core catalytic domain of histone acetyltransferase, a protein / domain that provides a detectable signal, a nuclease domain, and a base editor. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 247-592 or 1147-1231 fused to a polypeptide selected from the group consisting of a domain for reducing transcription, a domain with enzymatic activity, a core catalytic domain of histone acetyltransferase, a protein / domain that provides a detectable signal, a nuclease domain, and a base editor. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 270-592 or 1147-1231 fused to a polypeptide described above. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 415-592 or 1147-1231 fused to a polypeptide described above. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 760-789 fused to a polypeptide selected from the group consisting of a domain for reducing transcription, a domain having enzymatic activity, a core catalytic domain of a histone acetyltransferase, a protein / domain that provides a detectable signal, a nuclease domain, and a base editor. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 411-592 fused to a polypeptide selected from the group consisting of a domain for reducing transcription, a domain having enzymatic activity, a core catalytic domain of a histone acetyltransferase, a protein / domain that provides a detectable signal, a nuclease domain, and a base editor.
[0241] In some cases, a reference CasX protein or CasX variant of the present disclosure is fused to a base editor. Base editors include those that can modify guanine, adenine, cytosine, thymine, or uracil bases on nucleosides or nucleotides. Base editors include, but are not limited to, adenosine deaminase, cytosine deaminase (e.g., APOBEC1), and guanine oxidase. Thus, any of the CasX variants provided herein can comprise (i.e., be fused to) a base editor. For example, a CasX variant of the present disclosure can be fused to an adenosine deaminase, cytosine deaminase, or guanine oxidase. In an exemplary embodiment, a CasX variant of the present disclosure comprising any one of SEQ ID NOs: 247-592 or 1147-1231 is fused to an adenosine deaminase, cytosine deaminase, or guanine oxidase. In further exemplary embodiments, a CasX variant of the disclosure comprising any one of SEQ ID NOs: 270-592 or 1147-1231 is fused to an adenosine deaminase, cytosine deaminase, or guanine oxidase. In further exemplary embodiments, a CasX variant of the disclosure comprising any one of SEQ ID NOs: 415-592 or 1147-1231 is fused to an adenosine deaminase, cytosine deaminase, or guanine oxidase.
[0242] In some cases, the fusion partner for the CasX variant has an enzymatic activity that modifies a protein (e.g., a histone, an RNA-binding protein, a DNA-binding protein, etc.) associated with a target nucleic acid (e.g., ssRNA, dsRNA, ssDNA, dsDNA). Examples of enzymatic activities (that modify a protein associated with a target nucleic acid) that can be provided by a fusion partner for a CasX variant include methyltransferase activity (e.g., a histone methyltransferase).methyltransferase, HMT) (e.g., suppressor of variegation 3-9 homolog 1 (SUV39H1, also known as KMT1A), euchromatin histone lysine methyltransferase 2 (G9A, also known as KMT1C and EHMT2), SUV39H2, ESET / SETDB1, SET1A, SET1B, MLL1-5, ASH1, SMYD2, NSD1, DOT1-like histone lysine methyltransferase (DOT1L), Pr-SET7 / 8, lysine methyltransferase histone demethylase activity (e.g., provided by histone demethylase 5B (SUV4-20H1), enhancer of zeste2 polycomb repressive complex 2 subunit (EZH2), and PR / SET domain 2 (RIZ1)), demethylase activity (e.g., histone demethylases (e.g., lysine demethylase 1A (KDM1A, also known as LSD1), JHDM2a / b, JMJD2A / JHDM3A, JMJD2B, JMJD2C / GASC1, JMJD2D, JARID1A / RBP2, JARID1B / PLU-1, JARID1C / SM), and CX, JARID1D / SMCY, UTX, JMJD3, etc.), acetyltransferase activity (e.g., provided by histone acetyltransferases (e.g., catalytic core / fragment of human acetyltransferase p300, GCN5, PCAF, CBP, TAF1, TIP60 / PLIP, MOZ / MYST3, MORF / MYST4, HB01 / MYST2, HMOF / MYST1, SRC1, ACTR, P160, CLOCK, etc.)), deacetyl ... For example, these include, but are not limited to, histone deacetylases (e.g., those provided by HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC7, HDAC9, SIRT1, SIRT2, HDAC11, etc.), kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylating activity, deadenylating activity, sumoylating activity, desumoylating activity, ribosylation activity, deribosylation activity, myristoylating activity, and demyristoylating activity.
[0243] Further examples of suitable fusion partners for CasX variants include (i) a dihydrofolate reductase (DHFR) destabilization domain (e.g., to generate chemically controllable RNA-guided polypeptides of interest), and (ii) a chloroplast transit peptide.
[0244] In some embodiments, the CasX variant is selected from the group consisting of any one of SEQ ID NOs: 247-592 or 1147-1231, or any one of SEQ ID NOs: 270-592 or 1147-1231, or any one of SEQ ID NOs: 415-592 or 1147-1231, or a sequence in Table 3 and a chloroplast transit peptide (MASMISSSAVTTVSRASRGQSAAMAPFGGLKSMTGFPVRKVNTDITSITSNGGR VKCMQVWPPIGKKKFETLSYLPPLTRDSRA (SEQ ID NO: 338); MASMISSSAVTTVSRASRGQSAAMAPFGGLKSMTGFPVRKVNTDITSITSNGGRVKS (SEQ ID NO: 339); MASSMLSSATMVASPAQATMVAPFNGLKSSAAFPATRKANNDITSITSNGGRVNCMQV WPPIEKKKFETLSYLPDLTDSGGRVNC (SEQ ID NO: 340); MAQVSRICNGVQNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIG SELRPLKVMSSVSTAC (SEQ ID NO: 341); MAQVSRICNGVWNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIG SELRPLKVMSSVSTAC (SEQ ID NO: 342); MAQINNMAQGIQTLNPNSNFHKPQVPKSSSFLVFGSKKLKNSANSMLVLKKDSIFMQLF CSFRISASVATAC (SEQ ID NO: 343); MAALVTSQLATSGTVLSVTDRFRRPGFQGLRPRNPADAALGMRTVGASAAPKQSRKPH RFDRRCLSMVV (SEQ ID NO: 344); MAALTTSQLATSATGFGIADRSAPSSLLRHGFQGLKPRSPAGGDATSLSVTTSARATPKQ QRSVQRGSRRFPSVVVC (SEQ ID NO: 345);MASSVLSSAAVATRSNVAQANMVAPFTGLKSAASFPVSRKQNLDITSIASNGGRVQC (SEQ ID NO: 346);MESLAATSVFAPSRVAVPAARALVRAGTVVPTRRTSSTSGTSGVKCSAAVTPQASPVIS RSAAAA (SEQ ID NO: 347);and MGAAATSMQSLKFSNRLVPPSRRLSPVPNNVTCNNLPKSAAPVRTVKCCASSWNSTINGAAATTNGASAASS (SEQ ID NO: 348);
[0245] In some embodiments, a CasX variant protein of the present disclosure may comprise an endosomal escape peptide. In some cases, the endosomal escape polypeptide comprises the amino acids GLFXALLXLLXSLWXLLLXA (SEQ ID NO: 349), where each X is independently selected from lysine, histidine, and arginine. In some cases, the endosomal escape polypeptide comprises the amino acid sequence GLFHALLHLLHSLWHLLLHA (SEQ ID NO: 350) or HHHHHHHHH (SEQ ID NO: 351). In some embodiments, the CasX variant comprises the sequence of any one of SEQ ID NOs: 247-592 or 1147-1231, or any one of SEQ ID NOs: 270-592 or 1147-1231, or any one of SEQ ID NOs: 415-592 or 1147-1231, or a sequence in Table 3, and an endosomal escape polypeptide.
[0246] When targeting ssRNA target nucleic acid sequences, non-limiting examples of fusion partners for CasX variants for use include (but are not limited to) splicing factors (e.g., RS domains); protein translation components (e.g., translation initiation, elongation, and / or termination factors; e.g., eukaryotic translation initiation factor 4 gamma {eIF4G}); RNA methylases; RNA editing enzymes (e.g., RNA deaminases (e.g., adenosine deaminase acting on RNA (ADAR)), including A-to-I and / or C-to-U editing enzymes); helicases; RNA binding proteins, etc. It is understood that the heterologous polypeptide can comprise an entire protein, or in some cases, can comprise a fragment of a protein (e.g., a functional domain).
[0247] In some embodiments, the CasX variant of any one of SEQ ID NOs: 247-592 or 1147-1231, or any one of SEQ ID NOs: 270-592 or 1147-1231, or any one of SEQ ID NOs: 415-592 or 1147-1231, or a sequence in Table 3, comprises a fusion partner of any domain capable of interacting with ssRNA (for purposes of this disclosure, this includes, for example, double-stranded RNA duplexes (e.g., hairpins, stem-loops, etc.) containing intramolecular and / or intermolecular secondary structures). This includes effector domains, whether transient or irreversible, direct or indirect, selected from the group including, but not limited to: endonucleases (e.g., RNase III, CRR22 DYW domain, Dicer, and PIN (PilT N-terminal) domains from proteins such as SMG5 and SMG6); proteins and protein domains involved in stimulating RNA cleavage (e.g., cleavage and polyadenylation specificity factor {CPSF}, cleavage stimulation factor {CstF}, CFIm, and CFIIm); exonucleases (e.g., chromatin-binding exonuclease XRN1 (XRN-1) or exonuclease T); deadenylases (e.g., DNA 5'-adenosine monophosphate hydrolase {HNT3}); factors and protein domains involved in nonsense-mediated RNA decay (e.g., UPF1 RNA helicase and ATPase {UPF1}, UPF2, UPF3, UPF3b, RNP SI, RNA-binding motif protein 8A {Y14}, DEK proto-oncogene {DEK}, RNA processing protein REF2 {REF2}, and serine-arginine repeat matrix 1 {SRm160}); proteins and protein domains involved in RNA stabilization (e.g., cytoplasmic poly(A)-binding protein 1 {PABP}); proteins and protein domains involved in repression of translation (e.g., argonaute RISC catalytic component 2 {Ago2} and Ago4); proteins and protein domains involved in stimulation of translation (e.g., Staufen);Proteins and protein domains involved in (e.g., capable of regulating) translation (e.g., translation factors (e.g., initiation factors, elongation factors, termination factors, etc., e.g., eIF4G)); proteins and protein domains involved in RNA polyadenylation (e.g., poly(A) polymerase (PAP1), PAP-related domain-containing protein; poly(A) RNA polymerase gld-2 {GLD-2}, and Star-PAP); proteins and protein domains involved in RNA polyuridinylation (e.g., terminal uridylyltransferase {CID1} and terminal uridylate transferase); proteins and protein domains involved in RNA localization (e.g., insulin-like growth factor 2 {CID2}, terminal uridylate transferase {CID3}, terminal uridylate transferase {CID4}, terminal uridylate transferase {CID5}, terminal uridylate transferase {CID6}, terminal uridylate transferase {CID7}, terminal uridylate transferase {CID8}, terminal uridylate transferase {CID9}, terminal uridylate transferase {CID1}, terminal uridylate transferase {CID1}, terminal uridylate transferase {CID1}, terminal uridylate transferase {CID2}, terminal uridylate transferase {CID3}, terminal uridylate transferase {CID4}, terminal uridylate transferase {CID5}, terminal uridylate transferase {CID6 ... proteins and protein domains involved in the nuclear retention of RNA (e.g., Rrp6); proteins and protein domains involved in the nuclear export of RNA (e.g., nuclear RNA export factor 1 {TAP}, nuclear RNA export factor 1 {NXF1}, THO complex {THO}, TREX, REF, and Aly / REF export factor {Aly}); proteins and protein domains involved in the repression of RNA splicing (e.g., polypyrimidine tract binding protein 1 {PTB}, KH RNA-binding domain-containing, signal transduction-associated 1 {Sam68}, and heterogeneous nuclear ribonucleoprotein A1 {hnRNP A1}); proteins and protein domains involved in the stimulation of RNA splicing (e.g., serine / arginine-rich (SR) domains); proteins and protein domains involved in the reduction of transcription efficiency (e.g., FUS RNA-binding proteins {FUS (TLS)); and proteins and protein domains involved in stimulating transcription (e.g., cyclin-dependent kinase 7 {CDK7} and HIV Tat). Alternatively, the effector domain can be selected from the group comprising: endonucleases; proteins and protein domains capable of stimulating RNA cleavage; exonucleases; deadenylases; proteins and protein domains with nonsense-mediated RNA degradation activity;Proteins and protein domains capable of stabilizing RNA; proteins and protein domains capable of repressing translation; proteins and protein domains capable of stimulating translation; proteins and protein domains capable of regulating translation (e.g., translation factors (e.g., initiation factors, elongation factors, release factors, etc., e.g., eIF4G)); proteins and protein domains capable of polyadenylation of RNA; proteins and protein domains capable of polyuridinylation of RNA; proteins and protein domains with RNA localization activity; proteins and protein domains capable of nuclear retention of RNA; proteins and protein domains with RNA export activity; proteins and protein domains capable of repressing RNA splicing; proteins and protein domains capable of stimulating RNA splicing; proteins and protein domains capable of reducing transcription efficiency; and proteins and protein domains capable of stimulating transcription. Another suitable heterologous polypeptide is a PUF RNA-binding domain, which is described in more detail in WO 2012 / 068627 (incorporated herein by reference in its entirety);
[0248] Several RNA splicing factors that can be used (in whole or in fragments) as fusion partners with CasX variants have a modular organization, with distinct sequence-specific RNA-binding and splicing effector domains. For example, members of the serine / arginine-rich (SR) protein family contain an N-terminal RNA recognition motif (RRM) that binds to exonic splicing enhancers (ESEs) in pre-mRNA and a C-terminal RS domain that promotes exon inclusion. As another example, the hnRNP protein hnRNP A1 binds to exonic splicing silencers (ESSs) via its RRM domain and inhibits exon inclusion via its C-terminal glycine-rich domain. Some splicing factors can regulate the selective use of splice sites (ss) by binding to regulatory sequences between the two alternative sites. For example, ASF / SF2 can recognize ESEs and promote the use of intron-proximal sites, whereas hnRNP A1 can bind to ESSs and shift splicing toward the use of intron-distal sites. One application of such factors is to create ESFs that regulate the alternative splicing of endogenous genes (especially disease-related genes). For example, BCL2-like 1 (Bcl-x) pre-mRNA produces two splicing isoforms with two alternative 5' splice sites that encode proteins of opposite function. The long splicing isoform, Bcl-xL, is a potent apoptosis inhibitor expressed in long-lived postmitotic cells and is upregulated in many cancer cells, protecting them from apoptotic signals. The short isoform, Bcl-xS, is a pro-apoptotic isoform and is expressed at high levels in cells with high metabolic rates (e.g., developing lymphocytes).The ratio of the two Bcl-x splicing isoforms is regulated by multiple cc elements located either in the core exon region or in the exon extension region (i.e., between the two alternative 5' splice sites). For further examples, see WO 2010 / 075303, which is incorporated herein by reference in its entirety.
[0249] Additional suitable fusion partners for use with CasX variants include, but are not limited to, proteins (or fragments thereof) that are boundary elements (e.g., CTCF), proteins and fragments thereof that provide peripheral recruitment (e.g., lamin A, lamin B, etc.), and protein docking elements (e.g., FKBP / FRB, Pill / Abyl, etc.).
[0250] Additionally or alternatively, the CasX variant proteins of the present disclosure can be fused to a polypeptide permeabilization domain to facilitate cellular uptake. Several permeabilization domains are known in the art and can be used in the non-integrating polypeptides of the present disclosure, including peptides, peptidomimetics, and non-peptide carriers. For example, International Publication No. 2017 / 106569 and U.S. Patent Application Publication No. 2018 / 0363009(A1), incorporated herein by reference in their entireties, describe fusions of Cas proteins with one or more nuclear localization sequences (NLSs) to facilitate cellular uptake. In other embodiments, the permeabilization peptide can be derived from the third alpha helix of the Drosophila melanogaster transcription factor Antennapedia, called penetratin, which contains the amino acid sequence RQIKIWFQNRRMKWKK (SEQ ID NO: 398). As another example, the permeabilization peptide can include the HIV-1 tat basic region amino acid sequence, e.g., amino acids 49-57 of the naturally occurring tat protein. Other permeability domains include polyarginine motifs, such as the region of amino acids 34-56 of the HIV-1 rev protein, nonaarginine, octaarginine, etc. The fusion site can be selected to optimize the biological activity, secretion, or binding characteristics of the polypeptide. Optimal sites can be determined by routine experimentation.
[0251] In some cases, a heterologous polypeptide (fusion partner) for use with a CasX variant provides for subcellular localization. That is, the heterologous polypeptide comprises a subcellular localization sequence (e.g., a nuclear localization signal (NLS) for targeting to the nucleus, a sequence for retaining the fusion protein outside the nucleus (e.g., a nuclear export sequence (NES)), a sequence for retaining the fusion protein in the cytoplasm, a mitochondrial localization signal for targeting to mitochondria, a chloroplast localization signal for targeting to chloroplasts, an ER retention signal, etc.). In some embodiments, the subject RNA guide polypeptide or conditionally active RNA guide polypeptide and / or the subject CasX fusion protein does not comprise an NLS, so that the protein is not targeted to the nucleus (this can be advantageous, for example, when the target nucleic acid is an RNA present in the cytosol). In some embodiments, the fusion partner can provide a tag to facilitate tracking and / or purification. That is, the heterologous polypeptide is detectably labeled (e.g., a fluorescent protein, e.g., green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), cyan fluorescent protein (CFP), mCherry, tdTomato, etc.; a histidine tag, e.g., a 6xHis tag; a hemagglutinin (HA) tag; a FLAG tag; a Myc tag, etc.). In some embodiments, the CasX variant comprises any one of SEQ ID NOs: XX-XX and a subcellular localization sequence or tag.
[0252] In some cases, the reference protein or the CasX variant protein comprises (is fused to) a nuclear localization signal (NLS). Non-limiting examples of NLSs suitable for use with CasX variants include sequences that are at least about 80%, at least about 90%, or at least about 95% identical to or identical to sequences derived from: the SV40 virus large T antigen NLS having the amino acid sequence PKKKRKV (SEQ ID NO: 352); an NLS from nucleoplasmin (e.g., the nucleoplasmin bisecting NLS having the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 353)); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: 354) or RQRRNELKRSP (SEQ ID NO: 355); or the hRNPAl M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 356). NLS; sequence of the IBB domain from importin alpha RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 357); sequences of fibroid T protein VSRKRPRP (SEQ ID NO: 358) and PPKKARED (SEQ ID NO: 359); sequence of human p53 PQPKKKPL (SEQ ID NO: 360); sequence of mouse c-abl the sequence of IV SALIKKKKKMAP (SEQ ID NO: 361); the sequences DRLRR (SEQ ID NO: 362) and PKQKKRK (SEQ ID NO: 363) of influenza virus NS1; the sequence of herpesvirus δ antigen RKLKKKIKKL (SEQ ID NO: 364); the sequence of mouse MxI protein REKKKFLKRR (SEQ ID NO: 365); the sequence of human poly(ADP-ribose) polymerase KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 366); the sequence of steroid hormone receptor (human) glucocorticoid RKCLQAGMNLEARKTKK (SEQ ID NO: 367); the sequence of Borna disease virus P protein,the sequence of EBV-P1 (PRPRKIPR) (SEQ ID NO: 368); the sequence of Hepatitis C virus nonstructural protein (HCV-NS5A) (PPRKKRTVV) (SEQ ID NO: 369); the sequence of LEF1 (NLSKKKKRKREK) (SEQ ID NO: 370); the sequence of ORF57 simirae (RRPSRPFRKP) (SEQ ID NO: 371); the sequence of EBV LANA (KRPRSPSS) (SEQ ID NO: 372); the sequence of influenza A protein (KRGINDRNFWRGENERKTR) (SEQ ID NO: 373); A, RHA) sequence PRPPKMARYDN (SEQ ID NO: 374); nucleolar RNA helicase II sequence KRSFSKAF (SEQ ID NO: 375); TUS-protein sequence KLKIKRPVK (SEQ ID NO: 376); importin alpha-related sequence PKKKRKVPPPPAAKRVKLD (SEQ ID NO: 377); HTLV-1 Rex protein-derived sequence PKTRRRPRRSQRKRPPT (SEQ ID NO: 378); Caenorhabditis the sequence SRRRKANPTKLSENAKKLAKEVEN (SEQ ID NO: 379) from the EGL-13 protein of C. elegans; and the sequences KTRRRPRRSQRKRPPT (SEQ ID NO: 380), RRKKRRPRRKKRR (SEQ ID NO: 381), PKKKSRKPKKKSRK (SEQ ID NO: 382), HKKKHPDASVNFSEFSK (SEQ ID NO: 383), QRPGPYDRPQRPGPYDRP (SEQ ID NO: 384), LSPSLSPLLSPSLSPL (SEQ ID NO: 385), RGKGGKGLGKGGAKRHRK (SEQ ID NO: 386), PKRGRGRPKRGRGR (SEQ ID NO: 387), No. 387), PKKKRKVPPPPAAKRVKLD (SEQ ID NO: 388), PKKKRKVPPPPKKKRKV (SEQ ID NO: 389), PAKRARRGYKC (SEQ ID NO: 63), KLGPRKATGRW (SEQ ID NO: 64), PRRKREE (SEQ ID NO: 65), PYRGRKE (SEQ ID NO: 66), PLRKRPRR (SEQ ID NO: 67), PLRKRPRRGSPLRKRPRR (SEQ ID NO: 68), PAAKRVKLDGGKRTADGSEFESPKKKRKV (SEQ ID NO: 69), PAAKRVKLDGGKRTADGSEFESPKKKRKVGIHGVPAA (SEQ ID NO: 70),PAAKRVKLDGGKRTADGSEFESPKKKRKVAEAAAKEAAAKEAAAKA (SEQ ID NO: 71), PAAKRVKLDGGKRTADGSEFESPKKKRKVPG (SEQ ID NO: 72), KRKGSPERGERKRHW (SEQ ID NO: 73), KRTADSQHSTPPKTKRKVEFEPKKKRKV (SEQ ID NO: 74), and PKKKRKVGGSKRTADSQHSTPPKTKRKVEFEPKKKRKV (SEQ ID NO: 75). In some embodiments, one or more NLSs are linked to the CRISPR protein or an adjacent NLS using a linker peptide, wherein the linker peptide is selected from the group consisting of RS, (G)n (SEQ ID NO: 1023), (GS)n (SEQ ID NO: 1024), (GSGGS)n (SEQ ID NO: 399), (GGSGGS)n (SEQ ID NO: 400), (GGGS)n (SEQ ID NO: 401), GGSG (SEQ ID NO: 402), GGSGG (SEQ ID NO: 403), GSGSG (SEQ ID NO: 404), GSGGG (SEQ ID NO: 405), The NLS is typically selected from the group consisting of GGGSG (SEQ ID NO: 406), GSSSG (SEQ ID NO: 407), GPGP (SEQ ID NO: 408), GGP, PPP, PPAPPA (SEQ ID NO: 409), PPPG (SEQ ID NO: 24), PPPGPPP (SEQ ID NO: 410), PPP(GGGS)n (SEQ ID NO: 25), (GGGS)nPPP (SEQ ID NO: 26), AEAAAKEAAAKEAAAKA (SEQ ID NO: 1025), and TPPKTKRKVEFE (SEQ ID NO: 27), where n is 1 to 5. Generally, the NLS (or NLSs) is sufficiently strong to drive accumulation of the CasX variant fusion protein in the nucleus of a eukaryotic cell. Detection of nuclear accumulation can be performed by any suitable technique. For example, a detectable marker can be fused to the CasX variant fusion protein so that its subcellular location can be visualized. Cell nuclei can also be isolated from cells, and their contents can then be analyzed by any suitable process for detecting proteins (e.g., immunohistochemistry, Western blot, or enzyme activity assay). Accumulation in the nucleus can also be determined indirectly.
[0253] The present disclosure contemplates the assembly of multiple NLSs in various configurations for linkage to a CRISPR protein. In some embodiments, one, two, three, four, or more NLSs are linked to the N-terminus of a CRISPR protein by a linker peptide. In other embodiments, one, two, three, four, or more NLSs are linked to the C-terminus of a CRISPR protein by a linker peptide. In some embodiments, the NLS linked to the N-terminus of a CRISPR protein is the same as the NLS linked to the C-terminus. In other embodiments, the NLS linked to the N-terminus of a CRISPR protein is different from the NLS linked to the C-terminus. In some embodiments, the NLS linked to the N-terminus of a CRISPR protein is selected from the group consisting of the N-terminal sequences shown in Table 8. In some embodiments, the NLS linked to the C-terminus of a CRISPR protein is selected from the group consisting of the C-terminal sequences shown in Table 8. Detection of nuclear accumulation can be performed by any suitable technique. For example, a detectable marker can be fused to a reference or CasX variant fusion protein so that its subcellular location can be visualized. Cell nuclei can also be isolated from cells, and their contents can then be analyzed by any suitable process for detecting proteins (e.g., immunohistochemistry, Western blot, or enzyme activity assays). Accumulation in the nucleus can also be determined indirectly.
[0254] [Table 8-1]
[0255] [Table 8-2]
[0256] [Table 8-3]
[0257] [Table 8-4]
[0258] In some embodiments, the CasX variant comprises any one of SEQ ID NOS: 247-592 or 1147-1231, or any one of SEQ ID NOS: 270-592 or 1147-1231, or any one of SEQ ID NOS: 415-592 or 1147-1231, or a sequence in Table 3, fused to one or more NLSs of any one of SEQ ID NOS: 63-75, 219-236, 239, 352-389, 983-1021, 1237-1278, or any of the sequences in Table 8. In some embodiments, one or more NLSs are fused to or near the N-terminus of the CasX variant. In some embodiments, one or more NLSs are fused to or near the C-terminus of the CasX variant. In some embodiments, one or more NLSs are fused to both the N- and C-termini of the CasX variant. In some embodiments, an NLS is linked to another NLS by a linker.
[0259] In some cases, the reference or CasX variant fusion protein contains a "protein transduction domain" or PTD (also known as a CPP cell-penetrating peptide), which refers to a protein, polynucleotide, carbohydrate, or organic or inorganic compound that facilitates crossing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD bound to another molecule (which can range from small polar molecules to large macromolecules and / or nanoparticles) facilitates the molecule's crossing of a membrane, e.g., translocation from the extracellular space to the intracellular space, or from the cytosol into an organelle. In some embodiments, the PTD is covalently attached to the amino terminus of the reference or CasX variant fusion protein. In some embodiments, the PTD is covalently attached to the carboxyl terminus of the reference or CasX variant fusion protein. In some cases, the PTD is inserted internally into the sequence of the reference or CasX variant fusion protein at a suitable insertion site. In some cases, the reference or CasX variant fusion protein comprises (conjugated to, fused to) one or more PTDs (e.g., two or more, three or more, four or more PTDs). In some cases, the PTDs comprise one or more nuclear localization signals (NLSs).Examples of PTDs include, but are not limited to, the peptide transduction domains of HIV TAT, including YGRKKRRQRRR (SEQ ID NO: 390), RKKRRQRR (SEQ ID NO: 391); YARAAARQARA (SEQ ID NO: 392); THRLPRRRRRR (SEQ ID NO: 393); and GGRRARRRRRR (SEQ ID NO: 394); a polyarginine sequence (SEQ ID NO: 1026) containing a sufficient number of arginines to direct cell entry (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginines); a VP22 domain (Zender et al. (2002) Cancer Gene Ther. 9(6): 489-96); the Drosophila antennapedia protein transduction domain (Noguchi et al. (2003) Diabetes 52(7): 1732-1737); a truncated human calcitonin peptide (Trehin et al. (2003) Diabetes 52(7): 1732-1737); al. (2004) Pharm. Research 21:1248-1256); polylysine (Wender et al. (2000) Proc. Natl. Acad. Sci. USA 97:13003-13008); RRQRRTSKLMKR (SEQ ID NO: 395); transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 396); KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO: 397); and RQIKIWFQNRRMKWKK (SEQ ID NO: 398). In some embodiments, the PTD is an activatable CPP (ACPP) (Aguilera et al. (2009) Integr Biol (Camb) June; 1(5-6):371-381). ACPPs contain a polycationic CPP (e.g., Arg9 or "R9") linked to a matching polyanion (e.g., Glu9 or "E9") via a cleavage-competent linker, which reduces the net charge to near zero, thereby inhibiting adhesion and uptake into cells. Upon cleavage of the linker, the polyanion is released, locally unmasking the polyarginine and its inherent adhesive properties, thus "activating" the ACPP and allowing it to cross membranes.In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 247-592 or 1147-1231, or any one of SEQ ID NOs: 270-592 or 1147-1231, or any one of SEQ ID NOs: 415-592 or 1147-1231, or a sequence and PTD in Table 3.
[0260] In some embodiments, a CasX variant fusion protein can comprise a CasX protein linked to a heterologous amino acid or polypeptide (heterologous amino acid sequence) inserted therein via a linker polypeptide (e.g., one or more linker polypeptides). In some embodiments, a reference or CasX variant fusion protein can be linked at its C-terminus and / or N-terminus to a heterologous polypeptide (fusion partner) via a linker polypeptide (e.g., one or more linker polypeptides). The linker polypeptide can have any of a variety of amino acid sequences. Proteins can be linked by a spacer peptide, which is generally flexible in nature, although other chemical bonds are not excluded. Suitable linkers include polypeptides between 4 and 40 amino acids in length, or between 4 and 25 amino acids in length. These linkers are generally generated by coupling proteins using oligonucleotides encoding synthetic linkers. Peptide linkers with some flexibility can be used. The connecting peptide can have virtually any amino acid sequence, with the understanding that preferred linkers will generally have sequences that result in flexible peptides. The use of small amino acids such as glycine and alanine is useful in generating flexible peptides. The generation of such sequences is routine for those skilled in the art. A variety of different linkers are commercially available and may be suitable for use. Exemplary linker polypeptides include glycine polymers (G)n, glycine-serine polymers (e.g., (GS)n (SEQ ID NO: 1024), (GSGGS)n (SEQ ID NO: 399), (GGSGGS)n (SEQ ID NO: 400), and (GGGS)n (SEQ ID NO: 401), where n is an integer of at least 1, glycine-alanine polymers, alanine-serine polymers, glycine-proline polymers, proline polymers, and proline-alanine polymers.Exemplary linkers can comprise amino acid sequences including, but not limited to, RS, (G)n, (GS)n (SEQ ID NO: 1024), (GSGGS)n (SEQ ID NO: 399), (GGSGGS)n (SEQ ID NO: 400), (GGGS)n (SEQ ID NO: 401), GGSG (SEQ ID NO: 402), GGSGG (SEQ ID NO: 403), GSGSG (SEQ ID NO: 404), GSGGG (SEQ ID NO: 405), GGGSG (SEQ ID NO: 406), GSSSG (SEQ ID NO: 407), GPGP (SEQ ID NO: 408), GGP, PPP, PPAPPA (SEQ ID NO: 409), PPPG (SEQ ID NO: 24), PPPGPPP (SEQ ID NO: 410), PPP(GGGS)n (SEQ ID NO: 25), (GGGS)nPPP (SEQ ID NO: 26), AEAAAKEAAAKEAAAKA (SEQ ID NO: 1025), and TPPKTKRKVEFE (SEQ ID NO: 27), where n is 1 to 5. Those skilled in the art will recognize that the design of peptides conjugated to any of the above elements can include all or partly flexible linkers, such that the linker can include flexible linkers as well as one or more moieties that impart a less flexible structure.
[0261] V. Methods for Producing CasX Variant Proteins and gRNA Variants The CasX variant proteins and gRNA variants described herein can be constructed by a variety of methods, including, for example, comprehensive mutational evolution (DME), as described below and in the Examples, and in International Application No. PCT / US20 / 36506 and International Publication No. WO2020247883(A2), which are incorporated herein by reference.
[0262] a. Comprehensive mutational evolution (DME) In some embodiments, DME is used to identify CasX protein and sgRNA scaffold variants with improved function. In some embodiments, the DME method involves constructing and testing a comprehensive set of mutations for a starting biomolecule to generate a library of biomolecule variants (e.g., a library of CasX variant protein or sgRNA scaffold variants). DME can involve making all possible amino acid (in the case of proteins) or nucleotide (in the case of RNA or DNA) substitutions, as well as all possible small insertions and all possible deletions, for the starting biomolecule. Figure 16 shows a schematic illustrating the DME method. In some embodiments, DME includes a subset of all such possible substitutions, insertions, and deletions. In certain embodiments of DME, one or more libraries of variants are constructed and evaluated for functional changes, and this information is used to construct one or more additional libraries. Such iterative construction and evaluation of variants can lead to the identification of mutational themes that lead to specific functional outcomes, such as regions of a protein or RNA that, when mutated in a particular way, result in one or more improved functions. Layering of such identified mutations can then further improve function, for example, through additive or synergistic interactions. DME involves library design, library construction, and library screening. In some embodiments, multiple rounds of design, construction, and screening are performed.
[0263] b. Library design The DME method generates variants of biomolecules that are polymers of many monomers. In some embodiments, the biomolecules comprise proteins or ribonucleic acid (RNA) molecules, where the monomer units are amino acids or ribonucleotides, respectively. The basic unit of biomolecule mutation involves either (1) exchanging one monomer for another monomer of a different identity (substitution), (2) inserting one or more additional monomers into the biomolecule (insertion), or (3) removing one or more monomers from the biomolecule (deletion). DME libraries containing substitutions, insertions, and deletions, alone or in combination, of any one or more monomers in any biomolecule described herein are considered within the scope of the present invention.
[0264] In some embodiments, DME is used to construct and test a comprehensive set of mutations for a biomolecule, encompassing all possible substitutions and small insertions and deletions of amino acids (in the case of proteins) or nucleotides (in the case of RNA). Construction and functional readout of these mutations can be achieved using a variety of established molecular biology methods. In some embodiments, the library contains a subset of all possible modifications to a monomer. For example, in some embodiments, the library collectively represents a single modification of one monomer for at least 10% of the total monomer positions in the biomolecule, with each single modification selected from the group consisting of a substitution, a single insertion, and a single deletion. In some embodiments, the library collectively represents a single modification of one monomer for at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or up to 100% of the total monomer positions in the starting biomolecule. In certain embodiments, for a particular percentage of the total monomer positions in the starting biomolecule, the library collectively represents each possible single modification of one monomer, e.g., all possible substitutions with 19 other naturally occurring amino acids (for proteins) or 3 other naturally occurring ribonucleotides (for RNA), insertions of each of 20 naturally occurring amino acids (for proteins) or 4 naturally occurring ribonucleotides (for RNA), or deletions of a monomer. In still further embodiments, the insertion at each position is independently an insertion of more than one monomer, e.g., two or more, three or more, or four or more monomers, or an insertion of one to four, two to four, or one to three monomers. In some embodiments, the deletion at a position is independently a deletion of more than one monomer, e.g., two or more, three or more, or four or more monomers, or an deletion of one to four, two to four, or one to three monomers. Examples of such libraries of CasX variants and gRNA variants are described in Example 14 and Example 15, respectively.
[0265] In some embodiments, the biomolecule is a protein and the individual monomers are amino acids. In embodiments where the biomolecule is a protein, the number of possible DME mutations at each monomer (amino acid) position in the protein includes 19 amino acid substitutions, 20 amino acid insertions, and 1 amino acid deletion, resulting in a total of 40 possible mutations per amino acid in the protein.
[0266] In some embodiments, the DME library of CasX variant proteins containing insertions is a 1 amino acid insertion library, a 2 amino acid insertion library, a 3 amino acid insertion library, a 4 amino acid insertion library, a 5 amino acid insertion library, a 6 amino acid insertion library, a 7 amino acid insertion library, an 8 amino acid insertion library, a 9 amino acid insertion library, or a 10 amino acid insertion library. In some embodiments, the DME library of CasX variant proteins containing insertions contains 1 to 4 amino acid insertions.
[0267] In some embodiments, the biomolecule is RNA. In embodiments where the biomolecule is RNA, the number of possible DME mutations at each monomer (ribonucleotide) position in the RNA includes 3 nucleotide substitutions, 4 nucleotide insertions, and 1 nucleotide deletion, resulting in a total of 8 possible mutations per nucleotide.
[0268] In some embodiments, designing a DME library involves enumerating all possible mutations for each of one or more target monomers in a biomolecule. As used herein, "target monomer" refers to a monomer in a biomolecular polymer targeted with a DME having substitutions, insertions, and deletions as described herein. For example, a target monomer can be an amino acid at a specific position in a protein or a nucleotide at a specific position in an RNA. A biomolecule can have at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, or more target monomers, which are systematically mutated to generate a DME library of biomolecule variants. In some embodiments, all monomers in a biomolecule are target monomers. For example, for a DME of a protein where two target amino acids exist, designing a DME library involves enumerating 40 possible DME mutations at each of the two target amino acids. As a further example, for a DME of an RNA where four target nucleotides exist, designing a DME library involves enumerating 8 possible DME mutations at each of the four target nucleotides. In some embodiments, each target monomer of a biomolecule is independently selected randomly or by deliberate design. Thus, in some embodiments, a DME library includes random variants, or designed variants, or variants comprising random and designed mutations within a single biomolecule, or any combination thereof.
[0269] In some embodiments of the DME method, the DME mutation is incorporated into double-stranded DNA encoding the biomolecule. This DNA can be maintained and replicated in a standard cloning vector (e.g., a bacterial plasmid, referred to herein as a target plasmid). An exemplary target plasmid contains a DNA sequence encoding the starting biomolecule to be subjected to DME, a bacterial origin of replication, and a suitable antibiotic resistance expression cassette. In some embodiments, the antibiotic resistance cassette confers resistance to kanamycin, ampicillin, spectinomycin, bleomycin, streptomycin, erythromycin, tetracycline, or chloramphenicol. In some embodiments, the antibiotic resistance cassette confers resistance to kanamycin.
[0270] Libraries containing such variants can be constructed in a variety of ways. In certain embodiments, libraries are constructed using plasmid recombination techniques. Such methods can use DNA oligonucleotides encoding one or more mutations to incorporate the mutations into a plasmid encoding a reference biomolecule. For biomolecule variants with multiple mutations, in some embodiments, two or more oligonucleotides are used. In some embodiments, the DNA oligonucleotides encode one or more mutations, and the mutated region is flanked by 10 to 100 nucleotides homologous to the target plasmid both 5' and 3' to the mutation. Such oligonucleotides can, in some embodiments, be commercially synthesized and used in PCR amplification. Exemplary templates for oligonucleotides encoding mutations are provided below. 5'-(N) 10-100 -Mutation-(N') 10-100 -3'
[0271] In this exemplary oligonucleotide design, N represents a sequence identical to the target plasmid (referred to herein as a homology arm). When a specific monomer in a biomolecule is targeted for mutation, these homology arms are immediately adjacent to the DNA encoding the monomer in the target plasmid. In some exemplary embodiments, in which the biomolecule undergoing DME is a protein, 40 different oligonucleotides using the same set of homology arms are used to encode 40 different amino acid mutations listed for each amino acid residue in the protein targeted for DME. When the mutation is a single amino acid mutation, the region encoding the one or more desired mutations contains three nucleotides encoding the amino acid (in the case of a substitution or single insertion) or zero nucleotides (in the case of a deletion). In some embodiments, the oligonucleotide encodes an insertion of more than one amino acid. For example, if the oligonucleotide encodes an insertion of X amino acid, the region encoding the desired mutation contains 3 x X nucleotides encoding the X amino acid. In some embodiments, the mutation region encodes two or more mutations, e.g., mutations to two or more monomers of a biomolecule that are in close proximity (e.g., adjacent to each other or within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more monomers of each other).
[0272] In some exemplary embodiments, where the biomolecule undergoing DME is RNA, eight different oligonucleotides use the same set of homology arms to encode eight different single-nucleotide mutations for each nucleotide in the RNA targeted by DME. When the mutation is a single ribonucleotide mutation, the region of the oligo encoding the mutation can consist of the following nucleotide sequence: one nucleotide (in the case of a substitution or insertion) or zero nucleotides (in the case of a deletion) specifying the nucleotide. In some embodiments, the oligonucleotides are synthesized as single-stranded DNA oligonucleotides. In some embodiments, all oligonucleotides targeting specific amino acids or nucleotides in the biomolecule being subjected to DME are pooled. In some embodiments, all oligonucleotides targeting the biomolecule being subjected to DME are pooled. There is no limit to the type or number of mutations that can be simultaneously generated in a DME library.
[0273] c. Library screening Any suitable method for screening or selecting a DME library is within the scope of the present invention and is contemplated as follows: High-throughput methods can be used to evaluate large libraries with thousands of individual mutations. In some embodiments, the throughput of a library screening or selection assay is equivalent to a throughput of millions of individual cells. In some embodiments, assays utilizing live cells are preferred because phenotypes and genotypes are physically associated in live cells by virtue of being contained within the same lipid bilayer. Live cells can also be used to directly amplify subpopulations of the entire library. In other embodiments, smaller assays are used in DME methods, for example, to screen focused libraries developed through multiple rounds of mutation and evaluation. Exemplary methods for screening libraries are described in Examples 14 and 15.
[0274] In some embodiments, the DME library screened or selected for highly functional variants is further characterized. In some embodiments, further characterizing the DME library involves individually analyzing the DME variants by sequencing (e.g., Sanger sequencing) to identify one or more specific mutations that resulted in the highly functional variants. Individual mutant variants of a biomolecule can be isolated by standard molecular biology techniques for subsequent functional analysis. In some embodiments, further characterizing the DME library involves high-throughput sequencing of both the I library and one or more libraries of highly functional variants. This approach, in some embodiments, can allow for the rapid identification of mutations that are over-represented in one or more libraries of highly functional variants compared to a naive DME library. Without wishing to be bound by any theory, it is likely that over-represented mutations in one or more libraries of highly functional variants are associated with the activity of the highly functional variants. In some embodiments, further characterizing the DME library includes both sequencing of individual variants and high-throughput sequencing of both the naive library and one or more libraries of highly functional variants.
[0275] High-throughput sequencing can generate high-throughput data indicating the functional effects of library members. In embodiments where one or more libraries represent all possible mutations at all monomer positions, such high-throughput sequencing can evaluate the functional effects of all possible DME mutations. Such sequencing can also be used to evaluate one or more highly functional subpopulations of a given library, which in some embodiments can lead to the identification of mutations that result in improved function. Comprehensive Mutation Scanning
[0276] In some embodiments, global mutation scanning (DMS) is used to identify CasX variant proteins with improved function. Global mutation scanning evaluates protein plasticity related to function. In DMS, every amino acid in a protein is changed to every other amino acid and absolute protein function is assayed. For example, every amino acid in a CasX protein can be changed to every other amino acid, and the mutated CasX proteins can be assayed for their ability to bind to or cleave DNA. Exemplary assays, such as CRISPRi assays or bacterial-based cleavage assays, that can be used to characterize the collection of DMS CasX variant proteins are described in Oakes et al. (2016) "Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch" Nat Biotechnol 34(6): 646-51 and Liu et al. (2019) "CasX enzymes comprise a distinct family of RNA-guided genome editors" Nature doi.org / 10.1038 / s41586-019-0908, the contents of which are incorporated herein by reference.
[0277] In some embodiments, DMS is used to identify CasX proteins with improved DNA-binding activity. In some embodiments, DNA-binding activity is assayed using a CRISPRi assay. In a non-limiting exemplary embodiment of a CRISPRi assay, cells expressing a fluorescent protein, such as green fluorescent protein (GFP) or red fluorescent protein (RFP), are assayed using FACS to identify CasX variants that can silence the expression of the fluorescent protein in an sgRNA-dependent manner. In this example, a catalytically inactive CasX (dCasX) is used to generate a collection of DMS mutants to be assayed. The wild-type CasX protein binds to its cognate sgRNA and forms a protein-RNA complex. This complex binds to a specific DNA target (in this case, a DNA sequence encoding a fluorescent protein) through Watson-Crick base pairing between the sgRNA and the DNA target. In the case of wild-type CasX, the DNA is cleaved by the nuclease activity of the CasX protein. However, without wishing to be bound by theory, it is likely that dCasX can still form a complex with the sgRNA and bind to a specific DNA target. When dCasX targeting occurs in a protein-coding region, it blocks RNA polymerase II and transcription initiation and / or elongation, resulting in reduced expression of a fluorescent protein that can be detected by FAC.
[0278] In some embodiments, DMS is used to identify CasX proteins with improved DNA cleavage activity. Methods for assaying the DNA cleavage efficiency of CasX variant proteins will be apparent to those skilled in the art. For example, a CasX protein complexed with an sgRNA having a spacer complementary to a specific target nucleic acid sequence can be used to cleave a DNA target sequence in vitro or in vivo in a suitable cell type, and the frequency of insertions and deletions at the cleavage site can be assayed. Without wishing to be bound by theory, cleavage or nicking by CasX generates a double-strand break in the DNA, and subsequent repair by the non-homologous end joining pathway (NHEJ) generates small insertions or deletions (indels) at the double-strand break site. The frequency of indels at the CasX cleavage site can be measured using high-throughput or Sanger sequencing of the target sequence. Alternatively, or additionally, the frequency of indel generation by CasX cleavage of a target sequence can be measured using a mismatch assay (e.g., T7 Endonuclease I (T7EI) or ...
Claims
1. 1. An engineered class 2, V-type CRISPR protein, a. a non-target strand binding (NTSB) domain obtained from Deltaproteobacteria comprising a sequence of SEQ ID NO: 2335, or a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto; b. a helix I-II domain obtained from Deltaproteobacteria comprising a sequence of SEQ ID NO: 2336, or a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto; c. A RuvC-I domain obtained from Planctomycetes comprising a sequence of SEQ ID NO: 2352 or a sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto; Including, The RuvC-I domain comprises a proline amino acid residue at position 793 compared to SEQ ID NO: 336, and the chimeric class 2, V-type CRISPR protein exhibits improved specificity compared to SEQ ID NO: 336; Engineered class 2, V-type CRISPR proteins.
2. 2. The class 2, type V CRISPR protein of claim 1, comprising one or more nuclear localization signals (NLS), optionally wherein the one or more NLSs are linked to the class 2, type V CRISPR protein or an adjacent NLS using a linker peptide, and optionally (a) the one or more NLS is located at or near the C-terminus of the protein; (b) the one or more NLSs are located at or near the N-terminus of the protein; or (c) the class 2, type V CRISPR protein comprises at least two NLSs, the at least two NLSs being located at or near the N-terminus and at or near the C-terminus of the protein; Class 2, V-type CRISPR proteins.
3. 416, or a sequence having at least 90% identity thereto, wherein the class 2, type V CRISPR protein comprises a proline amino acid at position 793 compared to SEQ ID NO:336, wherein the chimeric class 2, type V CRISPR protein comprises domains from two different class 2, type V CRISPR proteins, and wherein the chimeric class 2, type V CRISPR protein exhibits improved specificity compared to SEQ ID NO:
336.
4. An engineered class 2, type V CRISPR protein comprising a sequence selected from the group consisting of SEQ ID NOs: 415-592 and 1147-1231 as set forth in Table 3.
5. A guide RNA (gRNA) scaffold comprising a sequence having at least 70% sequence identity to SEQ ID NO:2239, wherein the sequence comprises the following modifications relative to SEQ ID NO:2239: C9, U11, U24, A29, U54, G64, A88, and A95. (a) the insertion of C at position 64 and substitution of A88G relative to the sequence of SEQ ID NO:2239 eliminates an asymmetric bulge element in the extension stem and enhances the stability of the extension stem of the gRNA scaffold; (b) the substitutions U11C, U24C, and A95G increase the stability of the triplex region of the gRNA scaffold; or (c) the A29C substitution increases the stability of the pseudoknot stem; 6. The gRNA scaffold of claim 5.
7. Optionally, the gRNA scaffold comprises one or more heterologous RNA sequences in the extension stem. (a) the heterologous RNA is selected from the group consisting of an MS2 hairpin, a Qβ hairpin, a U1 hairpin II, a Uvsx hairpin, and a PP7 stem loop, or a sequence variant thereof; (b) the heterologous RNA sequence increases the stability of the gRNA; (c) the heterologous RNA is capable of binding to a protein, RNA, DNA, or a small molecule; and / or (d) the gRNA scaffold comprises a Rev response element (RRE) or a portion thereof, optionally wherein the RRE or portion thereof has the sequence UGGGCGCAGCGUCAAUGACGCUGACGGUACA (SEQ ID NO: 1280), stem IIB of the RRE has the sequence CAGGAAGCACCUAUGGGCGCAGCGUCAAUGACGCUGACGGUACAGGCCAGACAAUUAUGUCUGG Stem II-V of the RRE having the sequence GCACUAUGGGCGCAGCAGAACAAUUUGCUGAGGGGCUAUUGAGGCGCAACAGCAUCUGUUGCAACUCACAGUCUGGGGCAUCAAGCAGCUCCAGGCAAGAAUCCUG (SEQ ID NO: 1282), A Rev binding element (RBE) in stem IIB having the sequence GCUGACGGUACAGGC (SEQ ID NO:1284), and a Rev binding element (RBE) in stem IIB having the sequence AGGAGCUUUGUUCCUUGGGUUCUUGGGAGCAGCAGGAAGCACUAUGGGCGCAGCGUCAAUGACGCUGCUGACGGUACAGGCCAGAC AAUUAUUGUCUGGUAUAGUGCAGCAGCAGAACAAUUUGCUGAGGGCUAUUGAGGCGCAACAGCAUCUGUUGCAACUCACAGUCUGGGGCAUCAAGCAGCUCCAGGCAAGAAUCCUGGCUGUGGAAAGAUACCUAAAGGAUCAACAGCUCCU (SEQ ID NO: 1283), 7. A gRNA scaffold according to claim 5 or 6.
8. A guide ribonucleic acid (gRNA) comprising an extended stem-loop sequence of sequence number 1286.
9. A guide RNA (gRNA) scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 2292, 2291, 2307, 2281-2290, 2293-2306, 2308-2332, and 2353-2398.
10. A gRNA comprising the gRNA scaffold of any one of claims 5 to 9 and a targeting sequence at the 3' end of the gRNA scaffold, the targeting sequence being complementary to a target nucleic acid sequence, Optionally, the targeting sequence has 15, 16, 17, 18, 19, 20, 21, or 22 nucleotides. Optionally, the targeting sequence has 18, 19, or 20 nucleotides. Optionally, the gRNA is capable of forming a ribonucleoprotein (RNP) complex with a class 2, type V CRISPR protein; gRNA.
11. A gene editing pair comprising a gRNA and a class 2, type V CRISPR protein, the pair comprising: a. A gRNA according to any one of claims 5 to 10; and a class 2, type V CRISPR protein according to any one of claims 1 to 4, wherein the gRNA and the class 2, type V CRISPR protein are capable of forming a ribonucleoprotein complex (RNP), and the class 2, type V CRISPR protein and the gRNA RNP exhibit at least one or more improved characteristics compared to a reference protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and a gRNA RNP comprising a sequence of SEQ ID NO: 4 or SEQ ID NO: 5, and wherein the RNP does not include any of the PAM sequences TTC, ATC, GTC, or CTC. wherein the RNP comprising the class 2, type V CRISPR protein and the gRNA exhibits higher editing efficiency at the target nucleic acid and / or binding of a target nucleic acid sequence in a comparable assay system compared to the editing efficiency and / or binding of an RNP comprising a reference protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, when one of the PAM sequences is located one nucleotide 5' to the non-target strand of a protospacer having identity to the targeting sequence of the gRNA in a cellular assay system. (a) is TTC; (b) is an ATC; (c) is a CTC; or (d) is GTC; Optionally, the RNP comprising the class 2, type V CRISPR and the gRNA exhibits an increased binding affinity for the one or more PAM sequences that is at least 1.5-fold, at least 2-fold, at least 4-fold, at least 10-fold, at least 20-fold, at least 30-fold, or at least 40-fold greater than the binding affinity of the RNP of any one of the reference proteins of SEQ ID NOs: 1-3 and the gRNA of SEQ ID NO: 4 or SEQ ID NO: 5, when assessed in a comparable in vitro assay system. Gene editing pairs.
12. A catalytically inactive class 2, type V CRISPR protein comprising a sequence selected from the group consisting of SEQ ID NOs: 44-62 and 1232-1235 as set forth in Table 7.
13. A nucleic acid comprising a sequence encoding a gRNA described in any one of claims 5 to 10.
14. 5. A nucleic acid comprising a sequence encoding a class 2, V-type CRISPR protein according to any one of claims 1 to 4, optionally wherein the sequence encoding the class 2, V-type CRISPR protein is codon-optimised for expression in a eukaryotic cell.
15. A vector comprising a gRNA according to any one of claims 5 to 10, a class 2 or V-type CRISPR protein according to any one of claims 1 to 4, or a nucleic acid according to claim 13 or 14.
16. The vector is (a) comprises a promoter; and / or (b) is selected from the group consisting of a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes simplex viral (HSV) vector, a plasmid, a minicircle, a nanoplasmid, a DNA vector, an RNA vector, and a lipid nanoparticle (LNP); Optionally, the vector comprises: (i) an AAV vector, optionally selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV-Rh74, or AAVRh10; (ii) is a retroviral vector; The vector described in claim 15.
17. A host cell comprising the vector of claim 15 or 16.
18. A method for modifying a target nucleic acid in a cell in vitro or ex vivo, comprising contacting the target nucleic acid of the cell with: i) a gene editing pair described in claim 11; ii) a gene editing pair and a donor template described in claim 11; iii) one or more nucleic acids encoding or containing the gene editing pair of (i) or (ii); iv) a vector containing the nucleic acid of (i) or (ii); or v) a combination of two or more of (i)-(iv), wherein the contacting of the target nucleic acid modifies the target nucleic acid.
19. The method of claim 19, further comprising: (a) contacting the target with a plurality of gene editing pairs comprising a first and a second gRNA or a plurality of gRNAs comprising targeting sequences complementary to different or overlapping regions of the target nucleic acid; or (b) contacting the target with a plurality of nucleic acids encoding a gene editing pair comprising a first and a second gRNA or a plurality of gRNAs comprising targeting sequences complementary to different or overlapping regions of the target nucleic acid; 20. The method of claim 18, wherein the contacting comprises binding the target nucleic acid and introducing one or more double-stranded breaks into the target nucleic acid, and the modifying comprises introducing a mutation, insertion, or deletion into the target nucleic acid. method.
20. 20. The method of claim 18 or 19, wherein the modification occurs in the cells of a subject that has a mutation in an allele of a gene, and the mutation causes a disease or disorder in the subject, optionally comprising: (a) converting the mutation to a wild-type allele of the gene or resulting in expression of a functional gene product; or (b) knocking down or knocking out the allele of the gene causing the disease or disorder in the subject; method.
21. The cells, (a) is autologous to the subject; or (b) is allogeneic and autologous to the subject; 21. The method of claim 20.
22. The vector is (a) an adeno-associated virus (AAV) vector, optionally wherein the AAV is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-Rh74, or AAVRh10; or (b) a lentiviral vector; The method according to any one of claims 18 to 21.
23. (a) comprising a class 2, V-type CRISPR protein according to any one of claims 1 to 4, optionally comprising a gRNA according to any one of claims 5 to 10, optionally wherein said protein and said gRNA are associated together in a ribonucleoprotein complex (RNP), optionally comprising a donor template nucleic acid, said donor template comprising a nucleotide sequence having homology to a target nucleic acid, optionally comprising a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing; (b) comprising a gRNA according to any one of claims 5 to 10, optionally comprising a class 2, type V CRISPR protein according to any one of claims 1 to 4, optionally wherein said class 2, type V CRISPR protein and said gRNA are associated together in a ribonucleoprotein complex (RNP), optionally comprising a donor template nucleic acid, said donor template comprising a nucleotide sequence having homology to a target nucleic acid, optionally comprising a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing; or (c) comprising the gene editing pair of claim 11, optionally comprising a donor template nucleic acid, the donor template comprising a nucleotide sequence having homology to a target nucleic acid, optionally comprising a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing; composition.
24. (a) A method comprising the steps of: (a) comprising administering to a subject a Class 2, V-type CRISPR protein as described in any one of claims 1 to 4; and a container; optionally comprising a gRNA scaffold as described in any one of claims 5 to 10; optionally comprising a donor template nucleic acid, the donor template comprising a nucleotide sequence having homology to a target nucleic acid sequence of a target nucleic acid; and optionally comprising a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing; (b) comprising a gRNA scaffold according to any one of claims 5 to 10, optionally comprising a class 2, type V CRISPR protein according to any one of claims 1 to 4, optionally comprising a donor template nucleic acid, said donor template comprising a nucleotide sequence having homology to a target nucleic acid sequence of a target nucleic acid, optionally comprising a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing; or (c) comprising the gene editing pair of claim 11, optionally comprising a donor template nucleic acid, the donor template comprising a nucleotide sequence having homology to a target nucleic acid, optionally comprising a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing; kit.
25. 11. A composition comprising: (a) an engineered class 2, type V CRISPR protein according to any one of claims 1 to 4; and (b) a gRNA according to any one of claims 5 to 10, for use as a medicament for the treatment of a subject having a disease.
